FEED Validator

Congratulations!

This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

• line 39, column 0: description should not contain decoding attribute [help]

  					<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" ...
  

• line 60, column 0: content:encoded should not contain decoding attribute (15 occurrences) [help]

  										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
  

• line 102, column 0: style attribute contains potentially dangerous content: 0.0001pt (480 occurrences) [help]

  <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">Acc ...
  

• line 114, column 0: content:encoded should not contain loading attribute (2 occurrences) [help]

  <p align="justify"><img loading="lazy" decoding="async" data-mce-src="/api/I ...
  

• line 114, column 0: content:encoded should not contain data-mce-src attribute (11 occurrences) [help]

  <p align="justify"><img loading="lazy" decoding="async" data-mce-src="/api/I ...
  

• line 114, column 0: content:encoded should not contain data-mce-style attribute (3 occurrences) [help]

  <p align="justify"><img loading="lazy" decoding="async" data-mce-src="/api/I ...
  

• line 114, column 0: content:encoded should not contain data-state attribute [help]

  <p align="justify"><img loading="lazy" decoding="async" data-mce-src="/api/I ...
  

• line 960, column 0: content:encoded should not contain referrerpolicy attribute (9 occurrences) [help]

  <p><img alt="" src='https://ml.globenewswire.com/media/ODljZjMyNTItN2ZiYy00M ...
  

Source: https://dailyindianews.com/feed/

1. <?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
2. xmlns:content="http://purl.org/rss/1.0/modules/content/"
3. xmlns:wfw="http://wellformedweb.org/CommentAPI/"
4. xmlns:dc="http://purl.org/dc/elements/1.1/"
5. xmlns:atom="http://www.w3.org/2005/Atom"
6. xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
7. xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
8. >
9.  
10. <channel>
11. <title>Daily India News</title>
12. <atom:link href="https://dailyindianews.com/feed/" rel="self" type="application/rss+xml" />
13. <link>https://dailyindianews.com</link>
14. <description>Latest breaking news headlines</description>
15. <lastBuildDate>Tue, 22 Apr 2025 02:45:00 +0000</lastBuildDate>
16. <language>en-US</language>
17. <sy:updatePeriod>
18. hourly </sy:updatePeriod>
19. <sy:updateFrequency>
20. 1 </sy:updateFrequency>
21. <generator>https://wordpress.org/?v=6.6.2</generator>
22.  
23. <image>
24. <url>https://dailyindianews.com/wp-content/uploads/2021/10/favicon-150x150.png</url>
25. <title>Daily India News</title>
26. <link>https://dailyindianews.com</link>
27. <width>32</width>
28. <height>32</height>
29. </image>
30. <item>
31. <title>Taggd launches IDJ Lighthouse Series Podcast on Latest Hiring Trends and Best Practices</title>
32. <link>https://dailyindianews.com/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices/2025/373787/</link>
34. <dc:creator><![CDATA[PR Newswire]]></dc:creator>
35. <pubDate>Tue, 22 Apr 2025 02:45:00 +0000</pubDate>
36. <category><![CDATA[Brand Post]]></category>
37. <guid isPermaLink="false">https://dailyindianews.com/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices</guid>
38.  
39. <description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="81" src="https://dailyindianews.com/wp-content/uploads/2025/04/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div>
40. <p><span class="legendSpanClass"><span class="xn-location">NEW DELHI</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 22, 2025</span></span> /PRNewswire/ -- Taggd, a leading digital recruitment platform in <span class="xn-location">India</span>, has launched the "<b>India Decoding Jobs Talent Council Lighthouse Series</b>," a new podcast series featuring Chief Human Resources Officers (CHROs) and talent acquisition leaders from top companies in <span class="xn-location">India</span>. Hosted by Mr. <span class="xn-person">Devashish Sharma</span>, Member, National Committee for Skills &#38; Livelihood, Confederation of Indian Industry and Founding Member &#38; CEO of <a href="https://in.linkedin.com/company/taggdasiatrk=public_post-text" rel="nofollow noopener" target="_blank"><b>Taggd</b></a>, the series explores emerging hiring trends, workforce transformation, and the future of talent acquisition in <span class="xn-location">India</span>. The IDJ Talent Council Lighthouse Series aims to democratize talent intelligence by offering actionable insights, strategic foresight, and real-world best practices directly from the industry's top minds.</p>
41. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
42. <p> <a href="https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.html" rel="nofollow noopener" target="_blank"> <img alt="Decoding Jobs: India’s Lighthouse Series on Talent Acquisition" src="https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.jpg" title="Decoding Jobs: India’s Lighthouse Series on Talent Acquisition"></img> </a> </p>
43. </p></div>
44. <p>Taggd has already launched two episodes of the series. While inaugurating the series, Mr. <span class="xn-person">Devashish Sharma</span> shared, "<i>The India Decoding Jobs Talent Council Lighthouse Series is a landmark initiative that will redefine the HR landscape in <span class="xn-location">India</span>. By engaging in conversation with CHROs, we aim to provide actionable strategies and insights that will empower businesses, academia, and policymakers to navigate the swiftly changing talent landscape adeptly and effectively. This series will not only shape the future of talent acquisition but also contribute significantly to <span class="xn-location">India's</span> growth story."</i> </p>
45. <p>The inaugural episode of the series features a compelling conversation with Mr. Tarun NP Varma, Global Chief Human Resources &#38; Sustainability Officer at Tata Consumer Products.</p>
46. <p>Mr. Tarun NP Varma stressed the importance of true diversity, including mindsets from all regions of <span class="xn-location">India</span>, not just metro cities. One of the key takeaways from the episode was, <i>"</i><i>To build a future-ready workforce, companies must embrace diversity in its truest sense—not just in demographics but in mindsets—and shed restrictive hiring practices like campus exclusivity. The focus should be on finding talent that resonates with customers and aligns with the organization's values,</i>" he said. He also advocated for skill-based hiring over pedigree, focusing on skills and value chains.</p>
47. <p>In the second episode, <span class="xn-person">Kevin Freitas</span>, CHRO at Dream11, shared powerful insights on attracting, retaining, and developing top talent in today's dynamic job market. On the aspect of diversity, Mr. <span class="xn-person">Kevin Freitas</span> said "<i>Diversity is not based on what you see, it's how you feel every day, and as long as we are giving that to people, you know we are on a winning team." </i>Mr. <span class="xn-person">Devashish Sharma</span> added while appreciating Dream 11's efforts to incorporate diverse cultures "<i>Diversity from thought, from the ability to participate in decisions, getting your voice heard, your thought tabled irrespective of your position in the organization". </i>The episode delves deeper into the spirit of Dream 11, employees' passion for sports and its effort to cultivate resilient work culture.</p>
48. <p>Therefore, the Taggd IDJ Talent Council Lighthouse Series is insightful and strategically important for business leaders, HR professionals and recruiters, academia and policymakers, and jobseekers navigating a rapidly evolving talent market and digitization.</p>
49. <p>Available on <b>YouTube, Spotify, and LinkedIn</b>, the series invites listeners to go beyond textbooks and gain first-hand perspectives from those shaping <span class="xn-location">India's</span> talent future.</p>
50. <p>Stay tuned for upcoming episodes, where marquee experts in the talent acquisition industry from <span class="xn-location">India's</span> top companies will share their impeccable journeys, forward-thinking strategies, and invaluable expertise! Such transformative conversations will truly redefine the future of talent acquisition.</p>
51. <p><b>About Taggd</b></p>
52. <p><a href="https://taggd.in/" rel="nofollow noopener" target="_blank">Taggd</a><span>, <span class="xn-location">India's</span> Digital Recruitment firm, is recharging talent acquisition for Indian and Multinational Enterprises with its industry-leading solutions. With a record of matching 55,000 jobs with the right candidates across 14+ sectors annually, Taggd combines data and human knowledge to provide businesses with ready-to-hire talent. It has partnered with prominent brands like Honeywell, Tata Motors, Mahindra &#38; Mahindra, HPE, Hyundai, Wipro and many more to deliver its Talent Mandate successfully.</span><br /></br><br /></br></p>
53. <p><span>Taggd's expertise in recruitment strategies, talent network access, and data intelligence has solidified its position as a leader in the industry. It is the only RPO player from <span class="xn-location">India</span> to feature as a Star Performer in Everest Group's RPO PEAK Matrix® Assessment 2024 – <span class="xn-location">Asia Pacific</span>.</span></p>
54. <p>Photo: <a href="https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.jpg" rel="nofollow noopener" target="_blank">https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.jpg</a></p>
55. <p> </p>
56. <p id="PURL"><img alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN68423&#38;sd=2025-04-21" title="Cision" width="12"></img> View original content to download multimedia:<a href="https://www.prnewswire.com/in/news-releases/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices-302433667.html" id="PRNURL" rel="nofollow noopener" target="_blank">https://www.prnewswire.com/in/news-releases/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices-302433667.html</a></p>
57. <p> <img alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN68423&#38;Transmission_Id=202504212245PR_NEWS_EURO_ND__EN68423&#38;DateId=20250421" style="border:0px; width:1px; height:1px;"></img></p>
58. <p>The post <a rel="nofollow" href="https://dailyindianews.com/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices/2025/373787/">Taggd launches IDJ Lighthouse Series Podcast on Latest Hiring Trends and Best Practices</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
59. ]]></description>
60. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="81" src="https://dailyindianews.com/wp-content/uploads/2025/04/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div><p><span class="legendSpanClass"><span class="xn-location">NEW DELHI</span></span>, <span class="legendSpanClass"><span class="xn-chron">April 22, 2025</span></span> /PRNewswire/ &#8212; Taggd, a leading digital recruitment platform in <span class="xn-location">India</span>, has launched the &#8220;<b>India Decoding Jobs Talent Council Lighthouse Series</b>,&#8221; a new podcast series featuring Chief Human Resources Officers (CHROs) and talent acquisition leaders from top companies in <span class="xn-location">India</span>. Hosted by Mr. <span class="xn-person">Devashish Sharma</span>, Member, National Committee for Skills &amp; Livelihood, Confederation of Indian Industry and Founding Member &amp; CEO of <b>Taggd</b>, the series explores emerging hiring trends, workforce transformation, and the future of talent acquisition in <span class="xn-location">India</span>. The IDJ Talent Council Lighthouse Series aims to democratize talent intelligence by offering actionable insights, strategic foresight, and real-world best practices directly from the industry&#8217;s top minds.</p>
61. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
62. <p>  <img decoding="async" alt="Decoding Jobs: India’s Lighthouse Series on Talent Acquisition" src="https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.jpg" title="Decoding Jobs: India’s Lighthouse Series on Talent Acquisition"></img>  </p>
63. </p></div>
64. <p>Taggd has already launched two episodes of the series. While inaugurating the series, Mr. <span class="xn-person">Devashish Sharma</span> shared, &#8220;<i>The India Decoding Jobs Talent Council Lighthouse Series is a landmark initiative that will redefine the HR landscape in <span class="xn-location">India</span>. By engaging in conversation with CHROs, we aim to provide actionable strategies and insights that will empower businesses, academia, and policymakers to navigate the swiftly changing talent landscape adeptly and effectively. This series will not only shape the future of talent acquisition but also contribute significantly to <span class="xn-location">India&#8217;s</span> growth story.&#8221;</i> </p>
65. <p>The inaugural episode of the series features a compelling conversation with Mr. Tarun NP Varma, Global Chief Human Resources &amp; Sustainability Officer at Tata Consumer Products.</p>
66. <p>Mr. Tarun NP Varma stressed the importance of true diversity, including mindsets from all regions of <span class="xn-location">India</span>, not just metro cities. One of the key takeaways from the episode was, <i>&#8220;</i><i>To build a future-ready workforce, companies must embrace diversity in its truest sense—not just in demographics but in mindsets—and shed restrictive hiring practices like campus exclusivity. The focus should be on finding talent that resonates with customers and aligns with the organization&#8217;s values,</i>&#8221; he said. He also advocated for skill-based hiring over pedigree, focusing on skills and value chains.</p>
67. <p>In the second episode, <span class="xn-person">Kevin Freitas</span>, CHRO at Dream11, shared powerful insights on attracting, retaining, and developing top talent in today&#8217;s dynamic job market. On the aspect of diversity, Mr. <span class="xn-person">Kevin Freitas</span> said &#8220;<i>Diversity is not based on what you see, it&#8217;s how you feel every day, and as long as we are giving that to people, you know we are on a winning team.&#8221; </i>Mr. <span class="xn-person">Devashish Sharma</span> added while appreciating Dream 11&#8217;s efforts to incorporate diverse cultures &#8220;<i>Diversity from thought, from the ability to participate in decisions, getting your voice heard, your thought tabled irrespective of your position in the organization&#8221;. </i>The episode delves deeper into the spirit of Dream 11, employees&#8217; passion for sports and its effort to cultivate resilient work culture.</p>
68. <p>Therefore, the Taggd IDJ Talent Council Lighthouse Series is insightful and strategically important for business leaders, HR professionals and recruiters, academia and policymakers, and jobseekers navigating a rapidly evolving talent market and digitization.</p>
69. <p>Available on <b>YouTube, Spotify, and LinkedIn</b>, the series invites listeners to go beyond textbooks and gain first-hand perspectives from those shaping <span class="xn-location">India&#8217;s</span> talent future.</p>
70. <p>Stay tuned for upcoming episodes, where marquee experts in the talent acquisition industry from <span class="xn-location">India&#8217;s</span> top companies will share their impeccable journeys, forward-thinking strategies, and invaluable expertise! Such transformative conversations will truly redefine the future of talent acquisition.</p>
71. <p><b>About Taggd</b></p>
72. <p>Taggd<span>, <span class="xn-location">India&#8217;s</span> Digital Recruitment firm, is recharging talent acquisition for Indian and Multinational Enterprises with its industry-leading solutions. With a record of matching 55,000 jobs with the right candidates across 14+ sectors annually, Taggd combines data and human knowledge to provide businesses with ready-to-hire talent. It has partnered with prominent brands like Honeywell, Tata Motors, Mahindra &amp; Mahindra, HPE, Hyundai, Wipro and many more to deliver its Talent Mandate successfully.</span><br /></br><br /></br></p>
73. <p><span>Taggd&#8217;s expertise in recruitment strategies, talent network access, and data intelligence has solidified its position as a leader in the industry. It is the only RPO player from <span class="xn-location">India</span> to feature as a Star Performer in Everest Group&#8217;s RPO PEAK Matrix® Assessment 2024 – <span class="xn-location">Asia Pacific</span>.</span></p>
74. <p>Photo: https://mma.prnewswire.com/media/2668851/Taggd_Lighthouse_Series.jpg</p>
75. <p> </p>
76. <p id="PURL"><img decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN68423&amp;sd=2025-04-21" title="Cision" width="12"></img> View original content to download multimedia:https://www.prnewswire.com/in/news-releases/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices-302433667.html</p>
77. <p> <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN68423&amp;Transmission_Id=202504212245PR_NEWS_EURO_ND__EN68423&amp;DateId=20250421" style="border:0px; width:1px; height:1px;"></img>Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Daily India News takes no editorial responsibility for the same.</p>
78. <p>The post <a rel="nofollow" href="https://dailyindianews.com/taggd-launches-idj-lighthouse-series-podcast-on-latest-hiring-trends-and-best-practices/2025/373787/">Taggd launches IDJ Lighthouse Series Podcast on Latest Hiring Trends and Best Practices</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
79. ]]></content:encoded>
83. </item>
84. <item>
85. <title>Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs &#124; DelveInsight</title>
86. <link>https://dailyindianews.com/malignant-pleural-mesothelioma-market-poised-for-growth-across-the-7mm-during-the-study-period-2020-2034-amid-advances-in-immunotherapy-and-targeted-drugs-delveinsight/2025/373784/</link>
88. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
89. <pubDate>Mon, 21 Apr 2025 17:00:00 +0000</pubDate>
90. <category><![CDATA[Brand Post]]></category>
91. <guid isPermaLink="false">https://dailyindianews.com/malignant-pleural-mesothelioma-market-poised-for-growth-across-the-7mm-during-the-study-period-2020-2034-amid-advances-in-immunotherapy-and-targeted-drugs-delveinsight</guid>
92.  
93. <description><![CDATA[<p>The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others will drive this expansion across the 7MM. New York, USA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Malignant Pleural Mesothelioma Market Poised for [&#8230;]</p>
94. <p>The post <a rel="nofollow" href="https://dailyindianews.com/malignant-pleural-mesothelioma-market-poised-for-growth-across-the-7mm-during-the-study-period-2020-2034-amid-advances-in-immunotherapy-and-targeted-drugs-delveinsight/2025/373784/">Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
95. ]]></description>
96. <content:encoded><![CDATA[<p><em>The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others will drive this expansion across the 7MM.</em></p>
97. <p align="justify">New York, USA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; <b>Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight </b></p>
98. <p align="justify"><b><i>The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, and others will drive this expansion across the 7MM.</i></b></p>
99. <p align="justify">DelveInsight’s <b>Malignant Pleural Mesothelioma Market Insights</b> report includes a comprehensive understanding of current treatment practices, emerging malignant pleural mesothelioma drugs, market share of individual therapies, and current and forecasted malignant pleural mesothelioma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].</p>
100. <p align="justify"><b>Key Takeaways from the Malignant Pleural Mesothelioma Market Report</b></p>
101. <ul type="disc">
102. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">According to DelveInsight’s analysis, the market size of malignant pleural mesothelioma was found to be <b>USD 210 million</b> in the 7MM in 2024.</li>
103. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">As per the estimates, among the currently marketed drugs currently in use, <b>OPDIVO (Nivolumab) + YERVOY (Ipilimumab)</b> held the largest market share, generating approximately <b>USD 140 million</b> in revenue in 2024 across the 7MM.</li>
104. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">According to DelveInsight’s estimates, in 2024, the total number of mesothelioma cases across the 7MM was around <b>11K</b>. However, this figure is expected to decline by 2034, with a projected <b>CAGR of 0.3%</b>.</li>
105. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Prominent companies working in the domain of malignant pleural mesothelioma, including <b>AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, Tango Therapeutics, </b>and others, are actively working on innovative Malignant Pleural Mesothelioma drugs. These novel malignant pleural mesothelioma therapies are anticipated to enter the malignant pleural mesothelioma market in the forecast period and are expected to change the market.</li>
106. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Some of the key malignant pleural mesothelioma treatments include <b>Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, Thiostrepton (RSO-021), alinpepimut-S, CTX131, VT3888, NUC-3373 (Fosifloxuridine Nafalbenamide), A2B694, TNG462</b>, and others. </li>
107. </ul>
108. <p align="justify">Discover which therapies are expected to grab the malignant pleural mesothelioma market share @ <b>Malignant Pleural Mesothelioma Market Report</b></p>
109. <p align="justify"><b>Malignant Pleural Mesothelioma Overview</b></p>
110. <p align="justify">Malignant pleural mesothelioma (MPM) is an aggressive cancer that develops from mesothelial cells lining the pleura and is strongly associated with long-term asbestos exposure. It is marked by rapid disease progression and a high mortality rate, primarily affecting older men decades after initial exposure. The disease&#8217;s complexity, due to significant tumor heterogeneity, contributes to resistance to treatment and poses considerable management challenges. In an effort to improve diagnostic clarity, the 2021 WHO Classification of Thoracic Tumors (by IARC) updated its terminology—changing &#8220;diffuse malignant pleural mesothelioma&#8221; to &#8220;diffuse pleural mesothelioma&#8221; and &#8220;localized malignant pleural mesothelioma&#8221; to &#8220;localized pleural mesothelioma.&#8221;</p>
111. <p align="justify">Asbestos remains the most prominent risk factor, with inhaled fibers causing chronic inflammation and long-term cellular damage. Other risk contributors include exposure to naturally occurring minerals like erionite, previous radiation therapy, and possible links to simian virus 40. Genetic predispositions—particularly BAP1 mutations—along with age and male sex also increase the likelihood of developing MPM.</p>
112. <p align="justify">Typical symptoms include shortness of breath and chest pain, often due to pleural effusion in the early stages or tumor encasement of the lungs in advanced disease. Systemic symptoms such as fatigue, weight loss, and general malaise are driven by cytokine release. Less commonly, tumor spread may lead to complications like superior vena cava syndrome or difficulty swallowing. In some cases, patients remain asymptomatic, highlighting the importance of regular monitoring for individuals with a history of asbestos exposure.</p>
113. <p align="justify">Diagnosis involves a combination of clinical assessment, imaging, and tissue analysis. CT and PET scans help detect pleural irregularities, but histopathological confirmation remains the definitive diagnostic method. Immunohistochemical markers support differentiation from other malignancies, while biomarkers like mesothelin show promise but lack sufficient accuracy for use alone. Accurate disease staging, often requiring invasive techniques, is crucial for effective treatment planning and prognosis estimation.</p>
114. <p align="justify"><img loading="lazy" decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=042c5fa1-c177-49b8-bd02-182f42982b71&amp;size=0" data-mce-style="display: block; margin-left: auto; margin-right: auto;" data-state="draft" height="420" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/042c5fa1-c177-49b8-bd02-182f42982b71/malignant-pleural-mesothelioma-market.jpg" style="display:block; margin-left:auto; margin-right:auto;" title="Malignant-Pleural-Mesothelioma-Market.jpg" width="800" /></p>
115. <p align="justify"><b>Malignant Pleural Mesothelioma Epidemiology Segmentation</b></p>
116. <p align="justify">The malignant pleural mesothelioma epidemiology section provides insights into the historical and current malignant pleural mesothelioma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.</p>
117. <p align="justify">The <b>malignant pleural mesothelioma market report</b> proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:</p>
118. <ul type="disc">
119. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">Total Incident Cases of MPM </li>
120. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Gender-specific Incident Cases of MPM </li>
121. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Age-specific Incident Cases of MPM </li>
122. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Histology-specific Incident Cases of MPM </li>
123. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Stage-specific Incident Cases of MPM</li>
124. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Line-wise Treated Cases of MPM </li>
125. </ul>
126. <p align="justify">Download the report to understand which factors are driving malignant pleural mesothelioma epidemiology trends @ <b>Malignant Pleural Mesothelioma Epidemiological Insights</b></p>
127. <p align="justify"><b>Malignant Pleural Mesothelioma Treatment Market </b></p>
128. <p align="justify">The management of malignant pleural mesothelioma typically involves a multimodal approach, combining surgery, radiation therapy, and chemotherapy, with chemotherapy remaining the cornerstone of treatment. Due to the aggressive nature of MPM, surgical procedures are only feasible for a carefully selected group of patients, while radiotherapy is mainly employed for symptom control rather than curative intent. Chemotherapy—most commonly using pemetrexed, cisplatin, gemcitabine, and carboplatin—continues to be the most frequently used strategy.</p>
129. <p align="justify">Chemotherapy is divided into first-line and subsequent lines based on the disease stage and the patient’s response to prior treatments. However, each treatment modality presents limitations: surgery is an option for only a few patients, radiotherapy is palliative, and chemotherapy is often challenged by issues like resistance and recurrence. In light of these challenges, newer therapies—including targeted drugs and immunotherapies—have been developed to improve clinical outcomes and extend survival.</p>
130. <p align="justify">One such immunotherapy is <b>KEYTRUDA (pembrolizumab)</b>, a PD-1 checkpoint inhibitor that enhances immune system activity by preventing PD-1 interactions, allowing T cells to recognize and destroy tumor cells. This humanized monoclonal antibody received U.S. FDA approval in September 2024 for use in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adults with unresectable advanced or metastatic MPM, based on the <b>KEYNOTE-483 trial</b>, which demonstrated a significant survival benefit. It marked the first U.S. approval of KEYTRUDA for MPM. In November 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) also issued a positive opinion on the same regimen for first-line treatment of unresectable nonepithelioid MPM, and regulatory review is ongoing in Japan.</p>
131. <p align="justify">In addition, the combination of <b>nivolumab and ipilimumab</b>—two immune checkpoint inhibitors targeting PD-1 and CTLA-4 respectively—was approved by the U.S. FDA in October 2020 as a first-line treatment for unresectable MPM. This approval was based on results from the <b>CHECKMATE 743 study</b>, which demonstrated a significant survival benefit through immune system activation. OPDIVO (nivolumab), as a monotherapy, was approved in Japan in August 2018 for patients with unresectable, advanced, or recurrent MPM that progressed following chemotherapy, based on data from the Phase II MERIT trial, which confirmed its clinical benefit.</p>
132. <p align="justify">Learn more about the market of malignant pleural mesothelioma @ <b>Malignant Pleural Mesothelioma Treatment </b></p>
133. <p align="justify"><b>Malignant Pleural Mesothelioma Emerging Drugs and Companies</b></p>
134. <p align="justify">A significant progress has been made in understanding molecular pathogenesis and developing promising new therapeutic approaches for mesothelioma. Many different therapies have been attempted for malignant pleural mesothelioma over the years, including, immune therapy, gene therapy, and various combinations of investigational therapies. A few key players such as <b>Astrazeneca </b>(volrustomig), <b>Amphera </b>(mesopher), <b>PrECOG </b>(DuRvalumab), and others are under early to mid-stage clinical development.</p>
135. <p align="justify"><b>Volrustomig (MEDI5752)</b> is an innovative bispecific antibody developed to boost anti-tumor immune responses by simultaneously targeting PD-1 and CTLA-4 checkpoints. This dual-action design seeks to enhance immune activation against tumors while potentially reducing the side effects commonly seen with combination immunotherapies. A Phase III clinical trial is currently underway to assess its safety and effectiveness in combination with carboplatin and pemetrexed for patients with unresectable MPM. </p>
136. <p align="justify">This study is comparing volrustomig-based therapy with standard platinum chemotherapy and with the combination of nivolumab and ipilimumab as a first-line treatment, with results anticipated post-2026. In April 2022, AstraZeneca introduced findings from the first-in-human trial of MEDI5752 at the American Association for Cancer Research (AACR) annual meeting, highlighting its potential as a novel bispecific immune checkpoint inhibitor for advanced solid tumors.</p>
137. <p align="justify"><b>Pegargiminase (ADI-PEG 20)</b> is a pioneering enzyme-based therapy designed to deprive certain cancers of arginine—an amino acid some tumors rely on for growth and survival. By converting arginine into citrulline and ammonia, it interrupts protein synthesis, thereby selectively inducing cancer cell death. It is currently being evaluated in the Phase III ATOMIC-Meso trial in combination with chemotherapy for patients with nonepithelioid pleural mesothelioma. Based on positive data showing improvements in progression-free and overall survival, a rolling regulatory submission is underway, which could potentially expedite its approval.</p>
138. <p align="justify">According to the JP Morgan Healthcare Conference held in January 2024, Polaris Pharma planned to submit a Marketing Authorization Application (MAA) for Pegargiminase in Europe within the year. However, there have been no recent updates on the status of this submission. The company is also aiming for a commercial launch in 2025.</p>
139. <p align="justify"><b>MesoPher</b>, developed by <b>Amphera BV</b>, is an autologous dendritic cell-based immunotherapy aimed at triggering a targeted anti-tumor immune response. It utilizes a patient’s own dendritic cells, which are loaded with the PheraLys lysate to improve antigen presentation. Following leukapheresis and activation, the modified cells are reinfused to stimulate the immune system—potentially transforming immunologically “cold” tumors into “hot” ones that are more responsive to treatment. Now in Phase III trials, MesoPher has demonstrated encouraging immunogenicity and a favorable safety profile. In June 2024, findings from the randomized Phase II/III MesoPher trial for pleural mesothelioma were published in The Lancet Oncology, highlighting the therapy’s clinical potential.</p>
140. <p align="justify">Other therapies in the pipeline for MPM include </p>
141. <ul type="disc">
142. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">Thiostrepton (RSO-021): RS Oncology</li>
143. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Galinpepimut-S: Sellas Life Sciences Group</li>
144. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">CTX131: CRISPR Therapeutics AG</li>
145. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">VT3888: Vivace Therapeutics</li>
146. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">NUC-3373 (Fosifloxuridine Nafalbenamide): NuCana plc</li>
147. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">A2B694: A2 Biotherapeutics</li>
148. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">A2B694: A2 Biotherapeutics</li>
149. </ul>
150. <p align="justify">The anticipated launch of these emerging therapies are poised to transform the malignant pleural mesothelioma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the malignant pleural mesothelioma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.</p>
151. <p align="justify">To know more about malignant pleural mesothelioma clinical trials, visit @ <b>Malignant Pleural Mesothelioma Treatment Drugs </b></p>
152. <p align="justify"><b>Malignant Pleural Mesothelioma Market Dynamics</b></p>
153. <p align="justify">The malignant pleural mesothelioma market dynamics are anticipated to change in the coming years. MPM presents unique market dynamics shaped by both <b>clinical and legal factors</b>. Many MPM patients have legal claims due to <b>asbestos exposure</b>, which often provides them with financial resources to cover the <b>cost of treatments and supportive services</b>, potentially easing access to premium-priced therapies.</p>
154. <p align="justify">The <b>clinical pipeline for MPM is robust</b>, featuring a range of innovative therapies under development with diverse mechanisms of action, including <b>gene therapies, immunotherapies, arginine-degrading enzymes, and PD-L1 inhibitors</b>. Promising pipeline candidates like <b>MesoPher </b>and others have received <b>Orphan Drug Designation (ODD)</b>, which offers key regulatory incentives such as seven years of market exclusivity in the U.S., <b>reduced regulatory fees, and clinical trial subsidies</b>—enhancing the commercial viability of these therapies.</p>
155. <p align="justify">Moreover, advancements in <b>blood-based biomarkers</b> are opening new avenues in MPM management, with potential applications in diagnostics, prognosis, and predicting treatment response. These developments support a more personalized approach to care and may further differentiate emerging therapies. As a result, companies with therapies that demonstrate a <b>clear clinical advantage </b>over current standards like <b>nivolumab </b>could justify premium pricing, positioning themselves competitively in a high-need, specialized market.</p>
156. <p align="justify">Furthermore, many potential therapies are being investigated for the treatment of malignant pleural mesothelioma, and it is safe to predict that the treatment space will significantly impact the malignant pleural mesothelioma market during the forecast period. Moreover, the <b>anticipated introduction of emerging therapies</b> with improved efficacy and a further <b>improvement in the diagnosis rate</b> is expected to drive the growth of the malignant pleural mesothelioma market in the 7MM.</p>
157. <p align="justify">However, several factors may impede the growth of the malignant pleural mesothelioma market. MPM is typically <b>diagnosed at an advanced stage</b> due to its nonspecific symptoms—such as chest pain and shortness of breath—and the lack of effective early detection methods. This delayed diagnosis contributes to a <b>poor prognosis</b>, with median survival ranging from just 7 to 12 months. While chemotherapy and radiation remain standard treatments, they are often associated with significant side effects, including fatigue and general weakness, which greatly diminish patients’ quality of life. Common regimens like <b>cisplatin and pemetrexed </b>provide only modest survival benefits, typically extending life by approximately three months.</p>
158. <p align="justify">Given the <b>limited efficacy of existing therapies</b>, healthcare authorities are likely to scrutinize the pricing and usage of new high-cost treatments that do not clearly outperform current standards. Furthermore, while legal settlements and financial support offer access advantages for some patients, the overall <b>incidence of MPM is on the decline</b> in most of the 7MM—with the exception of Spain and Japan—leading to a shrinking eligible patient population for emerging therapies. These factors underscore the importance of demonstrating significant clinical value and cost-effectiveness for any new entrants in the MPM treatment landscape.</p>
159. <p align="justify">Moreover, malignant pleural mesothelioma treatment poses a <b>significant economic burden</b> and disrupts patients’ overall well-being and QOL. Furthermore, the malignant pleural mesothelioma market growth may be offset by <b>failures and discontinuation of emerging therapies</b>, <b>unaffordable pricing</b>, <b>market access and reimbursement issues</b>, and a <b>shortage of healthcare specialists</b>. In addition, the <b>undiagnosed, unreported cases and the unawareness</b> about the disease may also impact the malignant pleural mesothelioma market growth.</p>
160. <table style="border-collapse: collapse; border-collapse:collapse ;">
161. <tr>
162. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; "><b>Malignant Pleural Mesothelioma Report Metrics</b></td>
163. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; "><b>Details</b></td>
164. </tr>
165. <tr>
166. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Study Period</td>
167. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">2020–2034</td>
168. </tr>
169. <tr>
170. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Malignant Pleural Mesothelioma Report Coverage</td>
171. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]</td>
172. </tr>
173. <tr>
174. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Malignant Pleural Mesothelioma Market CAGR</td>
175. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">0.7%</td>
176. </tr>
177. <tr>
178. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Malignant Pleural Mesothelioma Market Size in 2024</td>
179. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">USD 210 Million</td>
180. </tr>
181. <tr>
182. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Key Malignant Pleural Mesothelioma Companies</td>
183. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, Tango Therapeutics, and others</td>
184. </tr>
185. <tr>
186. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Key Malignant Pleural Mesothelioma Therapies</td>
187. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, Thiostrepton (RSO-021), alinpepimut-S, CTX131, VT3888, NUC-3373 (Fosifloxuridine Nafalbenamide), A2B694, TNG462, and others</td>
188. </tr>
189. </table>
190. <p align="justify"><b>Scope of the </b><b>Malignant Pleural Mesothelioma</b><b> Market Report</b></p>
191. <ul type="disc">
192. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;"><b>Malignant Pleural Mesothelioma Therapeutic Assessment: </b>Malignant Pleural Mesothelioma current marketed and emerging therapies</li>
193. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Malignant Pleural Mesothelioma</b> <b>Market Dynamics:</b> Conjoint Analysis of Emerging Malignant Pleural Mesothelioma Drugs</li>
194. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Competitive Intelligence Analysis:</b> SWOT analysis and Market entry strategies</li>
195. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Unmet Needs, KOL’s views, Analyst’s views, Malignant Pleural Mesothelioma Market Access and Reimbursement</b></li>
196. </ul>
197. <p align="justify">Discover more about malignant pleural mesothelioma drugs in development @ <b>Malignant Pleural Mesothelioma Clinical Trials</b></p>
198. <p align="justify"><b>Table of Contents</b></p>
199. <table style="border-collapse: collapse; border-collapse:collapse ;">
200. <tr>
201. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">1</td>
202. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Insights</td>
203. </tr>
204. <tr>
205. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">2</td>
206. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Report Introduction</td>
207. </tr>
208. <tr>
209. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">3</td>
210. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">MPM Market Overview at a Glance</td>
211. </tr>
212. <tr>
213. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">3.1</td>
214. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Share (%) Distribution of MPM by Therapies in the 7MM in 2020</td>
215. </tr>
216. <tr>
217. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">3.2</td>
218. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Share (%) Distribution of MPM by Therapies in the 7MM in 2034</td>
219. </tr>
220. <tr>
221. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">4</td>
222. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Executive Summary</td>
223. </tr>
224. <tr>
225. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">5</td>
226. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Events</td>
227. </tr>
228. <tr>
229. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6</td>
230. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Disease Background and Overview</td>
231. </tr>
232. <tr>
233. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.1</td>
234. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Introduction</td>
235. </tr>
236. <tr>
237. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.2</td>
238. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Types of MPM</td>
239. </tr>
240. <tr>
241. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.3</td>
242. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Signs and Symptoms</td>
243. </tr>
244. <tr>
245. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.4</td>
246. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Risk Factors and Causes</td>
247. </tr>
248. <tr>
249. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.5</td>
250. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Pathophysiology</td>
251. </tr>
252. <tr>
253. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.6</td>
254. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Diagnosis</td>
255. </tr>
256. <tr>
257. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.6.1</td>
258. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Differential Diagnosis</td>
259. </tr>
260. <tr>
261. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.6.2</td>
262. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Diagnostic Algorithm</td>
263. </tr>
264. <tr>
265. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.6.3</td>
266. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Diagnostic Guidelines and Recommendations</td>
267. </tr>
268. <tr>
269. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.7</td>
270. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Treatment and Management</td>
271. </tr>
272. <tr>
273. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.7.1</td>
274. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Treatment Algorithm</td>
275. </tr>
276. <tr>
277. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">6.7.2</td>
278. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Treatment Guidelines and Recommendations</td>
279. </tr>
280. <tr>
281. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">7</td>
282. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Epidemiology and Market Methodology</td>
283. </tr>
284. <tr>
285. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8</td>
286. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Epidemiology and Patient Population</td>
287. </tr>
288. <tr>
289. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.1</td>
290. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Findings</td>
291. </tr>
292. <tr>
293. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2</td>
294. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Assumptions and Rationale: 7MM</td>
295. </tr>
296. <tr>
297. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.1</td>
298. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Incidence of Mesothelioma</td>
299. </tr>
300. <tr>
301. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.2</td>
302. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Incidence of MPM in Mesothelioma</td>
303. </tr>
304. <tr>
305. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.3</td>
306. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Gender-specific Incidence of MPM</td>
307. </tr>
308. <tr>
309. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.4</td>
310. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Age-specific Incidence of MPM</td>
311. </tr>
312. <tr>
313. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.5</td>
314. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Histology-specific Incidence of MPM</td>
315. </tr>
316. <tr>
317. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.2.6</td>
318. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Stage-specific Incidence of MPM</td>
319. </tr>
320. <tr>
321. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.3</td>
322. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Incident Cases of Mesothelioma in the 7MM</td>
323. </tr>
324. <tr>
325. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.4</td>
326. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Incident Cases of MPM in the 7MM</td>
327. </tr>
328. <tr>
329. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5</td>
330. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">The United States</td>
331. </tr>
332. <tr>
333. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.1</td>
334. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Incident Cases of MPM in the US</td>
335. </tr>
336. <tr>
337. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.2</td>
338. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Gender-specific Incident Cases of MPM in the US</td>
339. </tr>
340. <tr>
341. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.3</td>
342. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Age-specific Incident Cases of MPM in the US</td>
343. </tr>
344. <tr>
345. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.4</td>
346. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Histology-specific Incident Cases of MPM in the US</td>
347. </tr>
348. <tr>
349. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.5</td>
350. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Stage-specific Incident Cases of MPM in the US</td>
351. </tr>
352. <tr>
353. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.5.6</td>
354. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Line-wise Treated Cases of MPM in the US</td>
355. </tr>
356. <tr>
357. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6</td>
358. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">EU4 and the UK</td>
359. </tr>
360. <tr>
361. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.1</td>
362. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Incident Cases of MPM in EU4 and the UK</td>
363. </tr>
364. <tr>
365. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.2</td>
366. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Gender-specific Incident Cases of MPM in EU4 and the UK</td>
367. </tr>
368. <tr>
369. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.3</td>
370. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Age-specific Incident Cases of MPM in EU4 and the UK</td>
371. </tr>
372. <tr>
373. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.4</td>
374. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Histology-specific Incident Cases of MPM in EU4 and the UK</td>
375. </tr>
376. <tr>
377. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.5</td>
378. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Stage-specific Incident Cases of MPM in EU4 and the UK</td>
379. </tr>
380. <tr>
381. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.6.6</td>
382. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Line-wise Treated Cases of MPM in EU4 and the UK</td>
383. </tr>
384. <tr>
385. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7</td>
386. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Japan</td>
387. </tr>
388. <tr>
389. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.1</td>
390. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Incident Cases of MPM in Japan</td>
391. </tr>
392. <tr>
393. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.2</td>
394. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Gender-specific Incident Cases of MPM in Japan</td>
395. </tr>
396. <tr>
397. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.3</td>
398. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Age-specific Incident Cases of MPM in Japan</td>
399. </tr>
400. <tr>
401. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.4</td>
402. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Histology-specific Incident Cases of MPM in Japan</td>
403. </tr>
404. <tr>
405. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.5</td>
406. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Stage-specific Incident Cases of MPM in Japan</td>
407. </tr>
408. <tr>
409. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">8.7.6</td>
410. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Line-wise Treated Cases of MPM in Japan</td>
411. </tr>
412. <tr>
413. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">9</td>
414. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Patient Journey</td>
415. </tr>
416. <tr>
417. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10</td>
418. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Marketed Therapies</td>
419. </tr>
420. <tr>
421. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.1</td>
422. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Cross of Marketed Drugs</td>
423. </tr>
424. <tr>
425. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2</td>
426. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">KEYTRUDA (Pembrolizumab): Merck</td>
427. </tr>
428. <tr>
429. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2.1</td>
430. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Product Description</td>
431. </tr>
432. <tr>
433. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2.2</td>
434. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Regulatory Milestone</td>
435. </tr>
436. <tr>
437. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2.3</td>
438. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
439. </tr>
440. <tr>
441. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2.4</td>
442. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
443. </tr>
444. <tr>
445. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.2.5</td>
446. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
447. </tr>
448. <tr>
449. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3</td>
450. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">OPDIVO (Nivolumab) and YERVOY (Ipilimumab): Bristol-Myers Squibb/Ono Pharmaceuticals</td>
451. </tr>
452. <tr>
453. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3.1</td>
454. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Product Description</td>
455. </tr>
456. <tr>
457. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3.2</td>
458. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Regulatory Milestone</td>
459. </tr>
460. <tr>
461. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3.3</td>
462. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
463. </tr>
464. <tr>
465. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3.4</td>
466. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
467. </tr>
468. <tr>
469. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.3.5</td>
470. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
471. </tr>
472. <tr>
473. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4</td>
474. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">OPDIVO (Nivolumab): Bristol-Myers Squibb/Ono Pharmaceuticals</td>
475. </tr>
476. <tr>
477. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4.1</td>
478. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Product Description</td>
479. </tr>
480. <tr>
481. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4.2</td>
482. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Regulatory Milestone</td>
483. </tr>
484. <tr>
485. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4.3</td>
486. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
487. </tr>
488. <tr>
489. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4.4</td>
490. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
491. </tr>
492. <tr>
493. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.4.5</td>
494. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
495. </tr>
496. <tr>
497. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5</td>
498. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">OPTUNE LUA: Novocure</td>
499. </tr>
500. <tr>
501. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5.1</td>
502. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Product Description</td>
503. </tr>
504. <tr>
505. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5.2</td>
506. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Regulatory Milestone</td>
507. </tr>
508. <tr>
509. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5.3</td>
510. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
511. </tr>
512. <tr>
513. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5.4</td>
514. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
515. </tr>
516. <tr>
517. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">10.5.5</td>
518. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
519. </tr>
520. <tr>
521. <td colspan="2" style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><i>To be continued in the report…</i></td>
522. </tr>
523. <tr>
524. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11</td>
525. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Emerging Drug Profiles</td>
526. </tr>
527. <tr>
528. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.1</td>
529. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Cross Competition of Emerging Drugs</td>
530. </tr>
531. <tr>
532. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2</td>
533. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Volrustomig (MEDI5752): AstraZeneca</td>
534. </tr>
535. <tr>
536. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2.1</td>
537. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
538. </tr>
539. <tr>
540. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2.2</td>
541. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
542. </tr>
543. <tr>
544. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2.3</td>
545. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
546. </tr>
547. <tr>
548. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2.4</td>
549. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
550. </tr>
551. <tr>
552. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.2.5</td>
553. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
554. </tr>
555. <tr>
556. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3</td>
557. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Pegargiminase with Pemetrexed and Cisplatin: Polaris Pharmaceuticals</td>
558. </tr>
559. <tr>
560. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3.1</td>
561. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
562. </tr>
563. <tr>
564. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3.2</td>
565. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
566. </tr>
567. <tr>
568. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3.3</td>
569. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
570. </tr>
571. <tr>
572. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3.4</td>
573. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
574. </tr>
575. <tr>
576. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.3.5</td>
577. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
578. </tr>
579. <tr>
580. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4</td>
581. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">MesoPher: Amphera BV</td>
582. </tr>
583. <tr>
584. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4.1</td>
585. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
586. </tr>
587. <tr>
588. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4.2</td>
589. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
590. </tr>
591. <tr>
592. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4.3</td>
593. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
594. </tr>
595. <tr>
596. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4.4</td>
597. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
598. </tr>
599. <tr>
600. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.4.5</td>
601. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
602. </tr>
603. <tr>
604. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5</td>
605. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Thiostrepton (RSO-021): RS Oncology</td>
606. </tr>
607. <tr>
608. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5.1</td>
609. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
610. </tr>
611. <tr>
612. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5.2</td>
613. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
614. </tr>
615. <tr>
616. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5.3</td>
617. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
618. </tr>
619. <tr>
620. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5.4</td>
621. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
622. </tr>
623. <tr>
624. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.5.5</td>
625. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
626. </tr>
627. <tr>
628. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6</td>
629. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Galinpepimut-S: Sellas Life Sciences Group</td>
630. </tr>
631. <tr>
632. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6.1</td>
633. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
634. </tr>
635. <tr>
636. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6.2</td>
637. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
638. </tr>
639. <tr>
640. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6.3</td>
641. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
642. </tr>
643. <tr>
644. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6.4</td>
645. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
646. </tr>
647. <tr>
648. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.6.5</td>
649. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
650. </tr>
651. <tr>
652. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7</td>
653. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">CTX131: CRISPR Therapeutics AG</td>
654. </tr>
655. <tr>
656. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7.1</td>
657. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
658. </tr>
659. <tr>
660. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7.2</td>
661. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
662. </tr>
663. <tr>
664. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7.3</td>
665. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
666. </tr>
667. <tr>
668. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7.4</td>
669. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
670. </tr>
671. <tr>
672. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.7.5</td>
673. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
674. </tr>
675. <tr>
676. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8</td>
677. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">VT3888: Vivace Therapeutics</td>
678. </tr>
679. <tr>
680. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8.1</td>
681. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
682. </tr>
683. <tr>
684. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8.2</td>
685. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
686. </tr>
687. <tr>
688. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8.3</td>
689. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
690. </tr>
691. <tr>
692. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8.4</td>
693. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
694. </tr>
695. <tr>
696. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.8.5</td>
697. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
698. </tr>
699. <tr>
700. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9</td>
701. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">NUC-3373 (Fosifloxuridine Nafalbenamide): NuCana plc</td>
702. </tr>
703. <tr>
704. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9.1</td>
705. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
706. </tr>
707. <tr>
708. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9.2</td>
709. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
710. </tr>
711. <tr>
712. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9.3</td>
713. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
714. </tr>
715. <tr>
716. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9.4</td>
717. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
718. </tr>
719. <tr>
720. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.9.5</td>
721. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
722. </tr>
723. <tr>
724. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10</td>
725. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">A2B694: A2 Biotherapeutics</td>
726. </tr>
727. <tr>
728. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10.1</td>
729. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
730. </tr>
731. <tr>
732. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10.2</td>
733. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
734. </tr>
735. <tr>
736. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10.3</td>
737. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
738. </tr>
739. <tr>
740. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10.4</td>
741. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
742. </tr>
743. <tr>
744. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.10.5</td>
745. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
746. </tr>
747. <tr>
748. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11</td>
749. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">TNG462: Tango Therapeutics</td>
750. </tr>
751. <tr>
752. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11.1</td>
753. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Drug Description</td>
754. </tr>
755. <tr>
756. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11.2</td>
757. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Other Developmental Activities</td>
758. </tr>
759. <tr>
760. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11.3</td>
761. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Clinical Trials Information</td>
762. </tr>
763. <tr>
764. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11.4</td>
765. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Safety and Efficacy</td>
766. </tr>
767. <tr>
768. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">11.11.5</td>
769. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analysts’ Views</td>
770. </tr>
771. <tr>
772. <td colspan="2" style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><i>To be continued in the report…</i></td>
773. </tr>
774. <tr>
775. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12</td>
776. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">MPM</td>
777. </tr>
778. <tr>
779. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.1</td>
780. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Findings</td>
781. </tr>
782. <tr>
783. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.2</td>
784. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Outlook</td>
785. </tr>
786. <tr>
787. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.3</td>
788. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Attribute Analysis</td>
789. </tr>
790. <tr>
791. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.4</td>
792. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Market Forecast Assumptions</td>
793. </tr>
794. <tr>
795. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.4.1</td>
796. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Cost Assumptions and Rebates</td>
797. </tr>
798. <tr>
799. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.4.2</td>
800. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Pricing Trends</td>
801. </tr>
802. <tr>
803. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.4.3</td>
804. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Analogue Assessment</td>
805. </tr>
806. <tr>
807. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.4.4</td>
808. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Launch Year and Therapy Uptake</td>
809. </tr>
810. <tr>
811. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.5</td>
812. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Market Size of MPM in the 7MM</td>
813. </tr>
814. <tr>
815. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.6</td>
816. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM by Therapies in the 7MM</td>
817. </tr>
818. <tr>
819. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.7</td>
820. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM in the United States</td>
821. </tr>
822. <tr>
823. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.7.1</td>
824. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Market Size of MPM</td>
825. </tr>
826. <tr>
827. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.7.2</td>
828. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM by Therapies in the United States</td>
829. </tr>
830. <tr>
831. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.8</td>
832. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM in EU4 and the UK</td>
833. </tr>
834. <tr>
835. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.8.1</td>
836. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Market Size of MPM</td>
837. </tr>
838. <tr>
839. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.8.2</td>
840. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM by Therapies in EU4 and the UK</td>
841. </tr>
842. <tr>
843. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.9</td>
844. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM in Japan</td>
845. </tr>
846. <tr>
847. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.9.1</td>
848. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Total Market Size of MPM</td>
849. </tr>
850. <tr>
851. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">12.9.2</td>
852. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Size of MPM by Therapies in Japan</td>
853. </tr>
854. <tr>
855. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">13</td>
856. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Key Opinion Leaders’ Views</td>
857. </tr>
858. <tr>
859. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">14</td>
860. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Unmet Needs</td>
861. </tr>
862. <tr>
863. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">15</td>
864. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">SWOT Analysis</td>
865. </tr>
866. <tr>
867. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16</td>
868. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Market Access and Reimbursement</td>
869. </tr>
870. <tr>
871. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.1</td>
872. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">The United States</td>
873. </tr>
874. <tr>
875. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.1.1</td>
876. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">CMS</td>
877. </tr>
878. <tr>
879. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2</td>
880. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">In EU4 and the UK</td>
881. </tr>
882. <tr>
883. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2.1</td>
884. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Germany</td>
885. </tr>
886. <tr>
887. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2.2</td>
888. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">France</td>
889. </tr>
890. <tr>
891. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2.3</td>
892. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Italy</td>
893. </tr>
894. <tr>
895. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2.4</td>
896. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Spain</td>
897. </tr>
898. <tr>
899. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.2.5</td>
900. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">The United Kingdom</td>
901. </tr>
902. <tr>
903. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.3</td>
904. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Japan</td>
905. </tr>
906. <tr>
907. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">16.3.1</td>
908. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">MHLW</td>
909. </tr>
910. <tr>
911. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">17</td>
912. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Appendix</td>
913. </tr>
914. <tr>
915. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">17.1</td>
916. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Acronyms and Abbreviations</td>
917. </tr>
918. <tr>
919. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">17.2</td>
920. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Bibliography</td>
921. </tr>
922. <tr>
923. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">17.3</td>
924. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Report Methodology</td>
925. </tr>
926. <tr>
927. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">18</td>
928. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">DelveInsight Capabilities</td>
929. </tr>
930. <tr>
931. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">19</td>
932. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Disclaimer</td>
933. </tr>
934. <tr>
935. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">20</td>
936. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">About DelveInsight</td>
937. </tr>
938. </table>
939. <p align="justify"><b>Related Reports</b></p>
940. <p align="justify"><b>Malignant Pleural Mesothelioma Pipeline</b></p>
941. <p align="justify"><b>Malignant Pleural Mesothelioma Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant pleural mesothelioma companies, including <b>MolMed, PharmaMar, Ys Therapeutics, Merck Sharp &amp; Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Novartis, Bristol-Myers Squibb, Novartis, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, </b>among others.</p>
942. <p align="justify"><b>Malignant Pleural Mesothelioma Epidemiology Forecast</b></p>
943. <p align="justify"><b>Malignant Pleural Mesothelioma Epidemiology Forecast – 2034</b> report delivers an in-depth understanding of the disease, historical and forecasted malignant pleural mesothelioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.</p>
944. <p align="justify"><b>Mesothelioma Market</b></p>
945. <p align="justify"><b>Mesothelioma Market Insights, Epidemiology, and Market Forecast – 2034 </b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mesothelioma companies including <b>Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc, VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp &amp; Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, Ascentage Pharma Group Inc., 7 Hills Pharma, LLC,</b> among others.</p>
946. <p align="justify"><b>Mesothelioma Pipeline</b></p>
947. <p align="justify"><b>Mesothelioma Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mesothelioma companies, including <b>Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc, VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp &amp; Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, Ascentage Pharma Group Inc., 7 Hills Pharma, LLC, </b>among others.</p>
948. <p align="justify"><b>Malignant Mesothelioma Pipeline</b></p>
949. <p align="justify"><b>Malignant Mesothelioma Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant mesothelioma companies, including <b>Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, </b>among others.</p>
950. <p align="justify"><b>DelveInsight’s</b><b> Pharma Competitive Intelligence Service</b><b>: </b>Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.</p>
951. <p align="justify"><b>Other Business Consulting Services</b></p>
952. <p align="justify"><b>Healthcare Conference Coverage</b></p>
953. <p align="justify"><b>Pipeline Assessment</b></p>
954. <p align="justify"><b>Healthcare Licensing Services</b></p>
955. <p align="justify">Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our <b>Due Diligence Case Study</b></p>
956. <p align="justify"><b>About DelveInsight</b></p>
957. <p align="justify">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve<b>.</b></p>
958. <p align="justify"><b>Connect with us on</b> <b>LinkedIn</b><b>|</b><b>Facebook</b><b>|</b><b>Twitter</b></p>
959. <pre>CONTACT: Contact Us Shruti Thakur  info@delveinsight.com  +14699457679  www.delveinsight.com</pre>
960. <p><img alt="" src='https://ml.globenewswire.com/media/ODljZjMyNTItN2ZiYy00MWNhLTkzZjYtZjI3NWNiOTBjMWU4LTEyMDQ5MzgtMjAyNS0wNC0yMS1lbg==/tiny/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
961. <p>The post <a rel="nofollow" href="https://dailyindianews.com/malignant-pleural-mesothelioma-market-poised-for-growth-across-the-7mm-during-the-study-period-2020-2034-amid-advances-in-immunotherapy-and-targeted-drugs-delveinsight/2025/373784/">Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
962. ]]></content:encoded>
966. </item>
967. <item>
968. <title>Dechlorination Chemical Market Size to Lead USD 20.58 Bn by 2034, says Towards chem and Materials Consultants</title>
969. <link>https://dailyindianews.com/dechlorination-chemical-market-size-to-lead-usd-20-58-bn-by-2034-says-towards-chem-and-materials-consultants/2025/373785/</link>
971. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
972. <pubDate>Mon, 21 Apr 2025 16:16:00 +0000</pubDate>
973. <category><![CDATA[Brand Post]]></category>
974. <guid isPermaLink="false">https://dailyindianews.com/dechlorination-chemical-market-size-to-lead-usd-20-58-bn-by-2034-says-towards-chem-and-materials-consultants</guid>
975.  
976. <description><![CDATA[<p>The global dechlorination chemical market size stood at USD 14.66 billion in 2024 and is predicted to exceed USD 20.58 billion by 2034, experiencing a CAGR of 3.45% from 2024 to 2034. Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; According to a new report, the global dechlorination chemical market size to record USD 15.17 billion [&#8230;]</p>
977. <p>The post <a rel="nofollow" href="https://dailyindianews.com/dechlorination-chemical-market-size-to-lead-usd-20-58-bn-by-2034-says-towards-chem-and-materials-consultants/2025/373785/">Dechlorination Chemical Market Size to Lead USD 20.58 Bn by 2034, says Towards chem and Materials Consultants</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
978. ]]></description>
979. <content:encoded><![CDATA[<p><em>The global dechlorination chemical market size stood at USD 14.66 billion in 2024 and is predicted to exceed USD 20.58 billion by 2034, experiencing a CAGR of 3.45% from 2024 to 2034.</em></p>
980. <p>Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; According to a new report, the global <strong><u>dechlorination chemical market</u></strong> size to record USD 15.17 billion in 2025 and is projected to grow beyond USD 20.58 billion by 2034, a study published by Towards chem and Materials a sister firm of Precedence Research. The dechlorination chemical market focuses on chlorine from water, especially in municipal industrial, and environmental applications. With increasing awareness around environmental safety and water conservation, these chemicals play a pivotal role in ensuring water quality across sectors.</p>
981. <p><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=4bfd9118-d2e0-4c84-ba58-e2c9ff66aece&amp;size=3" data-mce-style="display: block; margin-left: auto; margin-right: auto;" height="319.35px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/4bfd9118-d2e0-4c84-ba58-e2c9ff66aece/image1.png" style="display:block; margin-left:auto; margin-right:auto;" width="567.72px" /></p>
982. <p><strong>Get All the Details in Our Solutions – Download Brochure: </strong><strong><u>https://www.towardschemandmaterials.com/download-brochure/5510</u></strong></p>
983. <p><strong>Market overview</strong></p>
984. <p>The global dechorination chemical market is witnessing significant growth, driven by the rising demand for effective water treatment solutions. The presence of chlorine in treated water, while beneficial for disinfection, poses risks if not properly managed before distribution or discharge into the environment.</p>
985. <p>Dechlorination chemicals like sodium bisulfite, sodium metabisulfite, activated carbon, and ascorbic acid are widely used in <strong><u>wastewater treatment plants</u></strong>, industrial discharge processes, power generation facilities, and aquaculture systems. Furthermore, the tightening of environmental regulations and emphasis on sustainable water usage are key drivers accelerating the adoption of dichlorination solutions globally.</p>
986. <p><strong>Key Consumption Data of Dichlorination Chemicals:</strong></p>
987. <ul type="square">
988. <li style="margin-bottom:8pt;">In 2023, an estimated 78% of large-scale municipal water treatment facilities in India used sodium bisulfite or sodium thiosulfate as a primary dechlorination agent before discharging treated effluent into natural water bodies.</li>
989. <li style="margin-bottom:8pt;">According to CPCB data, over 4,500 registered industrial units in sectors like textiles, pulp &amp; paper, and power generation in India were required to neutralize residual chlorine in effluent streams under Environmental Protection Rules (Schedule VI).</li>
990. <li style="margin-bottom:8pt;">The Bureau of Indian Standards (BIS) limits free residual chlorine in treated wastewater discharge to 0.2 mg/L. Plants exceeding this level are mandated to use dechlorination chemicals, particularly before release into Class I and II surface water bodie</li>
991. <li style="margin-bottom:8pt;">Approximately 55% of urban swimming pool operators in Tier 1 cities in India now use ascorbic acid or sodium metabisulfite to dechlorinate pool water during monthly maintenance cycles to avoid skin and eye irritation complaints.</li>
992. </ul>
993. <p><strong>Dechlorination Chemical Market Key Trends: </strong></p>
994. <ul type="disc">
995. <li style="margin-bottom:8pt;"><strong>Eco-friendly solutions: </strong>A growing shift towards biodegradable and less toxic dechlorination agent is shaping the market. Industries are favouring green chemicals that meet environmental compliance standards.</li>
996. <li style="margin-bottom:8pt;"><strong>Automation in Water Treatment</strong>: Integration of smart sensors and real-time monitoring systems in water treatment facilities is enhancing the precision and efficiency of dechlorination processes.</li>
997. <li style="margin-bottom:8pt;"><strong>Expansion of Municipal Water Projects</strong>: Rapid urbanisation and the need for clean water in developing countries have led to the expansion of municipal water treatment projects, boosting demand for dechlorination chemicals.</li>
998. <li style="margin-bottom:8pt;"><strong>Industrial Compliance</strong>: Industries such as food &amp; beverage, <strong><u>pharmaceuticals</u></strong>, and textiles are increasingly aligning their wastewater treatment processes with global discharge standards, driving chemical usage.</li>
999. </ul>
1000. <p><strong>Immediate Delivery Available | Buy This Premium Report @ </strong><strong><u>https://www.towardschemandmaterials.com/price/5510</u></strong></p>
1001. <p><strong>Limitations and challenges in Dechlorination Chemical Market</strong></p>
1002. <ul type="disc">
1003. <li style="margin-bottom:8pt;"><strong>Health and Safety Concerns: </strong>Improper handling of some dechlorination chemicals can pose health hazards to workers and the environment.</li>
1004. <li style="margin-bottom:8pt;"><strong>Cost Sensitivity: </strong>The cost of alternative eco-friendly chemicals can be high, particularly for small-scale industries.</li>
1005. <li style="margin-bottom:8pt;"><strong>Regulatory Barriers</strong>: Stringent and region-specific regulations make it difficult for global manufacturers to standardise products across markets.</li>
1006. <li style="margin-bottom:8pt;"><strong>Storage and Transportation: </strong>Dechlorination agents, especially in liquid form, require specialised storage and transport infrastructure to maintain efficacy and safety.</li>
1007. </ul>
1008. <p><strong>You can place an order or ask any questions, please feel free to contact at </strong><strong><u>sales@towardschemandmaterials.com</u></strong><strong>| +1 804 441 9344</strong></p>
1009. <p><strong>Dechlorination Chemical Market Rising Tides of Innovation</strong></p>
1010. <p>The dechlorination chemical market is undergoing a significant transformation, fueled by a confluence of technological advancements, environmental consciousness, and regulatory evolution. As governments and industries shift their focus toward sustainable water management, the demand for safer and more efficient dechlorination chemicals is accelerating. Manufacturers are investing in research and development to create chemicals that are not only more effective in removing chlorine and chloramine residues but also eco-friendly and biodegradable. There is a growing trend towards using natural dechlorinates such as vitamin C derivatives, which are safer for aquatic life and require no neutralization. The market is witnessing a technological leap with the integration of IoT, automation, and real-time monitoring tools in dechlorination systems. These tools help industries and municipalities maintain optimal chemical dosing, minimise waste, and ensure consistent water quality.</p>
1011. <p>Additionally, Companies are establishing local manufacturing units in emerging markets to meet regional demand efficiently and reduce supply chain dependencies. This localization also allows for customization of solutions as per regional water treatment needs and regulatory standards. In essence, the development of the dechlorination chemical market is not just a response to environmental mandates but a proactive shift toward future-ready, sustainable, and intelligent water treatment solutions. With continued innovation and global collaboration, the market is poised for robust and responsible growth.</p>
1012. <p><strong>Regional Analysis:</strong></p>
1013. <p><strong>How Asia Pacific is Leading the Charge in Dichlorination Market?</strong></p>
1014. <p>Asia-pacific dominated the market in 2024, due to owing to rapid industrialization, urbanization, and increased focus on water infrastructure development in countries like China, India, Japan, South Korea, and Indonesia. Massive investments in <strong>municipal water systems</strong>, along with growing environmental awareness, have strengthened the region&#8217;s demand for dechlorination solutions.</p>
1015. <p><strong>Top Contributing Asia-Pacific Countries:</strong></p>
1016. <ul type="disc">
1017. <li style="margin-bottom:8pt;"><strong>China: </strong>Industrial growth &amp; large-scale municipal projects<strong>. </strong></li>
1018. <li style="margin-bottom:8pt;"><strong>India: </strong>Increasing government investment in wastewater recycling and clean water missions.</li>
1019. <li style="margin-bottom:8pt;"><strong>Japan: </strong>Technological advancements and strict regulations.</li>
1020. <li style="margin-bottom:8pt;"><strong>South Korea: </strong>Strong environmental policies and industrial water management.</li>
1021. <li style="margin-bottom:8pt;"><strong>Indonesia: </strong>Urbanization and growing aquaculture industry.</li>
1022. </ul>
1023. <p><strong>Why North America is Considered Fastest Growing?</strong></p>
1024. <p>North America is emerging as the fastest-growing region, mainly due to increasing regulatory pressure, advanced infrastructure, and the replacement of outdated systems. The United States and Canada are investing heavily in smart water management systems, including real-time monitoring and automated dosing technologies.</p>
1025. <p><strong>Major Factors Contributing:</strong></p>
1026. <ul type="disc">
1027. <li style="margin-bottom:8pt;">Stringent EPA regulations on chlorine discharge.</li>
1028. <li style="margin-bottom:8pt;">Technological innovation in water treatment equipment.</li>
1029. <li style="margin-bottom:8pt;">Sustainability goals driving chemical upgrades in industries.</li>
1030. <li style="margin-bottom:8pt;">High adoption of green chemicals in municipal and private sectors.</li>
1031. <li style="margin-bottom:8pt;">Public health initiatives encouraging safer water treatment methods</li>
1032. </ul>
1033. <p><strong>Join now to access the latest chemicals and materials in industry segmentation insights with our Annual Membership: </strong><strong><u>https://www.towardschemandmaterials.com/get-an-annual-membership</u></strong></p>
1034. <p><strong>Segment Outlook</strong></p>
1035. <p><strong>By application </strong></p>
1036. <p>Water treatment is dominating the market, due to rising urbanization and industrialization, water treatment facilities are under increasing pressure to provide safe, potable water. Chlorination agents, particularly sodium thiosulphate and sodium bisulfite, are widely deployed across municipal treatment plants, industrial water systems, and power plants. According to recent studies, more than 60% of global dechlorination of chemicals consumption is attributed to water treatment plants.</p>
1037. <p>On the other hand, Industries processes are attributed to grow in the market in its forecasting year. Due to water scarcity and sustainability goals are driving innovations in water reuse systems. Advanced filtration systems combined with chemical dechlorination enable the recycling of greywater and industrial effluents. The segment is expected to grow in coming years. Especially in the region of middle east, South east and drought prone areas of the U.S.</p>
1038. <p><strong>By chemical </strong></p>
1039. <p>Sodium Thiosulphate dominating the market, as it is Valued for its affordability and compatibility across applications, sodium thiosulphate commands over 40<strong>%</strong> of the market share. It effectively neutralizes both chlorine and chloramines and is frequently used in laboratory analysis, aquaculture, and municipal water dichlorination. The chemical’s non-toxic nature and minimal impact on pH balance make it a preferred choice globally.</p>
1040. <p>However, Sodium Bisulfite is attributed to grow in the market in its forecasting year. Due to its efficiency in reducing chlorine in high-pressure systems and its rapid neutralization capabilities. With the rise in food and beverage production and pharmaceutical industries requiring ultra-pure water, the demand for low-residual dechlorination solutions is pushing this segment forward. It is also increasingly used in closed-loop cooling systems and boiler water treatment.</p>
1041. <p><strong>By Form</strong></p>
1042. <p>Liquid segment dominating the market, due to their widespread use in automated dosing systems in industrial and municipal setups. Their ready-to-use nature ensures consistent results in large-scale operations, and their ability to mix seamlessly with other treatment chemicals streamlines the purification process. This segment accounts for more than <strong>65%</strong> of the total market share.</p>
1043. <p>Meanwhile, powder forms are becoming popular in disaster relief operations, portable water purification kits, and remote area installations where transporting liquid chemicals is impractical. Their light weight, long shelf life, and ease of measurement support growing adoption in mobile water treatment units and emergency infrastructure.</p>
1044. <p><strong>By end-user </strong></p>
1045. <p>Municipal water segment dominating the market, due to consistent demand, policy-driven regulations, and public health mandates. Large cities globally are upgrading ageing infrastructure and expanding treatment capacity, particularly in India, China, the US, and Brazil. In some regions, such as the EU, adherence to the Urban Waste Water Treatment Directive mandates the use of safe dechlorination chemicals before water is discharged into the environment.</p>
1046. <p>On the other hand, industrial sector is attributed to grow in the market in its forecasting year. Due to Zero liquid discharge (ZLD) systems, green factory certifications, and carbon neutrality goals are fueling the rapid uptake of high-efficiency dechlorination chemicals. Countries like South Korea, Japan, and Germany are leading in adopting such standards</p>
1047. <p><strong>Browse More Insights of Towards Chem and Materials:</strong></p>
1048. <ul type="disc">
1049. <li><strong>Specialty Chemicals Market : </strong>The global <strong><u>specialty chemicals market</u></strong> size was USD 671.19 billion in 2024 and is projected to grow from USD 706.36 billion in 2025 to USD 1,118.55 billion by 2034, exhibiting a CAGR of 5.24% during the forecast period.</li>
1050. <li><strong>Petrochemical Market  : </strong>The global <strong><u>petrochemical market</u></strong> size was reached at USD 657.45 billion in 2024 and is estimated to surpass around USD 1,336.24 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.35% during the forecast period 2025 to 2034.</li>
1051. <li><strong>Bio-Renewable Chemicals Market : </strong>The global <strong><u>bio-renewable chemicals market</u></strong> size was valued at USD 15.11 billion in 2024 and is growing to approximately USD 39.01 billion by 2034, with a developing compound annual growth rate (CAGR) of 9.95% over the forecast period 2025 to 2034.</li>
1052. <li><strong>Natural Aroma Chemicals Market : </strong>The global <strong><u>natural aroma chemicals market size</u></strong> was reached at USD 4.55 billion in 2024 and is estimated to surpass around USD 5.91 billion by 2034, growing at a compound annual growth rate (CAGR) of 2.65% during the forecast period 2025 to 2034.</li>
1053. <li><strong>Biochemical Market : </strong>The global <strong><u>biochemical market</u></strong> size was valued at USD 80.35 billion in 2024 and is predicted to increase from USD 88.89 billion in 2025 to approximately USD 220.66 billion by 2034, expanding at a CAGR of 10.63% from 2025 to 2034.</li>
1054. </ul>
1055. <p><strong>Frequently Asked Questions About This Report</strong></p>
1056. <p><strong>What are the key factors driving the demand for Dechlorination Chemicals?</strong></p>
1057. <ul type="disc">
1058. <li>The increasing need for clean water, stringent environmental regulations, and industrial expansion are major factors driving the demand for dechlorination chemicals. Industries such as municipal water treatment, food and beverage, and pharmaceuticals require effective solutions to remove chlorine from water to meet safety and compliance standards.</li>
1059. </ul>
1060. <p><strong>Which industries benefit the most from using Dechlorination Chemicals?</strong></p>
1061. <ul type="disc">
1062. <li>Industries that rely on high-purity water, such as municipal water treatment, food and beverage production, textiles, and pharmaceuticals, benefit significantly from dechlorination chemicals. These solutions ensure water quality, prevent contamination, and comply with regulatory requirements.</li>
1063. </ul>
1064. <p><strong>What are the different types of Dechlorination Chemicals available?</strong></p>
1065. <ul type="disc">
1066. <li>Dechlorination chemicals are primarily classified into sulfur-based chemicals such as sodium metabisulfite, sodium sulfite, and sodium bisulfite, as well as activated carbon-based solutions. Each type is used based on specific application requirements, efficiency, and environmental considerations.</li>
1067. </ul>
1068. <p><strong>How do government regulations impact the use of Dechlorination Chemicals?</strong></p>
1069. <ul type="disc">
1070. <li>Governments worldwide enforce strict water quality and environmental regulations, which influence the adoption of dechlorination solutions. Compliance with wastewater discharge limits and sustainability initiatives is pushing industries toward adopting advanced and eco-friendly dechlorination technologies.</li>
1071. </ul>
1072. <p><strong>What are the emerging trends in Dechlorination technology?</strong></p>
1073. <ul type="disc">
1074. <li>The shift toward environmentally friendly solutions, automation in water treatment processes, and the development of high-efficiency, low-toxicity dechlorination chemicals are key trends shaping the industry. Innovations in monitoring systems and smart dosing technologies are also improving process efficiency and compliance.</li>
1075. </ul>
1076. <p><strong>Dechlorination Chemical Market Top Key Companies:</strong></p>
1077. <p><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=af705f5c-1137-4cda-b960-bfa891668ffc&amp;size=3" height="362.05px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/af705f5c-1137-4cda-b960-bfa891668ffc/image2.png" width="611.48px" /></p>
1078. <ul type="disc">
1079. <li style="margin-bottom:8pt;">BASF SE</li>
1080. <li style="margin-bottom:8pt;">Solvay</li>
1081. <li style="margin-bottom:8pt;">Albemarle Corporation</li>
1082. <li style="margin-bottom:8pt;">Dow Chemical</li>
1083. <li style="margin-bottom:8pt;">Merck Group</li>
1084. <li style="margin-bottom:8pt;">Huntsman Corporation</li>
1085. <li style="margin-bottom:8pt;">Olin Corporation</li>
1086. <li style="margin-bottom:8pt;">Aqua Chem</li>
1087. <li style="margin-bottom:8pt;">Tetra Tech</li>
1088. <li style="margin-bottom:8pt;">Severstal</li>
1089. <li style="margin-bottom:8pt;">Clariant</li>
1090. <li style="margin-bottom:8pt;">Evonic Industries</li>
1091. <li style="margin-bottom:8pt;">Arkema Group</li>
1092. <li style="margin-bottom:8pt;">Thermo Fisher Scientific</li>
1093. <li style="margin-bottom:8pt;">Evonik Industries</li>
1094. <li style="margin-bottom:8pt;">Ecolab</li>
1095. <li style="margin-bottom:8pt;">BWA Water Additives</li>
1096. <li style="margin-bottom:8pt;">Acuro Organics Limited</li>
1097. </ul>
1098. <p><strong>Recent Developments</strong></p>
1099. <ul type="disc">
1100. <li style="margin-bottom:8pt;">In April 2024, Airedale Group acquired Mccan Chemicals t0o facilitate its growth and diversification.</li>
1101. <li style="margin-bottom:8pt;">In September 2024, INEOS announced the acquisition of the Eastman Taxes city site from the Eastman Chemical company, aiming to enhance its production capabilities.</li>
1102. </ul>
1103. <p><strong>Segments Covered in the Report</strong></p>
1104. <p><strong>By Application </strong></p>
1105. <ul type="disc">
1106. <li style="margin-bottom:8pt;">Water Treatment</li>
1107. <li style="margin-bottom:8pt;">Industrial Processes</li>
1108. <li style="margin-bottom:8pt;">Pulp And Paper</li>
1109. </ul>
1110. <p><strong>By Chemical Type </strong></p>
1111. <ul type="disc">
1112. <li style="margin-bottom:8pt;">Sodium Thiosulfate</li>
1113. <li style="margin-bottom:8pt;">Sodium Bisulfite</li>
1114. <li style="margin-bottom:8pt;">Calcium Thiosulfate</li>
1115. <li style="margin-bottom:8pt;">Hydrosulfite</li>
1116. </ul>
1117. <p><strong>By Form </strong></p>
1118. <ul type="disc">
1119. <li style="margin-bottom:8pt;">Liquid</li>
1120. <li style="margin-bottom:8pt;">Powder</li>
1121. <li style="margin-bottom:8pt;">Granular</li>
1122. </ul>
1123. <p><strong>By End Use </strong></p>
1124. <ul type="disc">
1125. <li style="margin-bottom:8pt;">Municipal</li>
1126. <li style="margin-bottom:8pt;">Industrial</li>
1127. <li style="margin-bottom:8pt;">Agricultural</li>
1128. </ul>
1129. <p><strong>By Regional</strong></p>
1130. <ul type="disc">
1131. <li style="margin-bottom:8pt;">North America</li>
1132. <li style="margin-bottom:8pt;">Europe</li>
1133. <li style="margin-bottom:8pt;">Asia Pacific</li>
1134. <li style="margin-bottom:8pt;">Latin America</li>
1135. <li style="margin-bottom:8pt;">Middle East Africa</li>
1136. </ul>
1137. <p><strong>Immediate Delivery Available | Buy This Premium Research Report@ </strong><strong><u>https://www.towardschemandmaterials.com/price/5510</u></strong></p>
1138. <p><strong>About Us</strong></p>
1139. <p>Towards Chem and Materials is a leading global consulting firm specializing in providing comprehensive and strategic research solutions across the chemical and materials industries. With a highly skilled and experienced consultant team, we offer a wide range of services designed to empower businesses with valuable insights and actionable recommendations.</p>
1140. <p><strong>Our Trusted Data Partners</strong></p>
1141. <p><strong><u>Precedence Research</u></strong><strong> | </strong><strong><u>Statifacts</u></strong><strong> | </strong><strong><u>Towards Packaging</u></strong><strong> | </strong><strong><u>Towards Healthcare</u></strong><strong> | </strong><strong><u>Towards Food and Beverages</u></strong><strong> | </strong><strong><u>Towards Chem and Materials</u></strong><strong> | </strong><strong><u>Towards Consumer Goods</u></strong><strong> | </strong><strong><u>Nova One Advisor</u></strong><strong> | </strong></p>
1142. <p><strong>For Latest Update Follow Us: </strong><strong><u>https://www.linkedin.com/company/towards-chem-and-materials/</u></strong></p>
1143. <p><img alt="" src='https://ml.globenewswire.com/media/YmEwZTQwZTItNTY4OS00OTRiLWEzOTctM2YwMjhhOTk4N2JjLTEyMTM4NDktMjAyNS0wNC0yMS1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
1144. <p>The post <a rel="nofollow" href="https://dailyindianews.com/dechlorination-chemical-market-size-to-lead-usd-20-58-bn-by-2034-says-towards-chem-and-materials-consultants/2025/373785/">Dechlorination Chemical Market Size to Lead USD 20.58 Bn by 2034, says Towards chem and Materials Consultants</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1145. ]]></content:encoded>
1149. </item>
1150. <item>
1151. <title>Molecular Diagnostic Market Size to Record USD 542.97 Million By 2034 &#124; Statifacts</title>
1152. <link>https://dailyindianews.com/molecular-diagnostic-market-size-to-record-usd-542-97-million-by-2034-statifacts/2025/373786/</link>
1154. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
1155. <pubDate>Mon, 21 Apr 2025 15:10:00 +0000</pubDate>
1156. <category><![CDATA[Brand Post]]></category>
1157. <guid isPermaLink="false">https://dailyindianews.com/molecular-diagnostic-market-size-to-record-usd-542-97-million-by-2034-statifacts</guid>
1158.  
1159. <description><![CDATA[<p>The global molecular diagnostic market size is projected to increase from USD 368.53 million in 2025 and is estimated to be worth around USD 542.97 million by 2034, growing at a CAGR of 4.4 % from 2025 to 2034. A study published by Statifacts a sister firm of Precedence Research. Ottawa, April 21, 2025 (GLOBE [&#8230;]</p>
1160. <p>The post <a rel="nofollow" href="https://dailyindianews.com/molecular-diagnostic-market-size-to-record-usd-542-97-million-by-2034-statifacts/2025/373786/">Molecular Diagnostic Market Size to Record USD 542.97 Million By 2034 | Statifacts</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1161. ]]></description>
1162. <content:encoded><![CDATA[<p><em>The global molecular diagnostic market size is projected to increase from USD 368.53 million in 2025 and is estimated to be worth around USD 542.97 million by 2034, growing at a CAGR of 4.4 % from 2025 to 2034. A study published by Statifacts a sister firm of Precedence Research.</em></p>
1163. <p>Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; According to Statifacts, the global <strong>molecular diagnostic market size was valued</strong> at USD 353 million in 2024 and is expected to attain USD 542.97 million by 2034, expanding at a CAGR of 4.4% during the forecast period from 2025 to 2034. The molecular diagnostic market growth is driven by an increase in investment from government and private organizations for the development of many diagnostic service centers, advanced technologies in the healthcare sector, increasing awareness about early diagnosis, and the rising prevalence of infectious diseases like COVID-19, HIV, influenza, pneumonia, and hepatitis.</p>
1164. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=cc364e20-cebf-42ba-bc3b-50190c2fb67f&amp;size=3" height="313.97px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/cc364e20-cebf-42ba-bc3b-50190c2fb67f/image1.png" width="558.17px" /></p>
1165. <p><strong>Request a Sample Databook to Explore our Insights@ </strong><strong>https://www.statifacts.com/stats/databook-download/7761</strong></p>
1166. <p align="justify"><strong>Market Overview</strong></p>
1167. <p align="justify">Molecular diagnostics, also known as molecular pathology, involves taking DNA or RNA, the different genetic codes found in our cells, and analyzing the sequences for red flags that can pinpoint the potential emergence of a specific disease. In recent years, this field has expanded rapidly. The molecular diagnostic techniques that help to detect the presence of a pathogen in its early stage of infection are ELISA, <strong>Recombinant DNA technology</strong>, and <strong>Polymerase Chain Reaction</strong>.</p>
1168. <p align="justify">The molecular diagnostic market growth is accelerated due to it being the branch of clinical pathology or laboratory medicine that uses the techniques of molecular biology to monitor the effectiveness of therapies, select treatments, predict disease course, and diagnose disease. Molecular diagnostics help medical professionals evaluate disease genetic predisposition and allow them to create and implement precise diagnosis techniques and personalize treatment strategies.</p>
1169. <p align="justify">As compared to traditional diagnostic methods like ELISA, inhibition tests, hemagglutination, and microbial culture, an advanced microbial diagnostic method provides an enhanced choice for the diagnosis of infectious diseases. Next-generation sequencing technology helps medical professionals better understand their patients’ tumors, discover actionable biomarkers, and make the proper clinical decisions for their patients.</p>
1170. <ul type="disc">
1171. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In November 2023, Roche launched the next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges was launched by Roche.</li>
1172. </ul>
1173. <p align="justify"><strong>Molecular Diagnostic Market</strong><strong> Key Highlights</strong></p>
1174. <ul type="disc">
1175. <li style="margin-top:12pt; margin-bottom:12pt;">North America dominated the global market with the largest market share in 2024.</li>
1176. <li style="margin-top:12pt; margin-bottom:12pt;">Asia-Pacific is estimated to expand the fastest CAGR between 2025 and 2034.</li>
1177. <li style="margin-top:12pt; margin-bottom:12pt;">By product, the reagents and kits segment is estimated to hold the highest market in 2024.</li>
1178. <li style="margin-top:12pt; margin-bottom:12pt;">By product, the instruments segment is expected to expand at the fastest CAGR over the projected period 2025 to 2034.</li>
1179. <li style="margin-top:12pt; margin-bottom:12pt;">By technology, the polymerase chain reaction (PCR) segment contributed the highest market share in 2024</li>
1180. <li style="margin-top:12pt; margin-bottom:12pt;">By technology, the in situ hybridization (ISH) segment is expected to expand at the fastest CAGR over the projected period.</li>
1181. <li style="margin-top:12pt; margin-bottom:12pt;">By application, the infectious disease diagnostics segment has held the largest market share in 2024.</li>
1182. <li style="margin-top:12pt; margin-bottom:12pt;">By application, the oncology testing segment is observed to grow at a notable rate during the forecast period.</li>
1183. <li style="margin-top:12pt; margin-bottom:12pt;">By end-user, the hospitals and clinics segment accounted the highest market share in 2024.</li>
1184. <li style="margin-top:12pt; margin-bottom:12pt;">By end-user, the diagnostic laboratories segment is anticipated to grow at the fastest rate in the market from 2025 to 2034.</li>
1185. </ul>
1186. <p align="justify"><strong>Major Key Trends in the Molecular Diagnostic Market:</strong></p>
1187. <ul type="disc">
1188. <li style="margin-top:12pt; text-align:justify;"><strong>Increasing incidences of infectious diseases: </strong>By offering more powerful tools for more accurate and earlier detection of infectious diseases, molecular diagnostics show a true transformation whose positive clinical impact is continuously demonstrated for many infections with benefits including more accurate use of pathogen targets.</li>
1189. <li style="text-align:justify;"><strong>Rising number of R&amp;D initiatives: </strong>Innovation and technology are two essential catalysts in diagnostic product development. R&amp;D involves creative work begun on a systematic basis to develop knowledge that can be used to generate new technologies and innovations.</li>
1190. <li style="margin-bottom:12pt; text-align:justify;"><strong>Rising senior population: Diagnostic tests</strong> are important for senior citizens due to they play an important role in the health and well-being of seniors. Rapid diagnostics produce fast results, enabling timely medical interventions if essential.</li>
1191. </ul>
1192. <p><strong>Order the Premium Databook Today at the Discounted Rate of $1550! </strong><strong>https://www.statifacts.com/order-databook/7761</strong></p>
1193. <p align="justify"><strong>Limitations &amp; Challenges in the Molecular Diagnostic Market:</strong></p>
1194. <ul type="disc">
1195. <li style="margin-top:12pt; text-align:justify;"><strong>High cost of disease diagnostics: </strong>Unnecessary diagnostic tests can generate unnecessary equipment, labor, and reagent costs, which can lead to high healthcare costs. Diagnostic tests can be expensive due to kits tied to use only on instruments.</li>
1196. <li style="text-align:justify;"><strong>Lack of regulatory framework: </strong>Lack of regulatory framework disadvantages include leading to inefficiencies and can be burdensome, hindering competition &amp; innovation, discouraging potential new market entrants, and creating barriers to entry.</li>
1197. <li style="margin-bottom:12pt; text-align:justify;"><strong>Infrastructure limitations: </strong>Infrastructure limitations may include insufficient technical support, inadequate internet bandwidth, and outdated hardware, which can stifle the effective use of technology.</li>
1198. </ul>
1199. <p align="justify"><strong>Development of Molecular Diagnostic Platforms: Market’s Largest Potential</strong></p>
1200. <p>The field of molecular diagnosis significantly transformed, driven by technological advancements and enhanced human genetics understanding. Advancements in molecular diagnostics include Polymerase Chain Reaction (PCR) which needs a small amount of genetic material making it easier to detect the presence of pathogens like bacteria and viruses, Next-generation sequencing enables rapid DNA and RNA sequencing which provides information about genetic variation and mutations, and <strong>liquid biopsies</strong> include blood sampling or other body fluids to detect genetic material or cancer cells.</p>
1201. <ul type="disc">
1202. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In January 2025, the CRISPR gene editing and diagnostic laboratory was launched by Bengaluru-based biotechnology startup CrisprBits in Bengaluru.</li>
1203. <li style="margin-top:12pt; text-align:justify;">CrisprBits inaugurates CRISPR gene editing and diagnostics laboratory in Bengaluru – Express Healthcare</li>
1204. </ul>
1205. <p align="justify"><strong>Regional Analysis:</strong></p>
1206. <p align="justify"><strong>What Expect from Asian Countries till 2034?</strong></p>
1207. <p align="justify">Asia Pacific is projected to host the fastest-growing market in the coming years. The increasing funding for research and development (R&amp;D) in molecular diagnostics, government initiatives, innovations in molecular diagnostics, and the rising prevalence of cancer and infectious diseases are driving the growth of the molecular diagnostic market in the Asia Pacific region.</p>
1208. <p align="justify"><strong>Top Asian Countries for Molecular Diagnostics</strong></p>
1209. <p align="justify"><strong>India: </strong>In India, there are high-quality molecular diagnostics lab equipment machines with the best prices. India has also developed innovative technologies, such as AI-based molecular diagnostics tools and digital X-rays.</p>
1210. <ul type="disc">
1211. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Japan: </strong>The growing senior population in Japan and the integration of advanced technologies like real-time PCR and next-generation sequencing help the growth of the molecular diagnostic market in Japan.</li>
1212. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In August 2024, Hitachi and Gencurix expanded their cancer molecular diagnostics. Hitachi High-Tech Corporation, a Japanese firm, collaborated with Korea-based Gencurix, Inc.</li>
1213. </ul>
1214. <p align="justify"><strong>North America Held the Dominant Position: Technological Advancement to Support Growth</strong></p>
1215. <p>North America held a significant share of the molecular diagnostic market in 2024. Rising healthcare spending, advanced technologies in molecular diagnostics, advanced technologies in molecular diagnostics, and the rising prevalence of communicable and non-communicable disorders are driving the growth of the market.</p>
1216. <p align="justify"><strong>Major Factors for the Market’s Expansion in North America</strong></p>
1217. <ul type="disc">
1218. <li style="margin-top:12pt; text-align:justify;">In December 2024, a new molecular diagnostic test was launched by Labcorp for patients suspected of infection with the H5N1 virus.</li>
1219. <li style="margin-bottom:12pt; text-align:justify;">In May 2022, the U.S. launched its new, fully automated, high-throughput infectious disease molecular diagnostics platform, announced by a leading global medical technology company, BD (Becton, Dickinson, and Company).</li>
1220. </ul>
1221. <p><strong>Molecular Diagnostic Market Scope</strong></p>
1222. <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;">
1223. <tr>
1224. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>Report Attribute</strong></td>
1225. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>Key Statistics</strong></td>
1226. </tr>
1227. <tr>
1228. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size in 2025</td>
1229. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">USD 368.53 Million</td>
1230. </tr>
1231. <tr>
1232. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size by 2034</td>
1233. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">USD 542.97 Million</td>
1234. </tr>
1235. <tr>
1236. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Growth Rate from 2025 to 2034</td>
1237. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">CAGR of 4.4%</td>
1238. </tr>
1239. <tr>
1240. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Base Year</td>
1241. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">2024</td>
1242. </tr>
1243. <tr>
1244. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Forecast Period</td>
1245. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">2025 to 2034</td>
1246. </tr>
1247. <tr>
1248. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Segments Covered</td>
1249. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By Product, By Technology, By Application, By End User, and By Region</td>
1250. </tr>
1251. <tr>
1252. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Regions Covered</td>
1253. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">North America, Europe, Asia-Pacific, Latin America, and Middle East &amp; Africa</td>
1254. </tr>
1255. </table>
1256. <p><strong>Product Insights</strong></p>
1257. <p><strong>The reagents and kits segment underwent notable growth in the molecular diagnostic market during 2024.</strong> The diagnostic reagents are used for testing many body functions like those in the liver and kidneys. The reagents test for biochemical markers that may indicate abnormal or normal functions.</p>
1258. <p><strong>The instruments segment will gain a significant share of the market over the studied period of 2025 to 2034.</strong> The instruments involved in molecular diagnostic labs generally include clinical chemistry analyzers, hematology analyzers, blotting systems, laminar airflow, water baths, pH meters, and DNA sequencers.</p>
1259. <p><strong>Technology Insights</strong></p>
1260. <p><strong>The polymerase chain reaction (PCR) segment captured a significant portion of the molecular diagnostic market in 2024.</strong> The PCR technique is used in molecular biology, which helps researchers clone and sequence genes for mutation detection. PCR testing benefits for infectious diseases include reducing healthcare costs, reducing unnecessary testing, and avoiding unnecessary antibiotics.</p>
1261. <p><strong>The in situ hybridization (ISH) segment is projected to expand rapidly in the market in the coming years.</strong> In situ hybridization (ISH) has benefits in that its reliability and sensitivity can be predicted from the nucleic acid sequence on which probes are designed. It detects total genome ploidy changes.</p>
1262. <p><strong>Application Insights</strong></p>
1263. <p><strong>The infectious disease diagnostics segment maintained a leading position in the molecular diagnostic market in 2024.</strong> Molecular diagnostics offer more powerful tools for more accurate and earlier infectious diseases. Its benefits include more precise use of pathogen target therapies, decreased unnecessary antibiotic use, reduced length of emergency department and hospital stays, and reduced total healthcare costs.</p>
1264. <p><strong>The oncology testing segment is set to experience the fastest rate of market growth from 2025 to 2034.</strong> There are many uses of molecular diagnostics in clinical <strong>oncology</strong>. Mutation analysis is now routinely used for hereditary cancer syndrome diagnosis. They can help to differentiate cancer from benign tumors and can also help identify the tissue type in which cancer originated. In September 2024, QIAcuity digital PCR platforms for clinical testing in oncology were launched by QIAGEN.</p>
1265. <p><strong>End-user Insights</strong></p>
1266. <p><strong>The hospitals and clinics segment held a sizeable share of the molecular diagnostics market.</strong> Hospitals and clinics are one of the biggest users of various medical tests for detecting diseases and following up on recovery. Hospitals routinely conduct a wide variety of diagnostic tests to ensure proper treatment management and prevention of the spread of infectious diseases. Hospitals still provide the bulk of healthcare treatment in most countries, leading to them leading this segment.</p>
1267. <p><strong>The diagnostic laboratories segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.</strong> Diagnostic laboratories are coming up rapidly in emerging economies, supplementing hospitals and clinics by helping perform molecular diagnostic tests. These labs are usually equipped with special infrastructure and state-of-the-art diagnostics protocols, allowing for the handling of testing accurately and efficiently. The continuous advancements in molecular diagnostic technologies have expanded the capabilities of diagnostic laboratories, enabling them to provide more comprehensive and precise testing services.</p>
1268. <p align="justify"><strong>Browse More Research Reports:</strong></p>
1269. <ul type="disc">
1270. <li style="margin-bottom:8pt;">The <strong>U.S. oncology molecular diagnostic market size</strong> accounted for USD 792 million in 2024 and is expected to exceed around USD 2,527 million by 2034, growing at a CAGR of 12.3% from 2025 to 2034.</li>
1271. <li style="margin-bottom:8pt;">The global <strong>point-of-care molecular diagnostics market size</strong> accounted for USD 8,670 million in 2024 and is predicted to touch around USD 12,710 million by 2034, growing at a CAGR of 3.9% from 2025 to 2034.</li>
1272. <li style="margin-bottom:8pt;">The global <strong>oncology companion diagnostic market size</strong> surpassed USD 5,204 million in 2024 and is predicted to reach around USD 12,095 million by 2034, registering a CAGR of 8.8% from 2025 to 2034.</li>
1273. <li style="margin-bottom:8pt;">The global <strong>hospital acquired infections diagnostics market size</strong> was estimated at USD 4,310 million in 2024 and is projected to be worth around USD 5,030 million by 2034, growing at a CAGR of 1.56% from 2025 to 2034.</li>
1274. <li style="margin-bottom:8pt;">The global <strong>next-generation in vitro diagnostics market size</strong> is calculated at USD 96 billion in 2024 and is predicted to reach around USD 163.98 billion by 2034, expanding at a CAGR of 5.5% from 2025 to 2034.</li>
1275. <li style="margin-bottom:8pt;">The <strong>U.S. artificial intelligence in diagnostics market size</strong> is calculated at USD 655 million in 2024 and is predicted to attain around USD 4,298.47 million by 2034, expanding at a CAGR of 20.7% from 2025 to 2034.</li>
1276. <li style="margin-bottom:8pt;">The <strong>U.S. tuberculosis diagnostics market size</strong> accounted for USD 594.53 million in 2024 and is expected to exceed around USD 1,025.21 million by 2034, growing at a CAGR of 5.6% from 2024 to 2034.</li>
1277. <li style="margin-bottom:8pt;">The <strong>U.S. in vitro diagnostics market size</strong> accounted for USD 41,440 million in 2024 and is predicted to touch around USD 72,140 million by 2034, growing at a CAGR of 5.7% from 2025 to 2034.</li>
1278. </ul>
1279. <p><strong>Order the Premium Databook Today at the Discounted Rate of $1550!</strong> <strong>https://www.statifacts.com/order-databook/7761</strong></p>
1280. <p align="justify"><strong>Recent Breakthroughs in the Global Molecular Diagnostic Market</strong>:</p>
1281. <ul type="disc">
1282. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In January 2025, the first<strong> oncology liquid biopsy products</strong> for research, a pan-cancer somatic mutation profiling panel called Northstar Select, was launched by Billion To One.</li>
1283. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In August 2024, the launch of two innovative diagnostic laboratories in Telangana were launched by Metropolis Healthcare Limited.</li>
1284. </ul>
1285. <p align="justify"><strong>Segments Covered in the Report</strong></p>
1286. <p align="justify"><strong>By Product</strong></p>
1287. <ul type="disc">
1288. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Reagents and Kits</li>
1289. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Instruments</li>
1290. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Service and Software</li>
1291. </ul>
1292. <p align="justify"><strong>By Technology</strong></p>
1293. <ul type="disc">
1294. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Polymerase Chain Reaction (PCR)</li>
1295. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Isothermal Nucleic Acid Amplification Technology (INNAT)</li>
1296. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">DNA Sequencing and Next-Generation Sequencing (NGS)</li>
1297. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">In Situ Hybridization (ISH)</li>
1298. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">DNA Microarrays</li>
1299. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Others</li>
1300. </ul>
1301. <p align="justify"><strong>By Application</strong></p>
1302. <ul type="disc">
1303. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Infectious Disease Diagnostics</li>
1304. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Oncology Testing</li>
1305. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Genetic Testing</li>
1306. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Others</li>
1307. </ul>
1308. <p align="justify"><strong>By End User</strong></p>
1309. <ul type="disc">
1310. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Diagnostic Laboratories</li>
1311. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Hospitals and Clinics</li>
1312. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Others</li>
1313. </ul>
1314. <p align="justify"><strong>By Region</strong></p>
1315. <ul type="disc">
1316. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">North America</li>
1317. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Europe</li>
1318. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Asia-Pacific</li>
1319. <li style="margin-top:5pt; margin-bottom:12pt; text-align:justify;">Latin America</li>
1320. <li style="margin-bottom:12pt; text-align:justify;">Middle East and Africa</li>
1321. </ul>
1322. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><strong>sales@statifacts.com</strong></p>
1323. <p>Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here &#8211;<strong> </strong><strong>https://www.statifacts.com/get-a-subscription</strong></p>
1324. <p><strong>Contact US</strong></p>
1325. <ul type="disc">
1326. <li style="margin-top:12pt; margin-bottom:5pt;"><strong>Ballindamm 22, 20095 Hamburg, Germany</strong></li>
1327. <li style="margin-top:12pt; margin-bottom:5pt;"><strong>Web: </strong><strong>https://www.statifacts.com/</strong></li>
1328. <li style="margin-top:12pt; margin-bottom:5pt;"><strong>Europe: </strong>+44 7383 092 044</li>
1329. </ul>
1330. <p><strong>About US</strong></p>
1331. <p>Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG.</p>
1332. <p align="justify"><strong>Our Trusted Data Partners:</strong></p>
1333. <p align="justify"><strong>Precedence Research</strong><strong> | </strong><strong>Towards Healthcare</strong><strong> | </strong><strong>Towards Packaging</strong><strong> | </strong><strong>Towards Automotive</strong><strong> | </strong><strong>Towards Food and Beverages</strong><strong> | </strong><strong>Towards Chemical and Materials</strong><strong> | </strong><strong>Towards Dental</strong><strong> | </strong><strong>Towards EV Solutions</strong><strong> | </strong><strong>Nova One Advisor</strong></p>
1334. <p><img alt="" src='https://ml.globenewswire.com/media/YTExZWE0ZmQtN2NjYi00MDI1LTk2MjYtNWFlNGE4YmM2NDdlLTEyMTM4NDktMjAyNS0wNC0yMS1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
1335. <p>The post <a rel="nofollow" href="https://dailyindianews.com/molecular-diagnostic-market-size-to-record-usd-542-97-million-by-2034-statifacts/2025/373786/">Molecular Diagnostic Market Size to Record USD 542.97 Million By 2034 | Statifacts</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1336. ]]></content:encoded>
1340. </item>
1341. <item>
1342. <title>Probiotic Food Market Size to Hit USD 377.20 Billion by 2034</title>
1343. <link>https://dailyindianews.com/probiotic-food-market-size-to-hit-usd-377-20-billion-by-2034/2025/373758/</link>
1345. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
1346. <pubDate>Mon, 21 Apr 2025 15:00:00 +0000</pubDate>
1347. <category><![CDATA[Brand Post]]></category>
1348. <guid isPermaLink="false">https://dailyindianews.com/probiotic-food-market-size-to-hit-usd-377-20-billion-by-2034</guid>
1349.  
1350. <description><![CDATA[<p>According to Towards FnB, the global probiotic food market size is anticipated to reach approximately USD 377.20 billion by 2034 and is projected to grow from USD 114.18 billion in 2025. The industry is expected to grow at a compound annual growth rate (CAGR) of 14.20% over the next decade. Ottawa, April 21, 2025 (GLOBE [&#8230;]</p>
1351. <p>The post <a rel="nofollow" href="https://dailyindianews.com/probiotic-food-market-size-to-hit-usd-377-20-billion-by-2034/2025/373758/">Probiotic Food Market Size to Hit USD 377.20 Billion by 2034</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1352. ]]></description>
1353. <content:encoded><![CDATA[<p><em>According to Towards FnB, the global probiotic food market size is anticipated to reach approximately USD 377.20 billion by 2034 and is projected to grow from USD 114.18 billion in 2025. The industry is expected to grow at a compound annual growth rate (CAGR) of 14.20% over the next decade.</em></p>
1354. <p>Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The global <strong>probiotic food market size</strong> was reached at USD 99.98 billion in 2024 and is projected to hit around USD 377.2 billion by 2034, expanding at a CAGR of 14.20 % during the forecast period from 2025 to 2034, a study published by Towards FnB a sister firm of Precedence Research.</p>
1355. <p>The growth of the probiotic food market is driven by growing consumer awareness regarding gut health, immune support, and preventive healthcare measures. A rise in demand for functional foods, along with innovations in probiotic strains and various product formats, is accelerating the growth of the market. Furthermore, the prevalence of lifestyle-related digestive issues is driving consumers to incorporate daily probiotics into their routines.</p>
1356. <p align="center"><img loading="lazy" decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=096edc27-85ba-4ff1-997a-04432461c797&amp;size=3" height="395" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/096edc27-85ba-4ff1-997a-04432461c797/image1.png" width="702" /></p>
1357. <p><strong>Explore All the Details in Our Solutions – Download the Brochure Now: </strong><strong>https://www.towardsfnb.com/download-brochure/5506</strong></p>
1358. <p><strong>Market Overview:</strong></p>
1359. <p>The global probiotic food sector is experiencing strong growth, spurred by heightened consumer consciousness about gut health, immunity, and general wellness. Probiotic foods, which are rich in live beneficial microorganisms, are increasingly regarded as <strong>functional foods</strong> that promote digestive well-being. This market includes a wide range of offerings, such as yogurts, fermented drinks, and fortified food items. Advances in food processing technology and the creation of new probiotic strains have broadened product selections to accommodate varying consumer tastes.</p>
1360. <p><strong><em>“Rise in health issues related to lifestyle choices and a greater focus on preventive healthcare have boosted the appetite for probiotic foods.”</em></strong></p>
1361. <p>“A 2022 WHO regional report noted a <strong>27% rise in non-communicable diseases (NCDs)</strong> such as diabetes and hypertension in South Asia over the past decade, further pushing dietary shifts toward <strong>functional foods like probiotics.”</strong></p>
1362. <p>The sector is also supported by growing investment in research and development to validate health claims and enhance product effectiveness. As consumers increasingly look for natural and health-enhancing food alternatives, the probiotic food market is set for continuous growth in several regions.</p>
1363. <p><strong>Probiotic Food Market Key Highlights:</strong></p>
1364. <ul type="disc">
1365. <li>Asia-Pacific led the probiotic food market with the highest share of 39% in 2024.</li>
1366. <li>North America is expected to grow at a significant rate in the market during the forecast period.</li>
1367. <li>By product, the probiotic food &amp; beverage segment registered the maximum market share of 62% in 2024.</li>
1368. <li>By product, the probiotic dietary supplements segment is expected to grow at the notable CAGR of 15% during the forecast period.</li>
1369. <li>By ingredient, the bacteria-based dominated the probiotic food market in 2024.</li>
1370. <li>By ingredient, yeast-based is expected to grow at the fastest rate in the market during the forecast period.</li>
1371. <li>By end use, the human segment contributed the largest market share in 2024.</li>
1372. <li>By end use, the animal segment is estimated to expand the fastest CAGR in the market during the forecast period.</li>
1373. <li>By distribution channel, the hypermarket/supermarket segment held the largest revenue share in 2024.</li>
1374. <li>By distribution channel, the online stores segment is the fastest-growing market during the forecast period.</li>
1375. </ul>
1376. <p><strong>Major Key Trends in Probiotic Food Market:</strong></p>
1377. <ul type="disc">
1378. <li><strong>Customized Probiotic Nutrition:</strong> Progress in microbiome studies is facilitating the creation of personalized probiotic formulations tailored to individual gut profiles. This customization improves effectiveness, addressing particular health requirements and fueling consumer interest in tailored probiotic options.</li>
1379. <li><strong>Growth of Functional Probiotic Foods and Drinks:</strong> Probiotics are being increasingly integrated into a variety of food and drink products, such as yogurts, kombucha, and enriched snacks. This trend satisfies consumer demand for accessible, health-focused choices in daily diets.</li>
1380. <li><strong>Focus on Clean Label and Plant-Based Products:</strong> Shoppers are looking for probiotic offerings containing natural ingredients without artificial additives. The emergence of plant-based probiotics, like dairy free yogurts and drinks, aligns with the clean label trend.</li>
1381. </ul>
1382. <p><strong>Limitations &amp; Challenges in Probiotic Food Market:</strong></p>
1383. <ul type="disc">
1384. <li><strong>Regulatory Challenges:</strong> Different international regulations regarding probiotic claims and labeling present obstacles for manufacturers, hindering product innovation and global market entry while necessitating considerable investment in research to validate health benefits.</li>
1385. <li><strong>Issues with Stability and Shelf Life:</strong> Probiotic strains are vulnerable to heat, moisture, and storage conditions, which can undermine product effectiveness over time. Maintaining viability until consumption remains a significant technical and logistical hurdle.</li>
1386. <li><strong>Elevated Production and R&amp;D Expenses:</strong> Creating effective, safe, and consumer-friendly probiotic products involves substantial R&amp;D, advanced processing, and rigorous quality assurance. These factors raise costs and restrict market entry for smaller companies and price-conscious consumers.</li>
1387. </ul>
1388. <p><strong>Future Opportunity in Probiotic Food Market</strong></p>
1389. <p>The greatest opportunity within the probiotic food market is found in enhancing product access and fostering innovation in developing regions, where awareness of gut health and functional foods is swiftly growing. With increasing disposable incomes and urbanization, consumers in Asia Pacific, Latin America, and Africa are becoming more receptive to health-centered products.</p>
1390. <p>Moreover, the incorporation of probiotics into everyday food items like cereals, snacks, and dairy substitutes presents significant potential for market expansion. As people pursue comprehensive wellness, opportunities also exist in targeting specific niches, such as prenatal health, nutrition for seniors, and immune support. Firms that invest in education, affordability, and the localized development of products can capitalize on this extensive opportunity.</p>
1391. <p><strong>Feel Free to Get in Touch with Us for Orders or Any Questions at: </strong><strong>sales@towardsfnb.com</strong></p>
1392. <p><strong>Probiotic Food Market Regional Analysis:</strong></p>
1393. <p><strong>Asia Pacific: Powerhouse of Probiotic Food- What to Expect from Asian Countries?</strong></p>
1394. <p>Asia Pacific dominated the probiotic food market with the largest market share due to its vast population, heightened health awareness, and a deep-rooted cultural affinity for fermented foods. Countries like China, Japan, South Korea, and India are seeing a significant increase in demand for probiotic-rich products such as yogurt, kefir, kimchi, and fermented drinks.</p>
1395. <ul type="square">
1396. <li>A 2023 study by the <strong>Indian Council of Medical Research (ICMR)</strong> found that nearly <strong>1 in 3 urban Indians</strong> reported <strong>chronic digestive issues</strong> such as bloating, constipation, or acid reflux—conditions often linked to poor dietary habits and sedentary lifestyles.</li>
1397. <li>In the same study, <strong>42% of respondents aged 25–45</strong> said they had <strong>increased their intake of fermented or probiotic foods</strong> over the past year as a <strong>preventive measure</strong> to improve gut health and immunity.</li>
1398. </ul>
1399. <p><strong>Top Asia Pacific Countries for Probiotic Food Production</strong></p>
1400. <ul type="disc">
1401. <li><strong>Japan:</strong> Japan significantly contributes to the Asia Pacific probiotic market because of a long-standing cultural acceptance of fermented foods and a high level of consumer awareness regarding the health benefits of probiotics.</li>
1402. <li><strong>China:</strong> China&#8217;s probiotic market is experiencing swift growth, spurred by rising disposable incomes, heightened health awareness, and a large population increasingly consuming probiotic-rich foods and supplements.</li>
1403. <li><strong>India:</strong> India&#8217;s probiotic market is on the rise, driven by increasing health consciousness, urban development, and a growing demand for functional foods, as consumers embrace probiotic products for improved digestive health.</li>
1404. </ul>
1405. <p>Factors like rapid urbanization, rising disposable incomes, and growing concerns about digestive health have boosted consumer interest in functional foods. The growth of organized retail and <strong>e-commerce</strong> platforms has also enhanced the accessibility of probiotic foods in the region. Additionally, ongoing innovation and governmental support for health-oriented dietary practices are further solidifying the region&#8217;s leadership.</p>
1406. <p><strong>North America’s Unstoppable growth in Probiotic Food</strong></p>
1407. <p>North America is the fastest growing market for the probiotic food market with a significant CAGR during the forecast period, propelled by a surge in health-conscious consumers who are becoming more aware of the benefits related to gut health and immunity. The area has seen a notable increase in the demand for functional foods, particularly among millennials and older demographics seeking preventive wellness alternatives. A growing interest in natural and <strong>organic food</strong> has boosted sales of probiotic-rich yogurts, kombucha, and <strong>dietary supplements</strong>.</p>
1408. <p><strong>Major Factors for the Market’s Expansion in North America:</strong></p>
1409. <ul type="disc">
1410. <li>Consumers are placing greater emphasis on digestive health and overall well-being, resulting in a spike in demand for probiotic-rich foods like yogurt and fermented beverages.</li>
1411. <li>The rise of online retail options has made probiotic products more accessible, enabling consumers to effortlessly buy a wide variety of options, thus enhancing market reach and increasing sales.</li>
1412. <li>Manufacturers are launching a range of diverse probiotic-infused products, including plant-based and functional beverages, which cater to various dietary preferences and broaden the consumer base.</li>
1413. </ul>
1414. <p>Furthermore, <strong>advancements in food technology</strong>, expanding retail availability, and strong marketing efforts by health-focused brands are enhancing market growth. Supportive clinical research and a favorable regulatory framework further establish North America as a crucial growth driver for the global probiotic food sector.</p>
1415. <p><strong>Book a Meeting with Towards FnB and Boost Your Food and Beverage Business: </strong><strong>https://www.towardsfnb.com/schedule-meeting</strong></p>
1416. <p><strong>Probiotic Food Market Report Scope</strong></p>
1417. <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;">
1418. <tr>
1419. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>Report Attribute</strong></td>
1420. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>Key Statistics</strong></td>
1421. </tr>
1422. <tr>
1423. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Base Year</td>
1424. <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: top ; ">2024</td>
1425. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: top ; "> </td>
1426. </tr>
1427. <tr>
1428. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Forecast Period</td>
1429. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">2025 to 2034</td>
1430. </tr>
1431. <tr>
1432. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">CAGR</td>
1433. <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: top ; ">14.20</td>
1434. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: top ; ">%</td>
1435. </tr>
1436. <tr>
1437. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size in 2024</td>
1438. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">USD 99.98 Billion</td>
1439. </tr>
1440. <tr>
1441. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size in 2025</td>
1442. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">USD 114.18 Billion</td>
1443. </tr>
1444. <tr>
1445. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Size by 2034</td>
1446. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">USD 377.20 Billion</td>
1447. </tr>
1448. <tr>
1449. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Dominated Region</td>
1450. <td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Asia-Pacific</td>
1451. </tr>
1452. </table>
1453. <p><strong>Probiotic Food Market Segment Analysis</strong></p>
1454. <p><strong>Product Analysis</strong></p>
1455. <p>The probiotic food and beverage segment dominated the market with the largest market share because of its general acceptance among consumers and its inclusion in daily diets. Items such as yogurt, kefir, kombucha, and fermented milk drinks are regarded as convenient sources of probiotics for supporting gut health. Effective marketing strategies, heightened availability in retail spaces, and ongoing innovation in flavors and formats play a significant role in the prominence and growing appeal of this segment among health-conscious individuals.</p>
1456. <p>The probiotic dietary supplements segment is the fastest growing segment with a notable CAGR during the forecast period, driven by increasing consumer demand for focused health solutions, particularly concerning digestion, immunity, and skin health. Available in formats like capsules, powders, and gummies, these supplements provide a concentrated dose of probiotics and are attractive to those seeking convenience and reliability. Heightened awareness of preventive healthcare and expanded research and development into specific probiotic strains for various health issues are propelling growth in this sector.</p>
1457. <p><strong>Ingredient Analysis</strong></p>
1458. <p>The bacteria segment dominated the market with the largest market share due to its long-established application in probiotic products and substantial evidence of health advantages. Strains such as Lactobacillus and Bifidobacterium are well-known for their effectiveness in enhancing digestive health and boosting immunity. Their compatibility with a variety of food and beverage applications and proven safety record have made them the top choice for manufacturers creating functional and fortified probiotic products.</p>
1459. <p>The yeast segment is the fastest growing segment with a significant CAGR during the forecast period, with Saccharomyces boulardii paving the way as an effective probiotic for digestive challenges and immune support. Yeast-based probiotics are gaining traction because of their resilience to antibiotics and extreme gastrointestinal conditions. Their growing application in dietary supplements, as well as emerging uses in pet nutrition and <strong>animal feed</strong>, is broadening their market prospects and driving substantial growth in this ingredient category.</p>
1460. <p><strong>End-Use Analysis</strong></p>
1461. <p>The human probiotics segment dominated the market with the largest market share, highlighting the increasing consumer focus on gut health, immunity, and general wellness. Products designed for adults, children, and the elderly are widely accessible in various formats, including beverages, capsules, and snacks. Rising health awareness, supportive clinical research, and the escalating demand for functional foods and supplements are propelling the segment&#8217;s dominance in both developed and emerging markets worldwide.</p>
1462. <p>The animal probiotics segment is the fastest growing segment with a notable CAGR during the forecast period, as livestock and pet owners recognize the benefits of probiotics in enhancing animal digestion, immune function, and overall performance. These products are being increasingly utilized in feed formulations for poultry, swine, cattle, and companion animals. As alternatives to antibiotics gain popularity and the pet food market expands, the demand for probiotic supplements and functional nutrition solutions for animals is anticipated to rise significantly in this sector.</p>
1463. <p><strong>Distribution Analysis</strong></p>
1464. <p>The hypermarkets and supermarkets segment dominated the market with the largest market share due to their wide reach, diverse product selections, and consumer confidence in these retail formats. These outlets provide a vast assortment of probiotic foods and supplements, frequently featuring well-known brands and promotions. Their established cold chain logistics guarantee product quality, while in-store visibility and convenience are key factors in drawing regular customers seeking probiotic items during their routine grocery shopping.</p>
1465. <p>The online stores segment is the fastest growing segment with a significant CAGR during the forecast period, as consumers increasingly favor the convenience of purchasing from home. E-commerce platforms provide a wide variety of probiotic products, including niche and international brands, often featuring customer reviews and subscription options. The rising digital literacy, smartphone usage, and direct-to-consumer models are enhancing the popularity of online platforms, especially among younger, tech-savvy, and health-conscious consumers in global markets.</p>
1466. <p><strong>Browse More Related Reports:</strong></p>
1467. <ul type="disc">
1468. <li>The global <strong>food fortifying agents market size</strong> is projected to witness strong growth from USD 109.69 billion in 2025 to USD 242.2 billion by 2034, reflecting a CAGR of 9.20% during the forecast period from 2025 to 2034.</li>
1469. <li>The global <strong>superfoods market size</strong> is expected to grow from USD 201.17 billion in 2025 to USD 288.82 billion by 2034, at a CAGR of 4.10% during the forecast period from 2025 to 2034.</li>
1470. <li>The global <strong>pet food market size</strong> is expected to increase from USD 113.02 billion in 2025 to USD 167.97 billion by 2034, growing at a CAGR of 4.50% throughout the estimated timeframe from 2025 to 2034.</li>
1471. <li>The global <strong>ethnic food market size</strong> is forecasted to expand from USD 93.47 billion in 2025 to USD 179.21 billion by 2034, growing at a CAGR of 7.50% during the forecast period from 2025 to 2034.</li>
1472. <li>The global <strong>snack food market size</strong> is expected to increase from USD 265.95 billion in 2025 to USD 468.76 billion by 2034, growing at a CAGR of 6.50% throughout the forecast period from 2025 to 2034</li>
1473. <li>The global <strong>vegan food market size</strong> is anticipated to grow from USD 22.38 billion in 2025 to USD 55.88 billion by 2034, with a CAGR of 10.7% during the forecast period from 2025 to 2034.</li>
1474. <li>The global <strong>sugar-free food market size</strong> is expected to grow from USD 48.14 billion in 2025 to USD 83.2 billion by 2034, growing at a CAGR of 6.27% from 2025 to 2034.</li>
1475. </ul>
1476. <p><strong>Probiotic Food Market Top Companies:</strong></p>
1477. <ul type="disc">
1478. <li>Nestle</li>
1479. <li>Danone</li>
1480. <li>Yakult Honsha Co., Ltd.</li>
1481. <li>BioGaia</li>
1482. <li>Arla Foods</li>
1483. <li>Chr. Hansen Holding A/S</li>
1484. <li>Probi</li>
1485. <li>ADM</li>
1486. <li>International Flavors &amp; Fragrances Inc.</li>
1487. <li>MORINAGA MILK INDUSTRY CO., LTD</li>
1488. <li>Lifeway Foods, Inc.</li>
1489. <li>Adisseo</li>
1490. <li>Winclove Probiotics</li>
1491. <li>AB-Biotics, S.A.</li>
1492. <li>Lallemand Inc.</li>
1493. <li>DSM-Firmenich</li>
1494. <li>Kerry Group Plc</li>
1495. <li>Novozymes A/S</li>
1496. <li>iHealth, Inc.</li>
1497. </ul>
1498. <p><strong>Recent Breakthroughs in Global Probiotic Food Market:</strong></p>
1499. <ul type="disc">
1500. <li><strong>In January 2023</strong>, KeVita, a brand owned by Tropicana, broadened its Sparkling Probiotic Lemonade line by introducing a mango flavor, complementing the existing classic and peach varieties. These products are available in US retail chains like Kroger and Walmart.</li>
1501. <li><strong>In March 2024</strong>, True North introduced its innovative probiotic solutions known as &#8216;Sensibiotics&#8217; for those with sensitive guts and for feminine health, aimed at India&#8217;s expanding gut health and feminine health markets. True North has also released two new products under the &#8216;Sensibiotics&#8217; name targeting today&#8217;s professionals. These probiotic supplements address common health issues such as travelers&#8217; diarrhea and urinary tract infections (UTIs), offering focused, preventive care.</li>
1502. </ul>
1503. <p><strong>Segments Covered in the Report</strong></p>
1504. <p><strong>By Product</strong></p>
1505. <ul type="disc">
1506. <li>Probiotic Food &amp; Beverages</li>
1507. <li>Probiotic Dietary Supplements</li>
1508. <li>Animal Feed</li>
1509. </ul>
1510. <p><strong>By Ingredient</strong></p>
1511. <ul type="disc">
1512. <li>Bacteria</li>
1513. <li>Yeast</li>
1514. </ul>
1515. <p><strong>By End-Use</strong></p>
1516. <ul type="disc">
1517. <li>Human Probiotics</li>
1518. <li>Animal Probiotics</li>
1519. </ul>
1520. <p><strong>By Distribution</strong></p>
1521. <ul type="disc">
1522. <li>Hypermarkets / Supermarkets</li>
1523. <li>Pharmacies / Drugstores</li>
1524. <li>Specialty Stores</li>
1525. <li>Online Stores</li>
1526. <li>Others</li>
1527. </ul>
1528. <p><strong>By Region</strong></p>
1529. <ul type="disc">
1530. <li>North America</li>
1531. <li>Asia Pacific</li>
1532. <li>Europe</li>
1533. <li>Middle East &amp; Africa</li>
1534. <li>Latin America</li>
1535. </ul>
1536. <p><strong>For Detailed Pricing and Tailored Market Report Options, Click Here: </strong><strong>https://www.towardsfnb.com/price/5506</strong></p>
1537. <p><strong>Feel Free to Get in Touch with Us for Orders or Any Questions at: </strong><strong>sales@towardsfnb.com</strong></p>
1538. <p>Unlock expert insights, custom research, and premium support with the Towards FnB Annual Membership. For USD 495/month (billed annually), get full access to exclusive F&amp;B market data and personalized guidance. It’s your strategic edge in the food and beverage industry: <strong>https://www.towardsfnb.com/get-an-annual-membership</strong></p>
1539. <p><strong>About Us</strong></p>
1540. <p>Towards FnB is a global consulting firm specializing in the food and beverage industry, providing innovative solutions and expert guidance to elevate businesses. With an in-depth understanding of the dynamic F&amp;B sector, we deliver customized market analysis and strategic insights. Our team of seasoned professionals is committed to empowering clients with the knowledge needed to make informed decisions, ensuring they stay ahead of market trends. Partner with us as we redefine success in the rapidly evolving food and beverage landscape, and together, we’ll navigate this transformative journey.</p>
1541. <p><strong>Our Trusted Data Partners</strong><br /><strong>Precedence Research</strong><strong> | </strong><strong>Statifacts</strong><strong> | </strong><strong>Towards Packaging</strong><strong> | </strong><strong>Towards Automotive</strong><strong> | </strong><strong>Towards Chemical and Materials</strong><strong> | </strong><strong>Towards Consumer Goods</strong><strong> |</strong> <strong>Towards Dental</strong><strong> | </strong><strong>Towards EV Solutions</strong><strong> | </strong><strong>Nova One Advisor</strong><strong> | </strong><strong>Healthcare Webwire</strong><strong> | </strong><strong>Packaging Webwire</strong><strong> | </strong><strong>Automotive Webwire</strong></p>
1542. <p><strong>For Latest Update Follow Us: </strong><strong>https://www.linkedin.com/company/towards-food-and-beverages</strong></p>
1543. <p><img alt="" src='https://ml.globenewswire.com/media/ODhhZTczMTctZDYzYS00YmE3LWIxMDYtNjZkMjQ1MmNhM2M2LTEyMTM4NDktMjAyNS0wNC0yMS1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
1544. <p>The post <a rel="nofollow" href="https://dailyindianews.com/probiotic-food-market-size-to-hit-usd-377-20-billion-by-2034/2025/373758/">Probiotic Food Market Size to Hit USD 377.20 Billion by 2034</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1545. ]]></content:encoded>
1549. </item>
1550. <item>
1551. <title>Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights</title>
1552. <link>https://dailyindianews.com/meningococcal-vaccines-market-size-to-surpass-9-05-billion-globally-by-2032-at-10-4-cagr-coherent-market-insights/2025/373757/</link>
1554. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
1555. <pubDate>Mon, 21 Apr 2025 15:00:00 +0000</pubDate>
1556. <category><![CDATA[Brand Post]]></category>
1557. <guid isPermaLink="false">https://dailyindianews.com/meningococcal-vaccines-market-size-to-surpass-9-05-billion-globally-by-2032-at-10-4-cagr-coherent-market-insights</guid>
1558.  
1559. <description><![CDATA[<p>Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Coherent Market Insights published a report, titled, the global meningococcal vaccines market size is estimated to grow from US$ 4.53 Billion in 2025 and is forecast to reach a value of US$ 9.05 Billion by 2032 at a CAGR of 10.4% between 2025 and 2032. Request Sample Pages: [&#8230;]</p>
1560. <p>The post <a rel="nofollow" href="https://dailyindianews.com/meningococcal-vaccines-market-size-to-surpass-9-05-billion-globally-by-2032-at-10-4-cagr-coherent-market-insights/2025/373757/">Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1561. ]]></description>
1562. <content:encoded><![CDATA[<p>Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Coherent Market Insights published a report, titled, the global meningococcal vaccines market size is estimated to grow from US$ 4.53 Billion in 2025 and is forecast to reach a value of US$ 9.05 Billion by 2032 at a CAGR of 10.4% between 2025 and 2032.</p>
1563. <p align="justify"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=49fe5dd5-734a-4ea2-af2d-738785bd785c&amp;size=3" height="338.54px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/49fe5dd5-734a-4ea2-af2d-738785bd785c/image1.jpeg" width="601.74px" /></p>
1564. <p><strong>Request Sample Pages: </strong>https://www.coherentmarketinsights.com/insight/request-sample/3864</p>
1565. <p align="justify"><strong>Global Meningococcal Vaccines Market Key Takeaways</strong></p>
1566. <p align="justify">• The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast period.</p>
1567. <p align="justify">• Based on type, conjugate vaccines segment is expected to account for half of the revenue share in the global meningococcal vaccines market by 2025. This is due to advantages of conjugate vaccines, including long-lasting immunity and high avidity.</p>
1568. <p align="justify">• In terms of sales channel, public segment will likely account for a dominant 60.1% of the global meningococcal vaccines market share in 2025.</p>
1569. <p align="justify">• By age group, children and adults (2 years &amp; above) segment is set to dominate the industry. Coherent Market Insights’ new meningococcal vaccines market research projects the target segment to account for around USD 3.193 Bn in 2025.</p>
1570. <p align="justify">• North America will likely retain its dominance during the forecast period, owing to strong presence of meningococcal vaccine manufacturers and continuous advancements in vaccine technologies. As per Coherent Market Insights’ latest meningococcal vaccines market analysis, North America is poised to account for around 2/5<sup>th</sup> of the global market share.</p>
1571. <p align="justify">• Asia Pacific is anticipated to emerge as a highly remunerative pocket for companies. This is attributable to increasing prevalence of meningococcal disease, growing health consciousness, and increasing healthcare investment across nations like India and China.</p>
1572. <p align="justify"><strong>Meningococcal Vaccines Market Report Coverage</strong></p>
1573. <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;">
1574. <tr>
1575. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Report Coverage</td>
1576. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Details</td>
1577. </tr>
1578. <tr>
1579. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Revenue in 2025</td>
1580. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">$4.53 billion</td>
1581. </tr>
1582. <tr>
1583. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Estimated Value by 2032</td>
1584. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">$9.05 billion</td>
1585. </tr>
1586. <tr>
1587. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Growth Rate</td>
1588. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Poised to grow at a CAGR of 10.4%</td>
1589. </tr>
1590. <tr>
1591. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Historical Data</td>
1592. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">2020 To 2024</td>
1593. </tr>
1594. <tr>
1595. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Forecast Period</td>
1596. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">2025 To 2032</td>
1597. </tr>
1598. <tr>
1599. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Forecast Units</td>
1600. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Value (USD Million/Billion)</td>
1601. </tr>
1602. <tr>
1603. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Report Coverage</td>
1604. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Revenue Forecast, Competitive Landscape, Growth Factors, and Trends</td>
1605. </tr>
1606. <tr>
1607. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Segments Covered</td>
1608. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By Type, By Sales Channel, By Age Group</td>
1609. </tr>
1610. <tr>
1611. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Geographies Covered</td>
1612. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">North America, Europe, Asia Pacific, and Rest of World</td>
1613. </tr>
1614. <tr>
1615. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Restraints &amp; Challenges</td>
1616. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">• Growing prevalence of meningococcal diseases across the globe</p>
1617. <p>• Increasing government support and funding</td>
1618. </tr>
1619. <tr>
1620. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Growth Drivers</td>
1621. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">• High cost of meningococcal vaccines</p>
1622. <p>• Stringent regulatory framework</td>
1623. </tr>
1624. </table>
1625. <p align="justify"><strong>Rising Meningitis Burden Triggering Sales Growth</strong></p>
1626. <p align="justify">A new report by Coherent Market Insights outlines significant meningococcal vaccines market growth factors. One such major factor expected to fuel growth of meningococcal vaccines industry is the increasing prevalence of meningitis globally.</p>
1627. <p align="justify">According to the Meningitis Research Foundation, around 2.3 million cases of meningitis are estimated to occur worldwide each year. This is expected to drive demand for meningococcal vaccines during the assessment period.</p>
1628. <p><strong>Get Up to 25% Discount on the US Tariff Impact Analysis Report: </strong>https://www.coherentmarketinsights.com/insight/buy-now/3864</p>
1629. <p align="justify"><strong>High Vaccine Costs and Limited Awareness Restraining Market Growth</strong></p>
1630. <p align="justify">The global meningococcal vaccines market forecast looks bright. However, certain factors are limiting its growth to some extent. These include high cost of meningococcal vaccines, storage challenges, and limited awareness in developing and underdeveloped regions.</p>
1631. <p align="justify">Meningococcal vaccines, especially conjugate and combination ones, are generally expensive. This limits their widespread adoption in low- and middle-income nations.</p>
1632. <p align="justify">There is also a lack of awareness regarding meningococcal disease and its prevention in many developing regions. Moreover, inadequate storage and transportation infrastructure for vaccines continues to be a challenge. These factors collectively restrain the meningococcal vaccines market growth.</p>
1633. <p align="justify"><strong>Rise in Government Immunization Programs Creating Growth Prospects</strong></p>
1634. <p align="justify">The burden of meningococcal disease is increasing significantly, especially in sub-Saharan Africa. This is prompting governments and healthcare organizations like WHO, UNICEF, and GAVI to launch immunization programs, thereby creating growth avenues for companies.</p>
1635. <p align="justify">For instance, in March 2024, Nigeria became the first nation globally to roll out the Men5CV vaccine. The new vaccine, recommended by WHO, offers protection against five strains of meningococcus bacteria. These vaccination activities are supported and funded by GAVI, the Vaccine Alliance.</p>
1636. <p align="justify">The introduction of Men5CV is crucial for Nigeria, which lies within the African Meningitis Belt and has witnessed recurrent meningitis outbreaks. Other meningitis-prone countries are also expected to increase vaccination drives. This will likely create revenue-generation opportunities for meningococcal vaccine manufacturers.</p>
1637. <p><strong>Emerging </strong><strong>Meningococcal Vaccines Market Trends</strong></p>
1638. <p align="justify">There is a growing interest in advanced vaccines that offer broader protection. This is putting conjugated vaccines like MenB and MenACWY into the limelight. More and more companies are focusing on developing conjugated meningococcal vaccines to meet growing end user demand.</p>
1639. <p align="justify">Rising emphasis on preventive healthcare is acting as a catalyst fueling meningococcal vaccines market demand. People are gradually opting for vaccines to reduce burden of infectious diseases like meningococcal meningitis.</p>
1640. <p align="justify">Ongoing innovations are paving way for more targeted and personalized immunization strategies with fewer side effects.</p>
1641. <p align="justify">Leading pharmaceutical and biotechnology companies are rigorously investing in R&amp;D to develop effective vaccines. They are also focusing on faster vaccine approvals to stay ahead of the competition.</p>
1642. <p align="left"><strong>Ask for Customization Report: </strong>https://www.coherentmarketinsights.com/insight/request-customization/3864</p>
1643. <p><strong>Analyst’s View</strong></p>
1644. <p align="justify"><strong>“</strong><strong><em>The global meningococcal vaccines market is poised for notable growth, driven primarily by rising burden of meningococcal meningitis, increasing number of immunization programs, and rising popularity of preventive healthcare,”</em></strong><strong> said senior analyst Nikhilesh Ravindra Patel. “</strong><strong><em>Shift towards multivalent vaccines that offer broader protection against multiple serogroups will also positively impact the overall </em></strong><strong><em>meningococcal vaccines market value.”</em></strong></p>
1645. <p align="justify"><strong>Competitor Insights</strong></p>
1646. <p align="justify">Key companies listed in meningococcal vaccines market report:</p>
1647. <ul type="disc">
1648. <li style="margin-bottom:8pt; text-align:justify;">Merck &amp; Co., Inc.</li>
1649. <li style="margin-bottom:8pt; text-align:justify;">Pfizer Inc.</li>
1650. <li style="margin-bottom:8pt; text-align:justify;">GlaxoSmithKline plc</li>
1651. <li style="margin-bottom:8pt; text-align:justify;">Walvax Biotechnology Co., Ltd.</li>
1652. <li style="margin-bottom:8pt; text-align:justify;">Sanofi Pasteur</li>
1653. <li style="margin-bottom:8pt; text-align:justify;">Serum Institute of India Pvt. Ltd.</li>
1654. <li style="margin-bottom:8pt; text-align:justify;">JN-International Medical Corporation</li>
1655. <li style="margin-bottom:8pt; text-align:justify;">Sinovac Biotech Ltd.</li>
1656. <li style="margin-bottom:8pt; text-align:justify;">Hualan Biological Engineering Inc.</li>
1657. <li style="margin-bottom:8pt; text-align:justify;">Chongqing Zhifei Biological Products Co., Ltd.</li>
1658. <li style="margin-bottom:8pt; text-align:justify;">Beijing Minhai Biotechnology Co., Ltd</li>
1659. <li style="margin-bottom:8pt; text-align:justify;">Panacea Biotec Ltd</li>
1660. <li style="margin-bottom:8pt; text-align:justify;">CSL Limited</li>
1661. <li style="margin-bottom:8pt; text-align:justify;">Bio-Manguinhos/Fiocruz</li>
1662. <li style="margin-bottom:8pt; text-align:justify;">Incepta Vaccine Ltd.</li>
1663. <li style="margin-bottom:8pt; text-align:justify;">Baxter International</li>
1664. <li style="margin-bottom:8pt; text-align:justify;">Bavarian Nordic</li>
1665. <li style="margin-bottom:8pt; text-align:justify;">Novartis</li>
1666. </ul>
1667. <p align="justify"><strong>Key Developments</strong></p>
1668. <p align="justify"><strong>In October 2023, </strong>the U.S. FDA approved Pfizer’s PENBRAYA, the first and only pentavalent vaccine designed to protect against the most common serogroups responsible for meningococcal disease in adolescents and young adults. The vaccine combines components from Pfizer’s existing meningococcal vaccines: Nimenrix and Trumenba.</p>
1669. <p align="justify"><strong>In May 2023, </strong>Funed and Fiocruz received registration for the production of the meningococcal ACWY conjugate vaccine from the Brazilian Health Regulatory Agency.</p>
1670. <p><strong>Make Smarter Decisions – Buy the US Tariff Impact Analysis Report: </strong>https://www.coherentmarketinsights.com/insight/buy-now/3864</p>
1671. <p><strong>Detailed Segmentation-</strong></p>
1672. <p><strong>By Type</strong></p>
1673. <ul type="circle">
1674. <li style="margin-bottom:8pt;">Polysaccharide Vaccines</li>
1675. <li style="margin-bottom:8pt;">Conjugate Vaccines</li>
1676. <li style="margin-bottom:8pt;">Combination Vaccines</li>
1677. <li style="margin-bottom:8pt;">Other  </li>
1678. </ul>
1679. <p><strong>By Sales Channel</strong></p>
1680. <ul type="circle">
1681. <li style="margin-bottom:8pt;">Public</li>
1682. <li style="margin-bottom:8pt;">Private</li>
1683. </ul>
1684. <p><strong>By Age Group</strong></p>
1685. <ul type="circle">
1686. <li style="margin-bottom:8pt;">Infants (0 to 2 years)</li>
1687. <li style="margin-bottom:8pt;">Children and Adults (2 years &amp; above)</li>
1688. </ul>
1689. <p><strong>By Region:    </strong></p>
1690. <ul type="disc">
1691. <li style="margin-bottom:8pt;"><strong>North America</strong>
1692. <ul type="circle">
1693. <li style="margin-bottom:8pt;">U.S.</li>
1694. <li style="margin-bottom:8pt;">Canada</li>
1695. </ul>
1696. </li>
1697. <li style="margin-bottom:8pt;"><strong>Latin America</strong>
1698. <ul type="circle">
1699. <li style="margin-bottom:8pt;">Brazil</li>
1700. <li style="margin-bottom:8pt;">Argentina</li>
1701. <li style="margin-bottom:8pt;">Mexico</li>
1702. <li style="margin-bottom:8pt;">Rest of Latin America</li>
1703. </ul>
1704. </li>
1705. <li style="margin-bottom:8pt;"><strong>Europe</strong>
1706. <ul type="circle">
1707. <li style="margin-bottom:8pt;">Germany</li>
1708. <li style="margin-bottom:8pt;">U,K.</li>
1709. <li style="margin-bottom:8pt;">Spain</li>
1710. <li style="margin-bottom:8pt;">France</li>
1711. <li style="margin-bottom:8pt;">Italy</li>
1712. <li style="margin-bottom:8pt;">Russia</li>
1713. <li style="margin-bottom:8pt;">Rest of Europe</li>
1714. </ul>
1715. </li>
1716. <li style="margin-bottom:8pt;"><strong>Asia Pacific</strong>
1717. <ul type="circle">
1718. <li style="margin-bottom:8pt;">China</li>
1719. <li style="margin-bottom:8pt;">India</li>
1720. <li style="margin-bottom:8pt;">Japan</li>
1721. <li style="margin-bottom:8pt;">Australia</li>
1722. <li style="margin-bottom:8pt;">South Korea</li>
1723. <li style="margin-bottom:8pt;">ASEAN</li>
1724. <li style="margin-bottom:8pt;">Rest of Asia Pacific</li>
1725. </ul>
1726. </li>
1727. <li style="margin-bottom:8pt;"><strong>Middle East</strong>
1728. <ul type="circle">
1729. <li style="margin-bottom:8pt;">GCC Countries</li>
1730. <li style="margin-bottom:8pt;">Israel</li>
1731. <li style="margin-bottom:8pt;">Rest of Middle East</li>
1732. </ul>
1733. </li>
1734. <li style="margin-bottom:8pt;"><strong>Africa</strong>
1735. <ul type="circle">
1736. <li style="margin-bottom:8pt;">South Africa</li>
1737. <li style="margin-bottom:8pt;">North Africa</li>
1738. <li style="margin-bottom:8pt;">Central Africa</li>
1739. </ul>
1740. </li>
1741. </ul>
1742. <p><strong>About Us</strong>:</p>
1743. <p align="justify">Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.</p>
1744. <p align="justify"><strong>Follow Us:</strong> <u>LinkedIn</u><u> | </u><u>Twitter</u></p>
1745. <p><img alt="" src='https://ml.globenewswire.com/media/NDE3ZDU0NjgtNjQ4Zi00ZTg2LTkwZDUtMzMzZjBhNGQ3YTI1LTExMDI1OTQtMjAyNS0wNC0yMS1lbg==/tiny/Coherent-Market-Insights-Pvt-L.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
1746. <p>The post <a rel="nofollow" href="https://dailyindianews.com/meningococcal-vaccines-market-size-to-surpass-9-05-billion-globally-by-2032-at-10-4-cagr-coherent-market-insights/2025/373757/">Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1747. ]]></content:encoded>
1751. </item>
1752. <item>
1753. <title>Meperidine (Demerol) Market Size to Reach $563.7 Million, Globally, by 2032 at 1.5% CAGR: Coherent Market Insights</title>
1754. <link>https://dailyindianews.com/meperidine-demerol-market-size-to-reach-563-7-million-globally-by-2032-at-1-5-cagr-coherent-market-insights/2025/373756/</link>
1756. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
1757. <pubDate>Mon, 21 Apr 2025 15:00:00 +0000</pubDate>
1758. <category><![CDATA[Brand Post]]></category>
1759. <guid isPermaLink="false">https://dailyindianews.com/meperidine-demerol-market-size-to-reach-563-7-million-globally-by-2032-at-1-5-cagr-coherent-market-insights</guid>
1760.  
1761. <description><![CDATA[<p>Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Coherent Market Insights published a report, titled, the global Meperidine (Demerol) Market size is estimated to grow from US$ 507.9 Million in 2025 and is forecast to reach a value of US$ 563.7 Million by 2032 at a CAGR of 1.5% between 2025 and 2032. Request a Sample [&#8230;]</p>
1762. <p>The post <a rel="nofollow" href="https://dailyindianews.com/meperidine-demerol-market-size-to-reach-563-7-million-globally-by-2032-at-1-5-cagr-coherent-market-insights/2025/373756/">Meperidine (Demerol) Market Size to Reach $563.7 Million, Globally, by 2032 at 1.5% CAGR: Coherent Market Insights</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1763. ]]></description>
1764. <content:encoded><![CDATA[<p>Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Coherent Market Insights published a report, titled, the global Meperidine (Demerol) Market size is estimated to grow from US$ 507.9 Million in 2025 and is forecast to reach a value of US$ 563.7 Million by 2032 at a CAGR of 1.5% between 2025 and 2032.</p>
1765. <p><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=3aa8665a-f632-4406-af66-c270d7f82244&amp;size=3" height="338.6px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/3aa8665a-f632-4406-af66-c270d7f82244/image1.png" width="601.74px" /></p>
1766. <p><strong>Request a Sample of the US Tariff Impact Analysis Report: </strong>https://www.coherentmarketinsights.com/insight/request-sample/3816</p>
1767. <p><strong>Global Meperidine (Demerol) Market Key Takeaways</strong></p>
1768. <p align="justify">The global meperidine (demerol) market size is anticipated to expand from USD 507.9 Mn in 2025 to USD 563.7 Mn by 2032. Global sales of meperidine (Demerol) will likely increase at a CAGR of 1.5% throughout the forecast period.</p>
1769. <p align="justify">By form, tablets segment is projected to account for around USD 284.42 million in 2025. This can be attributed to patients’ preference for meperidine (Demerol) tablets, owing to their convenience, longer shelf life, and ease of storage.</p>
1770. <p align="justify">Based on application, anesthesia segment is set to dominate the industry, accounting for a prominent meperidine (Demerol) market share in 2025.</p>
1771. <p align="justify">In terms of distribution channel, retail pharmacies segment will likely generate higher market revenues during the forecast period.</p>
1772. <p align="justify">North America is expected to remain the undisputed leader in the global meperidine (Demerol) market during the forecast period, owing to high number of surgeries performed and increasing consumption of opioids for pain management. As per Coherent Market Insights’ latest meperidine (Demerol) market analysis, North America is poised to account for around 1/2 of the global market share in 2025.</p>
1773. <p align="justify">Asia Pacific remains the second-largest market for meperidine (Demerol), and the trend will likely persist through 2032. This is attributed to increasing prevalence of acute and chronic pain conditions and expanding access to pain management medications, especially across nations like India, China, and Japan.</p>
1774. <p><strong>Get Up to 25% Discount on the US Tariff Impact Analysis Report: </strong>https://www.coherentmarketinsights.com/insight/buy-now/3816</p>
1775. <p><strong>Increasing Chronic Pain Prevalence Spurring Sales Growth</strong></p>
1776. <p align="justify">A new report by Coherent Market Insights outlines significant meperidine (Demerol) market growth factors. One major factor expected to fuel growth of meperidine (Demerol) industry is the increasing prevalence of chronic pain globally.</p>
1777. <p align="justify">According to the International Association for the Study of Pain, around 20% of the adult population globally suffers from chronic pain, making it a significant global health issue. To counter this, people use opioid pain management medications like meperidine.</p>
1778. <p align="justify">Meperidine is commonly used for its potent analgesic effects in treating moderate to severe pain, especially in cases where other pain management strategies have proven insufficient. Thus, as the prevalence of chronic pain rises, so does the demand for meperidine (Demerol).</p>
1779. <p align="justify"><strong>Side Effects and Use of Alternatives Limiting Market Growth</strong></p>
1780. <p align="justify">Meperidine (Demerol) usage is gradually declining in many countries due to its potential drug interactions, risk of neurotoxicity, and other safety concerns. Its usage can cause side effects like dizziness, nausea, vomiting, constipation, and breathing issues. These safety concerns are reducing overall meperidine (Demerol) market demand.</p>
1781. <p align="justify">Many healthcare professionals and patients are shifting their preference towards safer and more effective alternatives like fentanyl or non-opioid analgesics. This shift is expected to restrain growth of the global meperidine (Demerol) market during the forecast period.</p>
1782. <p align="justify"><strong>Rise in Surgical Procedures Population Creating Growth Prospects</strong></p>
1783. <p align="justify">Meperidine is commonly used for pain relief in surgical procedures. Thus, an increase in the number of surgeries, including minimally invasive ones, will likely fuel demand for analgesics like meperidine (Demerol).</p>
1784. <p align="justify">Rising geriatric population is also expected to create growth opportunities for meperidine (Demerol) manufacturers. This is because older people are more susceptible to chronic pain conditions and often require pain management medications, including opioids like meperidine.</p>
1785. <p align="justify">According to an article published in the National Library of Medicine, chronic pain affects a significant portion of the elderly population, with some studies indicating that up to 76% of older adults living in the community experience pain.</p>
1786. <p align="justify">Opioids like meperidine are often used by elderly to manage discomfort and improve quality of life. Therefore, an increase in the elderly population with pain conditions is expected to boost meperidine (Demerol) sales during the forecast period.</p>
1787. <p><strong>Ask for Customization Report: </strong>https://www.coherentmarketinsights.com/insight/request-customization/3816</p>
1788. <p><strong>Emerging </strong><strong>Meperidine (Demerol) Market Trends</strong></p>
1789. <p align="justify">Availability of cost-effective generic versions of meperidine is making it more accessible and affordable. This can drive its usage in regions and healthcare settings where cost is a significant factor.</p>
1790. <p align="justify">Technological advancements in drug delivery systems are paving way for more efficient injectable formulations and administration methods. This can make meperidine a more convenient option for healthcare providers as well as patients.</p>
1791. <p align="justify">Usage of meperidine (Demerol) for applications like cough relief and diarrhea treatment is also playing a key role in boosting the overall meperidine (demerol) market growth.</p>
1792. <p align="justify">Leading companies are focusing on developing abuse-deterrent formulations of meperidine to address concerns regarding opioid abuse.</p>
1793. <p><strong>Analyst’s View</strong></p>
1794. <p align="justify"><strong>“</strong><strong><em>The global meperidine (Demerol) market is set to witness sluggish growth, driven primarily by rising prevalence of acute and chronic pain conditions, increasing number of surgeries performed globally, and growing geriatric population,”</em></strong><strong> said senior analyst Vipul Patil. “</strong><strong><em>On the other hand, side effects associated with meperidine and transition towards safer alternatives are limited </em></strong><strong><em>meperidine (Demerol) market growth.</em></strong></p>
1795. <p align="justify"><strong>Competitor Insights</strong></p>
1796. <p align="justify">Key companies listed in meperidine (Demerol) market report:</p>
1797. <ul type="disc">
1798. <li style="margin-bottom:8pt; text-align:justify;">Hikma Pharmaceuticals USA Inc.</li>
1799. <li style="margin-bottom:8pt; text-align:justify;">Pfizer, Inc.</li>
1800. <li style="margin-bottom:8pt; text-align:justify;">Vintage Pharmaceuticals, Inc.</li>
1801. <li style="margin-bottom:8pt; text-align:justify;">Epic Pharma, Inc.</li>
1802. <li style="margin-bottom:8pt; text-align:justify;">Boehringer Ingelheim</li>
1803. <li style="margin-bottom:8pt; text-align:justify;">Sanofi</li>
1804. <li style="margin-bottom:8pt; text-align:justify;">Egalet Corporation</li>
1805. <li style="margin-bottom:8pt; text-align:justify;">Janssen Pharmaceuticals</li>
1806. <li style="margin-bottom:8pt; text-align:justify;">Mallinckrodt Pharmaceuticals.</li>
1807. <li style="margin-bottom:8pt; text-align:justify;">Sun Pharmaceutical</li>
1808. </ul>
1809. <p align="justify"><strong>Key Developments</strong></p>
1810. <p align="justify"><strong>In January 2023, </strong>Pfizer Inc. entered into an agreement with Abzena under which it will acquire Abzena’s manufacturing facility in Sanford, North Carolina. The new facility will improve Pfizer’s innovative pipeline products.</p>
1811. <p align="justify"><strong>In April 2022, </strong>Hikma Pharmaceuticals completed acquisition of Custopharm Inc., enhancing its portfolio of drugs, including meperidine, and expanding its market reach.</p>
1812. <p><strong>Make Smarter Decisions – Buy the US Tariff Impact Analysis Report: </strong>https://www.coherentmarketinsights.com/insight/buy-now/3816</p>
1813. <p><strong>Detailed Segmentation:</strong></p>
1814. <p><strong>By Form :</strong></p>
1815. <ul type="circle">
1816. <li style="margin-bottom:8pt;">Tablet</li>
1817. <li style="margin-bottom:8pt;">Injection</li>
1818. <li style="margin-bottom:8pt;">Syrup</li>
1819. </ul>
1820. <p><strong>By Application :</strong></p>
1821. <ul type="circle">
1822. <li style="margin-bottom:8pt;">Anesthesia</li>
1823. <li style="margin-bottom:8pt;">Cough Treatment</li>
1824. <li style="margin-bottom:8pt;">Diarrhea Treatment</li>
1825. </ul>
1826. <p><strong>By Distribution Channel :</strong></p>
1827. <ul type="circle">
1828. <li style="margin-bottom:8pt;">Hospital Pharmacies</li>
1829. <li style="margin-bottom:8pt;">Retail Pharmacies</li>
1830. <li style="margin-bottom:8pt;">Online Pharmacies</li>
1831. </ul>
1832. <p><strong>By Region:</strong></p>
1833. <ul type="disc">
1834. <li style="margin-bottom:8pt;"><strong>North America</strong>
1835. <ul type="circle">
1836. <li style="margin-bottom:8pt;">U.S.</li>
1837. <li style="margin-bottom:8pt;">Canada</li>
1838. </ul>
1839. </li>
1840. <li style="margin-bottom:8pt;"><strong>Latin America</strong>
1841. <ul type="circle">
1842. <li style="margin-bottom:8pt;">Brazil</li>
1843. <li style="margin-bottom:8pt;">Argentina</li>
1844. <li style="margin-bottom:8pt;">Mexico</li>
1845. <li style="margin-bottom:8pt;">Rest of Latin America</li>
1846. </ul>
1847. </li>
1848. <li style="margin-bottom:8pt;"><strong>Europe</strong>
1849. <ul type="circle">
1850. <li style="margin-bottom:8pt;">Germany</li>
1851. <li style="margin-bottom:8pt;">U,K.</li>
1852. <li style="margin-bottom:8pt;">Spain</li>
1853. <li style="margin-bottom:8pt;">France</li>
1854. <li style="margin-bottom:8pt;">Italy</li>
1855. <li style="margin-bottom:8pt;">Russia</li>
1856. <li style="margin-bottom:8pt;">Rest of Europe</li>
1857. </ul>
1858. </li>
1859. <li style="margin-bottom:8pt;"><strong>Asia Pacific</strong>
1860. <ul type="circle">
1861. <li style="margin-bottom:8pt;">China</li>
1862. <li style="margin-bottom:8pt;">India</li>
1863. <li style="margin-bottom:8pt;">Japan</li>
1864. <li style="margin-bottom:8pt;">Australia</li>
1865. <li style="margin-bottom:8pt;">South Korea</li>
1866. <li style="margin-bottom:8pt;">ASEAN</li>
1867. <li style="margin-bottom:8pt;">Rest of Asia Pacific</li>
1868. </ul>
1869. </li>
1870. <li style="margin-bottom:8pt;"><strong>Middle East</strong>
1871. <ul type="circle">
1872. <li style="margin-bottom:8pt;">GCC Countries</li>
1873. <li style="margin-bottom:8pt;">Israel</li>
1874. <li style="margin-bottom:8pt;">Rest of Middle East</li>
1875. </ul>
1876. </li>
1877. <li style="margin-bottom:8pt;"><strong>Africa</strong>
1878. <ul type="circle">
1879. <li style="margin-bottom:8pt;">South Africa</li>
1880. <li style="margin-bottom:8pt;">North Africa</li>
1881. <li style="margin-bottom:8pt;">Central Africa</li>
1882. </ul>
1883. </li>
1884. </ul>
1885. <p><strong>Transform your Strategy with Exclusive Trending Reports:</strong></p>
1886. <p>Inhalation Anesthesia Market is estimated to be valued at USD 1,483.6 Mn in 2025 and is expected to reach USD 2,129.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.</p>
1887. <p>Global anesthesia endotracheal tube market is estimated to be valued at US$ 178.7 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).</p>
1888. <p>The global cold, cough, and sore throat remedies market is estimated to account for US$ 36,325.0 Mn in terms of value in 2019 and is expected to reach US$ 46,869.6 Mn by the end of 2027.</p>
1889. <p>Cough Suppressant Drugs Market Analysis &amp; Forecast 2032</p>
1890. <p>Carcinoid Syndrome Diarrhea Treatment Market Analysis &amp; Forecast: 2025-2032</p>
1891. <p><strong>About Us</strong>:</p>
1892. <p align="justify">Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.</p>
1893. <p align="justify"><strong>Follow Us:</strong> <u>LinkedIn</u><u> | </u><u>Twitter</u></p>
1894. <p><img alt="" src='https://ml.globenewswire.com/media/MTA0MDE2MWQtYWNiZS00YWY3LTliMzYtZWE3NzUzOTIzZDgxLTExMDI1OTQtMjAyNS0wNC0yMS1lbg==/tiny/Coherent-Market-Insights-Pvt-L.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
1895. <p>The post <a rel="nofollow" href="https://dailyindianews.com/meperidine-demerol-market-size-to-reach-563-7-million-globally-by-2032-at-1-5-cagr-coherent-market-insights/2025/373756/">Meperidine (Demerol) Market Size to Reach $563.7 Million, Globally, by 2032 at 1.5% CAGR: Coherent Market Insights</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1896. ]]></content:encoded>
1900. </item>
1901. <item>
1902. <title>Mexico Gambling Market to Hit Valuation of US$ 40.64 Billion By 2033 &#124; Astute Analytica</title>
1903. <link>https://dailyindianews.com/mexico-gambling-market-to-hit-valuation-of-us-40-64-billion-by-2033-astute-analytica/2025/373759/</link>
1905. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
1906. <pubDate>Mon, 21 Apr 2025 14:30:00 +0000</pubDate>
1907. <category><![CDATA[Brand Post]]></category>
1908. <guid isPermaLink="false">https://dailyindianews.com/mexico-gambling-market-to-hit-valuation-of-us-40-64-billion-by-2033-astute-analytica</guid>
1909.  
1910. <description><![CDATA[<p>Mexico’s gambling market balances rapid digital adoption with entrenched social challenges. Online platforms dominate through mobile-first strategies, while land-based venues pivot hybrid tourism models. Regulatory tightening targets illegality and addiction, as tech innovations drive competition and transparency. Chicago, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The Mexico gambling market was valued at US$ 11.37 billion in [&#8230;]</p>
1911. <p>The post <a rel="nofollow" href="https://dailyindianews.com/mexico-gambling-market-to-hit-valuation-of-us-40-64-billion-by-2033-astute-analytica/2025/373759/">Mexico Gambling Market to Hit Valuation of US$ 40.64 Billion By 2033 | Astute Analytica</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
1912. ]]></description>
1913. <content:encoded><![CDATA[<p><em>Mexico’s gambling market balances rapid digital adoption with entrenched social challenges. Online platforms dominate through mobile-first strategies, while land-based venues pivot hybrid tourism models. Regulatory tightening targets illegality and addiction, as tech innovations drive competition and transparency.</em></p>
1914. <p>Chicago, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The Mexico gambling market was valued at US$ 11.37 billion in 2024 and is expected to reach US$ 40.64 billion by 2033, growing at a CAGR of 15.71% during the forecast period 2025–2033.</p>
1915. <p>Mexico’s gambling market navigates a transformative legal landscape under the Federal Gaming and Raffles Law (LJRS), amended in 2021 and further refined in 2023 to address emerging challenges. As of 2024, the Dirección General de Juegos y Sorteos (DGOJ) mandates that operators maintain audited capital reserves of at least US$2 million and implement geoblocking tools to prevent cross-border betting—key measures tightening Mexico’s historically porous regulatory regime. State-level disparities complicate compliance: Jalisco imposes a 7% local tax on gross gaming revenue (GGR), while Quintana Roo exempts integrated resorts to boost tourism. The FATF’s 2023 audit highlighted AML weaknesses, prompting real-time transaction reporting for bets exceeding $2,500 via SEGOB’s centralized platform.</p>
1916. <p><strong>Access Free Report Preview: https://www.astuteanalytica.com/request-sample/mexico-gambling-market</strong></p>
1917. <p>Despite progress, Mexico State and Guerrero remain hubs for illegal gambling dens in the Mexico gambling market, which SEGOB estimates siphon $450 million annually from licensed operators. Licensing delays (12–18 months) and hefty fines for noncompliance—up to $1.5 million for AML breaches—have consolidated market power among incumbents like Grupo Caliente and Codere. Looking ahead, federal rulings on cryptocurrency betting (pending Q4 2024) could redefine growth, as blockchain adoption accelerates among newer entrants like Betcris.</p>
1918. <p><b>Key Findings in Mexico Gambling Market </b></p>
1919. <table style="border-collapse: collapse; border-collapse:collapse ;">
1920. <tr>
1921. <td style="width:207.6px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Market Forecast (2033)</td>
1922. <td style="width:393.47px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">US$ 40.64 Billion</td>
1923. </tr>
1924. <tr>
1925. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">CAGR </td>
1926. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">15.71%</td>
1927. </tr>
1928. <tr>
1929. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By Type  </td>
1930. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Casino (44.86%)</td>
1931. </tr>
1932. <tr>
1933. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By Channel Type  </td>
1934. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Offline (53.97%)</td>
1935. </tr>
1936. <tr>
1937. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By Payment method    </td>
1938. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Credits and Debits Cards (39.36%)  </td>
1939. </tr>
1940. <tr>
1941. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">By End Users </td>
1942. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Gambling Enthusiasts (65.10%)</td>
1943. </tr>
1944. <tr>
1945. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Top Drivers </td>
1946. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">
1947. <ul>
1948. <li style="margin-top:0cm; margin-bottom:0cm;">Surging mobile internet penetration enabling online betting platform growth.</li>
1949. <li style="margin-top:0cm; margin-bottom:0cm;">Legal reforms attracting foreign investment and cross-border partnerships.</li>
1950. <li style="margin-top:0cm; margin-bottom:0cm;">Rising sports culture, especially soccer, driving domestic wagering demand.</li>
1951. </ul>
1952. </td>
1953. </tr>
1954. <tr>
1955. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Top Trends</td>
1956. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">
1957. <ul>
1958. <li style="margin-top:0cm; margin-bottom:0cm;">Accelerated shift to hybrid land-based and digital gambling experiences.</li>
1959. <li style="margin-top:0cm; margin-bottom:0cm;">AI integration for personalized betting and real-time fraud detection.</li>
1960. <li style="margin-top:0cm; margin-bottom:0cm;">Growing adoption of cryptocurrency deposits despite regulatory uncertainty.</li>
1961. </ul>
1962. </td>
1963. </tr>
1964. <tr>
1965. <td style="width:207.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Top Challenges </td>
1966. <td style="width:393.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">
1967. <ul>
1968. <li style="margin-top:0cm; margin-bottom:0cm;">Persistent illegal gambling operations eroding licensed market revenue.</li>
1969. <li style="margin-top:0cm; margin-bottom:0cm;">Infrastructure gaps limiting rural access to online gambling services.</li>
1970. <li style="margin-top:0cm; margin-bottom:0cm;">Public backlash over youth exposure and problem gambling spikes.</li>
1971. </ul>
1972. </td>
1973. </tr>
1974. </table>
1975. <p><b>Land-Based Casinos: Adapting to Declining Demand and Tourism Shifts</b></p>
1976. <p>Mexico’s 347 land-based casinos face structural challenges in the gambling market, with 2023 revenue dipping 5% year-over-year to $1.4 billion due to waning foot traffic and inflationary pressures. Urban centers like Mexico City and Monterrey—home to 45 and 32 casinos respectively—report an 8% decline in per-venue revenue, as labor costs surge by 12% and younger patrons migrate online. Luxury resorts buck the trend: Grupo Caliente’s Tijuana Hippodromo Casino saw VIP table game revenue climb 14% in 2023, driven by cross-border traffic from San Diego. Slot machines, still generating 78% of casino income, are evolving—Aristocrat’s “Skill-based Cash Claw” machines now feature mini-games targeting Gen Z. </p>
1977. <p>Meanwhile, 14 small casinos in Baja California closed since 2022, unable to afford biometric entry systems priced at $120,000 annually per venue in the Mexico gambling market. Diversification strategies are emerging: 22% of ancillary revenue now comes from non-gaming events, such as sold-out concerts at CDMX’s Casino Palace. In coastal regions, hurricane-related closures in Quintana Roo (affecting 7 casinos in 2023) underscore climate risks, prompting operators to invest in $40 million insurance pools.</p>
1978. <p><b>Online Gambling Boom: Mobile Adoption and Payment Innovations</b></p>
1979. <p>Mexico’s online gambling market, projected to hit $1.4 billion in 2024, thrives on smartphone penetration (82%) and cheap 4G data plans ($8/month average). Players aged 18–34 dominate the market (71%), drawn to Bet365’s live-streamed Liga MX matches and Codere’s bonus-heavy app. Live dealer games surged 33% YoY, with Evolution Gaming reporting 500,000 monthly users for its Mexico-specific baccarat tables. Payment integration bridges financial gaps: OXXO’s Spin service processes 41% of deposits via cash vouchers, while Bitcoin adoption grows slowly (6% of transactions) despite regulatory ambiguity. However, cybersecurity remains a hurdle—DGOJ’s post-February 2024 DDoS attack now requires SSL encryption and two-hour breach disclosure windows. Regional nuances persist: northern states prefer sports betting (67% of online revenue), while central Mexico favors slots (58%). However, monopolistic practices loom—Spain’s Luckia controls 19% of the poker market through exclusivity deals with Mexican influencers like Andrés “Kraneo” Chaurand. With 5G networks expanding to 15 cities by Q3, latency issues during live bets (a 27% complaint rate) may soon ease.</p>
1980. <p><b>Sports Betting Dominance: Soccer, Partnerships, and Integrity Risks</b></p>
1981. <p>Sports betting fuels 39.51% of Mexico’s gambling market revenue, driven by soccer’s cultural ubiquity. Liga MX’s 2023 Apertura saw $2.1 billion wagered, spiking 18% during América vs. Chivas clashes. Strategic sponsorships deepen engagement: Sorare’s NFT fantasy league with Tigres UANL attracted 200,000 users in six months, while Betcris’ in-stadium kiosks at Estadio Azteca process $3 million per matchday. The 2026 World Cup looms large—DraftKings’ $52 million ad blitz targets Mexican expats in the U.S., leveraging dual-national stars like Julián Quiñones. Yet match-fixing persists: SEGOB’s Integrity Unit uncovered 12 third-division players manipulating yellow card stats for Costa Rican syndicates. Automation is mitigating risks—Sportradar’s AI flags irregular betting patterns in 92% of Liga MX matches—but oversight gaps linger in amateur leagues. Basketball and baseball are niche bright spots; the NBA’s Mexico City games drove a 27% YoY increase in prop bets, while the Sultanes de Monterrey’s partnership with FanDuel boosted baseball handle by $12 million in 2023.</p>
1982. <p><b>Economic Contributions: Jobs, Tax Revenues, and Regional Disparities</b></p>
1983. <p>Gambling sustains 148,000 direct jobs in Mexico gambling market, though wages lag—dealers earn $460/month on average, 23% below the living wage. Federally, the industry contributed $700 million in taxes in 2023, with casinos providing 58% via a 30% GGR levy. State-level disparities are stark: Nuevo León (24% of tax contributions) and Quintana Roo (21%) benefit from dense casino clusters, while Chiapas and Oaxaca account for &lt;1%. Tourism multipliers are immense—Cancún’s casino visitors spend $290 daily versus $110 for others—but regional inequality widens: Mexico City captures 34% of revenue despite housing 13% of the population. IMCO estimates illegal operators drain $310 million in annual taxes, though SEGOB’s blockchain payment-tracker pilot (launched April 2024) slashed unlicensed revenue by 19% in three months. Unionization efforts are rising—30% of casino workers now belong to SUTTCLM, which negotiates healthcare benefits—but automation threatens roles: self-service betting terminals will replace 8,000 cashiers by 2026.</p>
1984. <p><b>Tourism Integration: Casinos, Resorts, and Cross-Border Opportunities in Mexico Gambling Market</b></p>
1985. <p>Integrated resorts drive Mexico’s $2.1 billion gambling-tourism nexus, blending gaming with luxury stays and golf. Grupo Vidanta’s Nuevo Vallarta property draws 500,000 annual visitors, 44% from the U.S., via packages bundling blackjack tournaments with yacht charters. Cruise tourism amplifies growth: Royal Caribbean’s Cozumel stopovers generate $180 million from casino excursions, targeting retirees with free-play credits. Cross-border betting is surging in gambling market of Mexico—23% of Texas bettors use VPNs to access Caliente’s U.S. college football markets—but peso volatility dampens foreign spending. Post-2023 devaluation, Californian visitors reduced average casino budgets by 14%, prompting operators to lure Argentinian high rollers with direct flights to Mérida. However, climate risks temper gains—Hurricane Otis disrupted 12 coastal casinos in 2023, costing $87 million in closures. For sustainability, SECTUR’s 2024 initiative promotes “golf-and-gaming” circuits in underdeveloped states like Aguascalientes, leveraging partnerships with PGA Tour Latinoamérica.</p>
1986. <p><b>Technology Adoption: AI, Blockchain, and Virtual Reality Advances</b></p>
1987. <p>Mexican operators in gambling market invested $230 million in tech upgrades in 2023, prioritizing AI tools for personalization and fraud detection. Codere’s chatbot resolves 83% of inquiries with a 4.7/5 satisfaction score, while Caliente’s machine learning model flags problem gamblers via behavioral cues like 3 AM logins. Virtual Reality casinos are expanding—Win Systems’ VR parlors in Guadalajara offer Meta Quest-powered blackjack, drawing 12,000 monthly users—but remain niche due to $600 headset costs. Blockchain adoption addresses transparency: 15% of licensees use Bitso for Bitcoin payouts, settling withdrawals in 22 minutes versus three days for banks. Cybersecurity gaps persist, evidenced by January 2024’s $4.5 million hack of Apuesta Total’s player database. Rural adoption lags—only 38% of Oaxaca’s casinos have 5G—but partnerships with Telcel aim to launch 150 5G gaming zones by 2025, slashing latency for esports bets.</p>
1988. <p><strong>Tailor the Report to Your Needs: https://www.astuteanalytica.com/ask-for-customization/mexico-gambling-market</strong></p>
1989. <p><b>Social Challenges: Addiction, Crime, and Regulatory Backlash</b></p>
1990. <p>Problem gambling afflicts 2.3% of Mexican adults, per CONADIC’s 2024 survey—double the global average—with Sonora (4.1%) and Sinaloa (3.8%) hardest hit in the gambling market. SEGOB mandates operators fund 134 addiction clinics via 1% GGR contributions, yet only 17% of users self-exclude despite pop-up prompts. Cartels exploit weak oversight: 2023 saw $270 million laundered through Michoacán casinos, triggering federal raids and 11 venue closures. Public resistance grows—49% oppose new casinos per IEP polls—stalling projects in Querétaro and Puebla. Youth protections tightened in January: influencers like Rivers_GG face $25,000 fines for promoting betting on Twitch. Meanwhile, industry-funded harm reduction campaigns—like Caliente’s “Juego Responsable” school workshops—reach 200,000 teens annually. Balancing growth and ethics remains pivotal, as unchecked expansion risks replicating Spain’s 2010 addiction crisis, warns OECD’s 2024 Mexico report.</p>
1991. <p><b>Mexico Gambling Market Key Players:</b></p>
1992. <ul type="disc">
1993. <li style="margin-top:0cm; margin-bottom:8pt;">Big Bola Casinos</li>
1994. <li style="margin-top:0cm; margin-bottom:8pt;">Caliente</li>
1995. <li style="margin-top:0cm; margin-bottom:8pt;">Codere México</li>
1996. <li style="margin-top:0cm; margin-bottom:8pt;">PlayCity Casino</li>
1997. <li style="margin-top:0cm; margin-bottom:8pt;">Strendus</li>
1998. <li style="margin-top:0cm; margin-bottom:8pt;">Betcris México</li>
1999. <li style="margin-top:0cm; margin-bottom:8pt;">Other Prominent Players</li>
2000. </ul>
2001. <p><b>Key Segmentation:</b></p>
2002. <p><b>By Type</b></p>
2003. <ul type="disc">
2004. <li style="margin-top:0cm; margin-bottom:8pt;">Sports
2005. <ul type="circle">
2006. <li style="margin-top:0cm; margin-bottom:8pt;">Fixed Odds Sports Betting</li>
2007. <li style="margin-top:0cm; margin-bottom:8pt;">Pari-Mutuel Betting (Horse and Dog racing)</li>
2008. <li style="margin-top:0cm; margin-bottom:8pt;">In-Play/Live Betting</li>
2009. <li style="margin-top:0cm; margin-bottom:8pt;">Exchange Betting</li>
2010. <li style="margin-top:0cm; margin-bottom:8pt;">Spread Betting</li>
2011. <li style="margin-top:0cm; margin-bottom:8pt;">Others</li>
2012. </ul>
2013. </li>
2014. <li style="margin-top:0cm; margin-bottom:8pt;">Casino
2015. <ul type="circle">
2016. <li style="margin-top:0cm; margin-bottom:8pt;">Blackjack</li>
2017. <li style="margin-top:0cm; margin-bottom:8pt;">Baccarat</li>
2018. <li style="margin-top:0cm; margin-bottom:8pt;">Teen Patti</li>
2019. <li style="margin-top:0cm; margin-bottom:8pt;">Three Card Poker</li>
2020. <li style="margin-top:0cm; margin-bottom:8pt;">Four card poker</li>
2021. <li style="margin-top:0cm; margin-bottom:8pt;">Red Dog</li>
2022. <li style="margin-top:0cm; margin-bottom:8pt;">Others</li>
2023. </ul>
2024. </li>
2025. <li style="margin-top:0cm; margin-bottom:8pt;">Lottery Games
2026. <ul type="circle">
2027. <li style="margin-top:0cm; margin-bottom:8pt;">Scratch-offs</li>
2028. <li style="margin-top:0cm; margin-bottom:8pt;">Bingo</li>
2029. <li style="margin-top:0cm; margin-bottom:8pt;">Keno</li>
2030. </ul>
2031. </li>
2032. <li style="margin-top:0cm; margin-bottom:8pt;">Electronic Gaming Machines</li>
2033. <li style="margin-top:0cm; margin-bottom:8pt;">Others</li>
2034. </ul>
2035. <p><b>By Channel Type</b></p>
2036. <ul type="disc">
2037. <li style="margin-top:0cm; margin-bottom:8pt;">Offline
2038. <ul type="circle">
2039. <li style="margin-top:0cm; margin-bottom:8pt;">Casinos</li>
2040. <li style="margin-top:0cm; margin-bottom:8pt;">Betting shops/halls</li>
2041. <li style="margin-top:0cm; margin-bottom:8pt;">Arcades</li>
2042. <li style="margin-top:0cm; margin-bottom:8pt;">Bookmakers</li>
2043. </ul>
2044. </li>
2045. <li style="margin-top:0cm; margin-bottom:8pt;">Online</li>
2046. <li style="margin-top:0cm; margin-bottom:8pt;">Virtual Game</li>
2047. </ul>
2048. <p><b>By Payment Method</b></p>
2049. <ul type="disc">
2050. <li style="margin-top:0cm; margin-bottom:8pt;">Credit and debit cards</li>
2051. <li style="margin-top:0cm; margin-bottom:8pt;">E-wallets</li>
2052. <li style="margin-top:0cm; margin-bottom:8pt;">Prepaid cards and Vouchers</li>
2053. <li style="margin-top:0cm; margin-bottom:8pt;">Bank Transfers</li>
2054. <li style="margin-top:0cm; margin-bottom:8pt;">Cryptocurrencies</li>
2055. <li style="margin-top:0cm; margin-bottom:8pt;">Others</li>
2056. </ul>
2057. <p><b>By End User</b></p>
2058. <ul type="disc">
2059. <li style="margin-top:0cm; margin-bottom:8pt;">Gambling Enthusiast</li>
2060. <li style="margin-top:0cm; margin-bottom:8pt;">Dabblers</li>
2061. <li style="margin-top:0cm; margin-bottom:8pt;">Others</li>
2062. </ul>
2063. <p><strong>Explore Report Details Before You Buy: https://www.astuteanalytica.com/inquire-before-purchase/mexico-gambling-market</strong></p>
2064. <p><strong>About Astute Analytica</strong></p>
2065. <p>Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.</p>
2066. <p>With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.</p>
2067. <p><strong>Contact Us:<br /></strong>Astute Analytica<br />Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)<br />For Sales Enquiries: <strong>sales@astuteanalytica.com</strong><br />Website: https://www.astuteanalytica.com/ <br />Follow us on: <strong>LinkedIn </strong>| <strong>Twitter </strong>| <strong>YouTube</strong></p>
2068. <pre>CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/</pre>
2069. <p><img alt="" src='https://ml.globenewswire.com/media/ODlhOTQwMTYtMDUzYS00ZTk3LWI5ZDgtNDExYmE4M2UxYTUwLTEyMTg1NTctMjAyNS0wNC0yMS1lbg==/tiny/AstuteAnalytica-India-Pvt-Ltd-.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
2070. <p>The post <a rel="nofollow" href="https://dailyindianews.com/mexico-gambling-market-to-hit-valuation-of-us-40-64-billion-by-2033-astute-analytica/2025/373759/">Mexico Gambling Market to Hit Valuation of US$ 40.64 Billion By 2033 | Astute Analytica</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
2071. ]]></content:encoded>
2075. </item>
2076. <item>
2077. <title>Sequencing Consumables Market Set to Surge to USD 66.79 Billion by 2034, Driven by a 22.84% CAGR</title>
2078. <link>https://dailyindianews.com/sequencing-consumables-market-set-to-surge-to-usd-66-79-billion-by-2034-driven-by-a-22-84-cagr/2025/373765/</link>
2080. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
2081. <pubDate>Mon, 21 Apr 2025 14:00:00 +0000</pubDate>
2082. <category><![CDATA[Brand Post]]></category>
2083. <guid isPermaLink="false">https://dailyindianews.com/sequencing-consumables-market-set-to-surge-to-usd-66-79-billion-by-2034-driven-by-a-22-84-cagr</guid>
2084.  
2085. <description><![CDATA[<p>The global sequencing consumables market size is calculated at USD 10.49 billion in 2025 and is expected to reach around USD 66.79 billion by 2034, growing at a CAGR of 22.84% for the forecasted period. Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The global sequencing consumables market size was valued at USD 8.54 billion in 2024 [&#8230;]</p>
2086. <p>The post <a rel="nofollow" href="https://dailyindianews.com/sequencing-consumables-market-set-to-surge-to-usd-66-79-billion-by-2034-driven-by-a-22-84-cagr/2025/373765/">Sequencing Consumables Market Set to Surge to USD 66.79 Billion by 2034, Driven by a 22.84% CAGR</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
2087. ]]></description>
2088. <content:encoded><![CDATA[<p><em>The global sequencing consumables market size is calculated at USD 10.49 billion in 2025 and is expected to reach around USD 66.79 billion by 2034, growing at a CAGR of 22.84% for the forecasted period.</em></p>
2089. <p>Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The global <strong>sequencing consumables market size</strong> was valued at USD 8.54 billion in 2024 and is predicted to hit around USD 66.79 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research.</p>
2090. <p>The latest advancements in genomics &amp; proteomics and the rising prevalence of chronic disorders potentiate the demand for sequencing consumables. North America dominated the global market owing to the growing demand for personalized medicines and technological advancements.</p>
2091. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=c5d5bf4b-c8fe-4d2f-9713-f938422b34cf&amp;size=3" height="338.47px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/c5d5bf4b-c8fe-4d2f-9713-f938422b34cf/image1.png" width="601.74px" /></p>
2092. <p><strong>Get All the Details in Our Solutions – Request a Brochure: </strong><strong>https://www.towardshealthcare.com/download-brochure/5350</strong></p>
2093. <p><strong>Sequencing Consumables Market Overview</strong></p>
2094. <p>Sequencing consumables are materials and reagents required for performing <strong>genome sequencing</strong> procedures. Common examples of consumables include flow cells, cartridges, clustering plates, pipette tips, and all necessary reagents for <strong>sequencing</strong>. Genome sequencing is a procedure used to determine the order of all the nucleotides in the genome. By identifying the sequences of the genome, researchers can predict the disease outcome and understand human evolution over time. Genomes of microbes can also be compared to identify the type of pathogens.</p>
2095. <p>The rising prevalence of chronic disorders, such as genetic disorders, increases the need for sequencing procedures. This leads to growing research and development activities. Several government and private organizations provide funding to conduct sequencing procedures, augmenting market growth. Favorable government initiatives and regulatory frameworks also contribute to the market, leading to new product launches. The burgeoning <strong>biotechnology sector</strong> also promotes market growth.</p>
2096. <p><strong>Sequencing Consumables Market Trends</strong></p>
2097. <ul type="disc">
2098. <li style="margin-bottom:8pt;"><strong>Growing Research and Development:</strong> The rising prevalence of chronic disorders necessitates researchers to develop novel drugs for their treatment. This requires complete knowledge of the disease. They utilize sequencing methodologies to identify the genetic sequence involved in disease progression and <strong>several potential biomarkers</strong>.</li>
2099. <li style="margin-bottom:8pt;"><strong>Demand for Personalized Medicines:</strong> The <strong>demand for personalized medicines</strong> is increasing as healthcare professionals can prescribe drugs based on an individual’s characteristics, such as genetic makeup, lifestyle, and environment. This leads to the <strong>development of cell and gene therapy</strong> products as well as <strong>monoclonal antibody therapeutics</strong>.</li>
2100. <li style="margin-bottom:8pt; text-align:justify;"><strong>Technological Advancements:</strong> The advent of advanced technologies transforms the sequencing procedures, enhancing operational efficiency and outcomes. <strong>Next-generation sequencing</strong> and <strong>long-read sequencing</strong> are some of the advanced sequencing procedures that are commonly used nowadays.</li>
2101. </ul>
2102. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><strong>sales@towardshealthcare.com</strong></p>
2103. <p><strong>Limitations &amp; Challenges in the Sequencing Consumables Market</strong></p>
2104. <ul type="disc">
2105. <li style="margin-bottom:8pt;"><strong>High Cost:</strong> The equipment used in sequencing procedures is very costly, requiring high capital investments. The laboratories and biotech companies located in several developing and underdeveloped countries are unable to afford such costly instruments and consumables.</li>
2106. <li style="margin-bottom:8pt;"><strong>Lack of Skilled Professionals:</strong> Certain low- and middle-income countries lack skilled professionals to operate sequencing instruments and handle complex research data. This may lead to incorrect outcomes and hamper accuracy and precision.</li>
2107. <li style="margin-bottom:8pt;"><strong>Supply Chain Challenges:</strong> Sequencing consumables faces significant international logistics and supply chain issues, restricting the timely delivery of products. Some products also require cold chain logistics, which is difficult to maintain throughout the transportation.</li>
2108. </ul>
2109. <p><strong>Automation Driving the Future of the Sequencing Consumables Market</strong></p>
2110. <p>Artificial intelligence (AI) introduces automation in the sequencing procedures, simplifying the task for researchers. Automation can significantly reduce the cost of the entire procedure and enhance efficiency. It increases productivity and speed of sequencing, thereby improving reproducibility. The increased speed enables researchers to perform multiple tasks, requiring the need for more samples. Additionally, automation can enhance the accuracy and throughput of sequencing workflows. AI-based robots can perform numerous tasks, including liquid handling and DNA extraction. This minimizes human intervention and reduces human-to-human variation. Automation can also overcome errors, such as misplacing or using the wrong reagents and consumables.</p>
2111. <p><strong>For instance,</strong></p>
2112. <ul type="disc">
2113. <li style="margin-bottom:8pt;"><strong>In March 2024</strong>, SPT Labtech, in collaboration with RevoluGen Ltd., announced the automation of RevoluGen’s Fire Monkey High Molecular Weight DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly automated liquid handling platform.</li>
2114. </ul>
2115. <p><strong>Get the latest insights on healthcare industry segmentation with our Annual Membership: </strong><strong>https://www.towardshealthcare.com/get-an-annual-membership</strong></p>
2116. <p><strong>Regional Analysis</strong></p>
2117. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=3b49a001-36ab-4f17-9393-7221ce23a4cb&amp;size=3" height="338.47px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/3b49a001-36ab-4f17-9393-7221ce23a4cb/image2.png" width="601.74px" /></p>
2118. <p><strong>Increasing Investments Dominated North America</strong></p>
2119. <p>North America dominated the global sequencing consumables market in 2024. The major growth factors driving the market in North America are the rising adoption of advanced technologies and state-of-the-art research and development facilities. The increasing prevalence of genetic disorders is a major concern in North American countries. The growing demand for personalized medicines and favorable regulatory frameworks leads to the launch of novel cell and <strong>gene therapy products</strong> and other personalized medicines. Additionally, the presence of key players also positively impacts market growth. Several <strong>government organizations also support genomics</strong> and proteomics research through funding, fueling market growth.</p>
2120. <ul type="disc">
2121. <li style="margin-bottom:8pt;"><strong>United States:</strong> In September 2024, the National Institute of Health (NIH) announced a total funding of $27 million to establish a new program that supports the integration of genomics into learning health systems. The investment would enable the network to advance approaches for integrating genomic information into learning health systems, improving medical care.</li>
2122. <li style="margin-bottom:8pt;"><strong>Canada:</strong> The Government of Canada announced an investment of $200 million for the Canadian Precision Health Initiative (CPHI) launched by Genome Canada. The initiative was launched to build Canada’s largest collection of human genomic data, of more than 100,000 genomes.</li>
2123. </ul>
2124. <p><strong>Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes—schedule a call today: </strong><strong>https://www.towardshealthcare.com/schedule-meeting</strong></p>
2125. <p><strong>Favorable Government Support Promotes Asia-Pacific</strong></p>
2126. <p>Asia-Pacific is anticipated to grow at the fastest rate in the sequencing consumables market during the forecast period. The burgeoning biotechnology sector and growing genomics and proteomics research boost the market. The rising healthcare expenditures and favorable government support also potentiate market growth. The rapidly evolving healthcare infrastructure and growing awareness of personalized medicines drive the market. The increasing investments, collaborations, and mergers &amp; acquisitions lead to growing research and development activities. <strong>Several established pharmaceutical</strong> and biotechnology companies adopt advanced technologies to streamline workflows. The increasing number of biotech startups also contributes to market growth.</p>
2127. <ul type="disc">
2128. <li style="margin-bottom:8pt;"><strong>China:</strong> The Chinese government has launched numerous policies and initiatives to address healthcare challenges, focusing on genetics and personalized treatment. According to a recent survey, 16 policies, 18 programs, and 11 actions have been implemented on both local and national bases in China.</li>
2129. <li style="margin-bottom:8pt;"><strong>India:</strong> The Indian government promotes the indigenous development of personalized medicines. The Genome India Project positions India to lead in personalized gene therapies. In April 2024, the President of India launched India’s first home-grown <strong>CAR-T cell therapy</strong>.</li>
2130. </ul>
2131. <p><strong>Segmental Outlook</strong></p>
2132. <p><strong>Product Insights</strong></p>
2133. <p>The kits segment held a dominant presence in the sequencing consumables market in 2024. Kits enable researchers to perform a variety of sequencing methods for numerous applications. It offers the ability to process large amounts of data. Kits contain all the necessary reagents, such as reagents, enzymes and buffers, for sequencing workflows, including target selection, library construction, and template preparation. Different types of kits are available for diverse applications. The selection of appropriate kits depends on research requirements.</p>
2134. <p>The reagents segment is anticipated to grow with the highest CAGR in the market during the studied years. Sequencing kits usually contain very small amounts of reagents, enabling researchers to perform the reaction only once. Hence, more reagents are required to perform sequencing experiments. They are also needed to customize the reaction protocols, based on the needs. Optimized reagent kits are available to provide increased cluster density and read length.</p>
2135. <p><strong>Platform Insights</strong></p>
2136. <p>The second-generation sequencing consumables segment led the global sequencing consumables market in 2024. Second-generation sequencing (SGS) platforms include 454 pyrosequencing, Illumina sequencing, and Ion Torrent sequencing. They are advanced forms of sequencing that are more accurate and faster than first-generation sequencing (FGS). These methods are most widely preferred due to their enhanced benefits compared to FGS. They are comparatively cost-effective, labor-intensive, and semi-automated. Hence, the growing demand for SGS methodologies promotes the use of SGS consumables.</p>
2137. <p>The third-generation sequencing consumables segment is projected to expand rapidly in the market in the coming years. PacBio sequencing and Oxford Nanopore sequencing are currently available third-generation sequencing (TGS) platforms. The major advantage of TGS platforms is that they can sequence large lengths of genomes up to 100 kb. These technologies eliminate the need for PCR amplification, reducing its bias and errors. They also require fewer sample preparation steps and increase the speed of sequencing.</p>
2138. <p><strong>Application Insights</strong></p>
2139. <p>The cancer diagnostics segment held the largest share of the sequencing consumables market in 2024. The rising prevalence of cancer and its complexity necessitate the development of cancer diagnostics. The American Cancer Society estimated that more than 2 million new cancer cases would be detected in the U.S. in 2025. Scientists have found the role of numerous genes involved in cancer progression. Next-generation sequencing is the most widely used technique to identify DNA mutations and compare cancer cell DNA with healthy cell DNA. This enables healthcare professionals to identify the root cause of the disease.</p>
2140. <p>The pharmacogenomics segment is predicted to witness significant growth in the market over the forecast period. Pharmacogenomics is the study of evaluating human response to drugs. Advancements in sequencing technologies enable the detection of variations across the human pharmacogenome. The growing demand for personalized therapeutics and the increasing use of long-read sequencing propel the segment’s growth. Pharmacogenomics helps healthcare professionals to prescribe medications with fewer side effects and enhanced efficacy.</p>
2141. <p><strong>End-Use Insights</strong></p>
2142. <p>The hospitals &amp; laboratories segment registered its dominance over the sequencing consumables market in 2024. The increasing potential of sequencing techniques in clinical applications fosters the segment’s growth. The rising prevalence of rare, genetic disorders and advancements in diagnostics contribute to the segment’s growth. Approximately 30 million Americans are estimated to be affected by rare disorders globally. New product launches also potentiate the demand for sequencing consumables. The U.S. Food and Drug Administration (FDA) approved a total of 16 personalized therapeutics for rare disorder patients.</p>
2143. <p>The pharmaceutical &amp; biotechnology companies segment is expected to grow at the fastest rate in the market during the forecast period. The growing research and development activities and the availability of suitable infrastructure augment the segment’s growth. These companies also have skilled professionals to conduct advanced research. The increasing number of pharma and biotech startups potentiate the need to stay ahead in the market by expanding their product pipeline. The growing venture capital investments also support the segment’s growth.</p>
2144. <p><strong>Top Companies in the Sequencing Consumables Market</strong></p>
2145. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=677cf786-c9e5-46a6-b69e-6d8afd9a69ab&amp;size=3" height="356.27px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/677cf786-c9e5-46a6-b69e-6d8afd9a69ab/image3.png" width="601.74px" /></p>
2146. <ul type="disc">
2147. <li style="margin-bottom:8pt;">Swift Biosciences, Inc.</li>
2148. <li style="margin-bottom:8pt;">New England Biolabs, Inc.</li>
2149. <li style="margin-bottom:8pt;">Eurofins Scientific</li>
2150. <li style="margin-bottom:8pt;">Oxford Nanopore Technologies Ltd.</li>
2151. <li style="margin-bottom:8pt;">BGI Genomics Co., Ltd.</li>
2152. <li style="margin-bottom:8pt;">PerkinElmer, Inc.</li>
2153. <li style="margin-bottom:8pt;">Macrogen Inc.</li>
2154. <li style="margin-bottom:8pt;">GenScript Biotech Corporation</li>
2155. <li style="margin-bottom:8pt;">Bio-Rad Laboratories, Inc.</li>
2156. <li style="margin-bottom:8pt;">Pacific Biosciences of California, Inc.</li>
2157. <li style="margin-bottom:8pt;">Agilent Technologies, Inc.</li>
2158. <li style="margin-bottom:8pt;">F. Hoffmann-La Roche Ltd.</li>
2159. <li style="margin-bottom:8pt;">Illumina, Inc.</li>
2160. <li style="margin-bottom:8pt;">Qiagen N.V.</li>
2161. <li style="margin-bottom:8pt;">Thermo Fisher Scientific Inc.</li>
2162. </ul>
2163. <p><strong>Recent Breakthroughs</strong></p>
2164. <ul type="disc">
2165. <li style="margin-bottom:8pt;"><strong>In November 2024</strong>, Quantum-Si announced a collaboration with SkyWater Technology to support the development of Proteus, a next-generation sequencing platform to transform proteomic research. The collaboration was made to develop consumables for the Proteus platform, enabling simultaneous protein sequencing with high accuracy.</li>
2166. <li style="margin-bottom:8pt;"><strong>In October 2024</strong>, Illumina, Inc. announced the launch of its MiSeq i100 Series of sequencing platforms to deliver high benchtop speed and simplicity to advance NGS for labs. These kits enable room-temperature storage and shipping to sequence on demand and same-day sample-to-analysis</li>
2167. </ul>
2168. <p><strong>Browse More Insights of Towards Healthcare:</strong></p>
2169. <ul type="disc">
2170. <li style="margin-bottom:8pt;"><strong>miRNA Sequencing and Assay Market Size: </strong><strong>https://www.towardshealthcare.com/insights/sequencing-consumables-market-sizing</strong></li>
2171. <li style="margin-bottom:8pt;"><strong>DNA Sequencing Market Size: </strong><strong>https://www.towardshealthcare.com/insights/dna-sequencing-market-sizing</strong></li>
2172. <li style="margin-bottom:8pt;"><strong>Healthcare Consumables Market Size: </strong><strong>https://www.towardshealthcare.com/insights/healthcare-consumables-market-sizing</strong></li>
2173. <li style="margin-bottom:8pt;"><strong>Consumer Genomics Market Size: </strong><strong>https://www.towardshealthcare.com/insights/consumer-genomics-market-sizing</strong></li>
2174. <li style="margin-bottom:8pt;"><strong>Regenerative Medicine Market Size: </strong><strong>https://www.towardshealthcare.com/insights/regenerative-medicine-market-size</strong></li>
2175. <li style="margin-bottom:8pt;"><strong>AI in Medical Coding Market Size: </strong><strong>https://www.towardshealthcare.com/insights/ai-in-medical-coding-market-size</strong></li>
2176. <li style="margin-bottom:8pt;"><strong>Europe Cell Culture Media Market Size: </strong><strong>https://www.towardshealthcare.com/insights/cell-culture-media-the-nourishment-for-microbials</strong></li>
2177. <li style="margin-bottom:8pt;"><strong>Sexually Transmitted Infections (STI) Market Size: </strong><strong>https://www.towardshealthcare.com/insights/sexually-transmitted-infections-market-sizing</strong></li>
2178. <li style="margin-bottom:8pt;"><strong>Active Pharmaceutical Ingredients (APIs) Market Size: </strong><strong>https://www.towardshealthcare.com/insights/active-pharmaceutical-ingredients-market-size</strong></li>
2179. <li style="margin-bottom:8pt;"><strong>High Concentration mAb Products Market Size: </strong><strong>https://www.towardshealthcare.com/insights/high-concentration-mab-products-market-sizing</strong></li>
2180. </ul>
2181. <p><strong>Segments Covered in the Report</strong></p>
2182. <p><strong>By Product</strong></p>
2183. <ul type="disc">
2184. <li style="margin-bottom:8pt;">Kits
2185. <ul type="circle">
2186. <li style="margin-bottom:8pt;">DNA Library Preparation</li>
2187. <li style="margin-bottom:8pt;">RNA Library Preparation</li>
2188. <li style="margin-bottom:8pt;">Target Enrichment</li>
2189. <li style="margin-bottom:8pt;">Library Quantification</li>
2190. <li style="margin-bottom:8pt;">Purification &amp; Quality Control</li>
2191. <li style="margin-bottom:8pt;">Others</li>
2192. </ul>
2193. </li>
2194. <li style="margin-bottom:8pt;">Reagents
2195. <ul type="circle">
2196. <li style="margin-bottom:8pt;">Sample Prep</li>
2197. <li style="margin-bottom:8pt;">Library Preparation &amp; Amplification</li>
2198. <li style="margin-bottom:8pt;">Sequencing</li>
2199. </ul>
2200. </li>
2201. <li style="margin-bottom:8pt;">Accessories
2202. <ul type="circle">
2203. <li style="margin-bottom:8pt;">Collection Tubes</li>
2204. <li style="margin-bottom:8pt;">Plates</li>
2205. <li style="margin-bottom:8pt;">Others</li>
2206. </ul>
2207. </li>
2208. </ul>
2209. <p><strong>By Platform</strong></p>
2210. <ul type="disc">
2211. <li style="margin-bottom:8pt;">2nd Generation Sequencing Consumables</li>
2212. <li style="margin-bottom:8pt;">3rd Generation Sequencing Consumables</li>
2213. <li style="margin-bottom:8pt;">1st Generation Sequencing Consumables</li>
2214. </ul>
2215. <p><strong>By Application</strong></p>
2216. <ul type="disc">
2217. <li style="margin-bottom:8pt;">Cancer Diagnostics</li>
2218. <li style="margin-bottom:8pt;">Pharmacogenomics</li>
2219. <li style="margin-bottom:8pt;">Infectious Disease Diagnostics</li>
2220. <li style="margin-bottom:8pt;">Reproductive Health Diagnostics</li>
2221. <li style="margin-bottom:8pt;">Agrigenomics</li>
2222. <li style="margin-bottom:8pt;">Others</li>
2223. </ul>
2224. <p><strong>By End-Use</strong></p>
2225. <ul type="disc">
2226. <li style="margin-bottom:8pt;">Hospitals &amp; Laboratories</li>
2227. <li style="margin-bottom:8pt;">Pharmaceutical &amp; Biotechnology Companies</li>
2228. <li style="margin-bottom:8pt;">Academic Research Institutes</li>
2229. <li style="margin-bottom:8pt;">Others</li>
2230. </ul>
2231. <p><strong>By Region</strong></p>
2232. <ul type="disc">
2233. <li style="margin-bottom:8pt;">North America
2234. <ul type="circle">
2235. <li style="margin-bottom:8pt;">U.S.</li>
2236. <li style="margin-bottom:8pt;">Canada</li>
2237. </ul>
2238. </li>
2239. <li style="margin-bottom:8pt;">Asia Pacific
2240. <ul type="circle">
2241. <li style="margin-bottom:8pt;">China</li>
2242. <li style="margin-bottom:8pt;">Japan</li>
2243. <li style="margin-bottom:8pt;">India</li>
2244. <li style="margin-bottom:8pt;">South Korea</li>
2245. <li style="margin-bottom:8pt;">Thailand</li>
2246. </ul>
2247. </li>
2248. <li style="margin-bottom:8pt;">Europe
2249. <ul type="circle">
2250. <li style="margin-bottom:8pt;">Germany</li>
2251. <li style="margin-bottom:8pt;">UK</li>
2252. <li style="margin-bottom:8pt;">France</li>
2253. <li style="margin-bottom:8pt;">Italy</li>
2254. <li style="margin-bottom:8pt;">Spain</li>
2255. <li style="margin-bottom:8pt;">Sweden</li>
2256. <li style="margin-bottom:8pt;">Denmark</li>
2257. <li style="margin-bottom:8pt;">Norway</li>
2258. </ul>
2259. </li>
2260. <li style="margin-bottom:8pt;">Latin America
2261. <ul type="circle">
2262. <li style="margin-bottom:8pt;">Brazil</li>
2263. <li style="margin-bottom:8pt;">Mexico</li>
2264. <li style="margin-bottom:8pt;">Argentina</li>
2265. </ul>
2266. </li>
2267. <li style="margin-bottom:8pt;">Middle East and Africa (MEA)
2268. <ul type="circle">
2269. <li style="margin-bottom:8pt;">South Africa</li>
2270. <li style="margin-bottom:8pt;">UAE</li>
2271. <li style="margin-bottom:8pt;">Saudi Arabia</li>
2272. <li style="margin-bottom:8pt;">Kuwait</li>
2273. </ul>
2274. </li>
2275. </ul>
2276. <p><strong>To invest in our premium strategic solution and customized market report options, click here: </strong><strong>https://www.towardshealthcare.com/price/5350</strong></p>
2277. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><strong>sales@towardshealthcare.com</strong></p>
2278. <p>Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare<strong>: </strong><strong>Get a Subscription</strong></p>
2279. <p><strong>About Us</strong></p>
2280. <p>Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.</p>
2281. <p><strong>Our Trusted Data Partners</strong></p>
2282. <p><strong>Precedence Research</strong><strong> | </strong><strong>Statifacts</strong><strong> | </strong><strong>Towards Packaging</strong><strong> | </strong><strong>Towards Automotive</strong><strong> |</strong> <strong>Towards Food and Beverages</strong><strong> | </strong><strong>Towards Chemical and Materials</strong><strong> | </strong><strong>Towards Consumer Goods</strong><strong> |</strong> <strong>Towards Dental</strong><strong> | </strong><strong>Towards EV Solutions</strong><strong> | </strong><strong>Nova One Advisor</strong><strong> | </strong><strong>Healthcare Webwire</strong><strong> | </strong><strong>Packaging Webwire</strong><strong> | </strong><strong>Automotive Webwire</strong></p>
2283. <p><strong>For Latest Update Follow Us: </strong><strong>https://www.linkedin.com/company/towards-healthcare</strong></p>
2284. <p><img alt="" src='https://ml.globenewswire.com/media/YzZhMjkwNzItMzg0ZS00YjA5LWE0NzMtODNhYjkzZDFjYWU2LTEyMTM4NDktMjAyNS0wNC0yMS1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
2285. <p>The post <a rel="nofollow" href="https://dailyindianews.com/sequencing-consumables-market-set-to-surge-to-usd-66-79-billion-by-2034-driven-by-a-22-84-cagr/2025/373765/">Sequencing Consumables Market Set to Surge to USD 66.79 Billion by 2034, Driven by a 22.84% CAGR</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
2286. ]]></content:encoded>
2290. </item>
2291. <item>
2292. <title>Automotive Sunroof Market Size to Apex USD 16.41 Bn by 2034, says Industry Experts</title>
2293. <link>https://dailyindianews.com/automotive-sunroof-market-size-to-apex-usd-16-41-bn-by-2034-says-industry-experts/2025/373764/</link>
2295. <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
2296. <pubDate>Mon, 21 Apr 2025 14:00:00 +0000</pubDate>
2297. <category><![CDATA[Brand Post]]></category>
2298. <guid isPermaLink="false">https://dailyindianews.com/automotive-sunroof-market-size-to-apex-usd-16-41-bn-by-2034-says-industry-experts</guid>
2299.  
2300. <description><![CDATA[<p>According to Towards Automotive Experts, the global automotive sunroof market size is calculated at USD 9.52 billion in 2025 and is expected to reach around USD 16.41billion by 2034, growing at a CAGR of 7.29% from 2024 to 2034. Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The global automotive sunroof market size was valued at USD [&#8230;]</p>
2301. <p>The post <a rel="nofollow" href="https://dailyindianews.com/automotive-sunroof-market-size-to-apex-usd-16-41-bn-by-2034-says-industry-experts/2025/373764/">Automotive Sunroof Market Size to Apex USD 16.41 Bn by 2034, says Industry Experts</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
2302. ]]></description>
2303. <content:encoded><![CDATA[<p><em>According to Towards Automotive Experts, the global automotive sunroof market size is calculated at USD 9.52 billion in 2025 and is expected to reach around USD 16.41billion by 2034, growing at a CAGR of 7.29% from 2024 to 2034.</em></p>
2304. <p>Ottawa, April 21, 2025 (GLOBE NEWSWIRE) &#8212; The global <strong>automotive sunroof market size</strong> was valued at USD 8.97 billion in 2024 and is predicted to hit around USD 16.41 billion by 2034, a study published by Towards Automotive, a sister firm of Precedence Research.</p>
2305. <p><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=d1fb49b4-411b-4f57-b093-23f579c5b2c5&amp;size=3" data-mce-style="display: block; margin-left: auto; margin-right: auto;" height="351.0px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/d1fb49b4-411b-4f57-b093-23f579c5b2c5/image1.png" style="display:block; margin-left:auto; margin-right:auto;" width="624.0px" /></p>
2306. <p><strong>Get All the Details in Our Solutions – Request a Brochure: </strong><strong>https://www.towardsautomotive.com/download-brochure/1041</strong></p>
2307. <p align="justify"><strong>Market Overview:</strong></p>
2308. <p align="justify">The automotive sunroof market is witnessing significant growth, driven by increasing consumer interest in superior in-vehicle comfort, luxury attributes, and visual appeal. Automakers are incorporating panoramic and electronically operated sunroofs to set apart their vehicle models and enhance the driving experience. Moreover, innovations in sunroof technologies, such as anti-pinch sensors, UV-filtering glass, and smart sunroof systems, have promoted their usage across diverse vehicle segments. Urbanization, rising disposable incomes, and the growing popularity of SUVs and <strong>electric vehicles are also aiding market growth</strong>. The increasing focus on vehicle customization, along with a consumer desire for open-air experiences, further enhances the attractiveness of sunroofs. As OEMs concentrate on lightweight materials and energy-efficient designs, the automotive sunroof market is set for strong growth in developed and developing economies.</p>
2309. <p align="justify"><strong>Key Trends in the Automotive Sunroof Market:</strong></p>
2310. <ul type="disc">
2311. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Incorporation of Smart Sunroof Technologies: </strong>Manufacturers are adding features such as automatic tint adjustment and rain sensors with vehicle systems, improving user convenience and promoting the uptake of advanced sunroof systems.</li>
2312. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Growing Demand for Panoramic Sunroofs: </strong>Consumers increasingly prefer panoramic sunroofs due to their broad views and improved cabin atmosphere, prompting automakers to include them in various vehicle segments, from mid-range to luxury models.</li>
2313. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Increase in Usage of Lightweight and Eco-Friendly Materials: </strong>There is a rising trend in utilizing tempered and laminated automotive glass, along with sustainable materials, to enhance vehicle efficiency and adhere to environmental standards, showcasing a commitment to sustainability.</li>
2314. </ul>
2315. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><strong>sales@towardsautomotive.com</strong></p>
2316. <p align="justify"><strong>Limitations &amp; Challenges in the Automotive Sunroof Market:</strong></p>
2317. <ul type="disc">
2318. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Elevated Production and Installation Expenses: </strong>Sunroofs require intricate engineering, premium materials, and specialized manufacturing processes, which drive up vehicle prices. This deters adoption in lower-cost vehicle categories, particularly in price-sensitive emerging markets.</li>
2319. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Risk of Leakage and Maintenance Problems: </strong>Sunroofs can experience water leaks, mechanical issues, and heightened cabin noise if not carefully maintained. These concerns regarding reliability can undermine consumer confidence and result in expensive repairs.</li>
2320. <li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;"><strong>Compromised Structural Integrity and Efficiency: </strong>The addition of large sunroofs may weaken a vehicle&#8217;s structural strength and thermal insulation, potentially reducing fuel efficiency or range in electric vehicles, especially under extreme weather conditions.</li>
2321. </ul>
2322. <p align="justify"><strong>Future Opportunity in the Automotive Sunroof Market</strong></p>
2323. <p>The primary opportunity within the automotive sunroof market lies in the <strong>rising demand for electric and autonomous vehicles</strong>, which emphasize comfort, aesthetics, and advanced functionalities. As consumer tastes shift towards premium and technology-driven interiors, panoramic and smart sunroofs are emerging as significant differentiators for OEMs. Emerging markets like India, Brazil, and Southeast Asia present immense growth opportunities owing to increasing disposable incomes and a surge in automotive sales. Furthermore, advancements in lightweight, energy-efficient materials and the integration of solar sunroof technology unlock new pathways for sustainability and innovation. Leveraging these trends can lead to considerable growth and market entry for manufacturers and suppliers.</p>
2324. <p align="justify"><strong>Regional Insights:</strong></p>
2325. <p><strong>Asia Pacific’s Sustained Dominance in the Market</strong></p>
2326. <p>Asia Pacific dominated the automotive sunroof market with the largest share in 2024, driven by growing vehicle production, rising consumer interest in premium features, and an increase in disposable incomes in nations like China, India, and South Korea. The region&#8217;s expanding middle class and strong preference for feature-rich vehicles, particularly SUVs and sedans, have accelerated the uptake of sunroofs.</p>
2327. <p align="justify"><strong>Top Asia Pacific Countries for Automotive Sunroof Production</strong></p>
2328. <ul type="disc">
2329. <li style="margin-top:12pt; margin-bottom:12pt;"><strong>China:</strong> China is at the forefront of the Asia Pacific automotive sunroof market, driven by its extensive automotive production, increasing demand for luxury vehicles, and consumer inclination towards features such as panoramic and smart sunroofs.</li>
2330. <li style="margin-top:12pt; margin-bottom:12pt;"><strong>India:</strong> India’s automotive sunroof market is experiencing rapid growth, propelled by rising disposable incomes, an expanding middle class, and greater demand for stylish and feature-rich vehicles, particularly among younger consumers.</li>
2331. <li style="margin-top:12pt; margin-bottom:12pt;"><strong>Japan:</strong> Japan holds a strong position in the automotive sunroof industry, facilitated by its sophisticated automotive sector, consumer interest in vehicle customization, and the incorporation of sunroofs in both domestically produced and exported vehicles.</li>
2332. </ul>
2333. <p>In addition, both local and international automakers are launching panoramic and smart sunroof options in mid-range vehicles to appeal to tech-savvy consumers. Favorable government policies that promote automotive production and the rapid proliferation of electric vehicles in the area further enhance demand, solidifying Asia Pacific’s position as the market leader.</p>
2334. <p><strong>Get the latest insights on automotive industry segmentation with our Annual Membership: </strong><strong>https://www.towardsautomotive.com/get-an-annual-membership</strong></p>
2335. <p><strong>Europe’s Unstoppable Growth in the Market</strong></p>
2336. <p>Europe is expected to witness significant growth during the forecast period, spurred by significant consumer interest in premium vehicles, increasing the adoption of luxury and electric cars, and proficient manufacturing capabilities. The region&#8217;s car manufacturers, such as BMW, Audi, Mercedes-Benz, and Volkswagen, are progressively outfitting their models with panoramic and smart sunroofs to enhance in-car aesthetics and comfort.</p>
2337. <p><strong>Major Factors for the Market’s Expansion in Europe:</strong></p>
2338. <ul type="disc">
2339. <li style="margin-top:12pt; margin-bottom:12pt;">Europe is home to prestigious luxury car brands like BMW, Audi, and Mercedes-Benz, who consistently integrate advanced sunroof systems to enhance vehicle desirability and satisfy consumer demand for premium features.</li>
2340. <li style="margin-top:12pt; margin-bottom:12pt;">Consumers in Europe are progressively gravitating towards panoramic and smart sunroofs for their visual and practical advantages, prompting manufacturers to include these features across various vehicle categories, including mid-range models.</li>
2341. <li style="margin-top:12pt; margin-bottom:12pt;">The European market prioritizes environmentally friendly innovations, such as solar-powered sunroofs and lightweight materials, in alignment with strict environmental regulations and consumer preferences for sustainable automotive solutions.</li>
2342. </ul>
2343. <p>Furthermore, stringent emissions regulations are encouraging the use of lightweight materials in sunroof designs to enhance vehicle efficiency. The growing interest among consumers in sustainable mobility and advanced technology features also supports market expansion. The development of EV infrastructure and a preference for high-end driving experiences further increases the adoption of sunroofs in Europe.</p>
2344. <p align="justify"><strong>Segment Outlook</strong></p>
2345. <p align="justify"><strong>Vehicle Class Insights</strong></p>
2346. <p>The luxury segment led the automotive sunroof market in 2024 due to consumer demand for upscale features such as panoramic, smart, and solar-powered sunroofs. Luxury manufacturers are constantly innovating to deliver superior in-cabin experiences, with sunroofs increasingly perceived as essential features rather than luxuries. The substantial demand for improved aesthetics, ambient lighting, and open-air driving experiences in premium vehicles is propelling the growth of this segment globally.</p>
2347. <p>The economic segment is projected to grow rapidly in the coming years, as manufacturers increasingly provide mid-range and compact vehicles with standard or optional sunroofs to appeal to budget-minded consumers. The growing desire for comfort and luxury at reasonable prices has led automakers to include sunroofs in entry-level sedans and hatchbacks. This trend of making premium features available across vehicle classes has led to broader adoption of sunroofs in this segment.</p>
2348. <p align="justify"><strong>Propulsion Type Insights</strong></p>
2349. <p>The Internal Combustion Engine (ICE) segment dominated the automotive sunroof market with the largest share in 2024. This is mainly due to the extensive installed base and high production volumes of ICEs worldwide. Manufacturers have widely integrated sunroofs into ICE-powered sedans, SUVs, and crossovers to enhance the appeal of their cabins and stand out in the competitive landscape. Consumers in both developed and emerging markets demonstrate a high demand for ICE vehicles equipped with sunroof features, ensuring this segment&#8217;s continued leadership despite growing interest in electric mobility solutions.</p>
2350. <p>The electric vehicles segment is projected to expand at the fastest rate during the forecast period, as original equipment manufacturers (OEMs) incorporate sunroofs to improve vehicle aesthetics and passenger experience. With the increasing popularity of EVs, features like panoramic sunroofs and solar roofs are becoming essential selling points. EV purchasers tend to be more tech-savvy and environmentally conscious, making them more open to innovations such as solar sunroofs that promote sustainability and energy efficiency.</p>
2351. <p><strong>Elevate your automotive strategy with Towards Automotive. Enhance efficiency and drive better outcomes—schedule a call today: </strong><strong>https://www.towardsautomotive.com/schedule-meeting</strong></p>
2352. <p align="justify"><strong>Material Type Insights</strong></p>
2353. <p>The glass segment dominated the market with the largest share in 2024, primarily due to its broad application in panoramic and built-in sunroofs. Tempered and laminated glass materials provide durability, visibility, and UV protection, contributing to both vehicle safety and passenger comfort. Automakers are <strong>increasingly favoring smart glass for its aesthetic appeal</strong> and the potential to incorporate features like tint control and solar panels, making it the most prevalent material in contemporary sunroof systems across all types of vehicles.</p>
2354. <p>The fabric segment is likely to expand to a notable CAGR during the forecast period. It is gaining popularity, especially in compact and convertible vehicle categories. These sunroofs offer design flexibility, lightweight advantages, and cost-effectiveness, making them particularly suitable for smaller vehicles and electric models. A rising interest in soft-top convertibles and retro-inspired vehicles is boosting the demand for fabric sunroofs, while improvements in weather-resistant materials and automation are enhancing their performance and encouraging adoption among niche consumer markets.</p>
2355. <p align="justify"><strong>Product Type Insights</strong></p>
2356. <p>The panoramic sunroofs segment dominated the automotive sunroof market with the largest market share in 2024 due to their extensive coverage and luxurious nature. These sunroofs extend across the roof, creating a spacious and open ambiance inside the cabin, which is especially popular in SUVs and crossovers. Automakers are integrating panoramic options to enhance passenger comfort and vehicle design, making it a desirable feature for mid-range and high-end vehicles, thus solidifying their significant market presence.</p>
2357. <p>The in-built sunroof segment is likely to expand at the fastest rate during the forecast period, as it strikes a balance between affordability and practicality. Built directly into the vehicle roof, in-built sunroofs allow for controlled airflow and light without sacrificing structural integrity. Innovations in electric sliding mechanisms and rain sensors are elevating the appeal of in-built sunroofs. Their compact design and compatibility with various types of vehicles, including sedans and hatchbacks, make them an appealing option for both automakers and consumers.</p>
2358. <p align="justify"><strong>Operation Type Insights</strong></p>
2359. <p>The electric segment dominated the automotive sunroof market in 2024. Electrically operated sunroofs provide enhanced convenience, safety, and integration with modern vehicle systems. Features such as one-touch operation, rain sensors, and anti-pinch technology improve the user experience. As consumer expectations rise for tech-enabled interiors and smart functionalities, electric sunroofs are starting to become standard in many new vehicle models. Their seamless integration with infotainment systems and in-cabin controls further solidify the segment’s position.</p>
2360. <p>The manual segment is projected to grow at a notable CAGR during the forecast period due to the affordability, simplicity, and lower maintenance of manual sunroofs. These sunroofs resonate with consumers in emerging markets where price sensitivity is significant. Automakers are progressively including manual sunroofs as standard features in entry-level models to cater to customer preferences for open-air experience without raising vehicle costs, which supports the consistent growth of this segment.</p>
2361. <p><strong>Competitive Landscape</strong></p>
2362. <ul type="disc">
2363. <li style="margin-top:12pt; margin-bottom:12pt;">Webasto Group</li>
2364. <li style="margin-top:12pt; margin-bottom:12pt;">CIE Automotive</li>
2365. <li style="margin-top:12pt; margin-bottom:12pt;">Inteva Products LLC</li>
2366. <li style="margin-top:12pt; margin-bottom:12pt;">Yachiyo Wuhan Manufacturing Co., Ltd.</li>
2367. <li style="margin-top:12pt; margin-bottom:12pt;">Magna International Inc.</li>
2368. <li style="margin-top:12pt; margin-bottom:12pt;">Mitsuba Corporation</li>
2369. <li style="margin-top:12pt; margin-bottom:12pt;">AISIN SEIKI Co. Ltd</li>
2370. <li style="margin-top:12pt; margin-bottom:12pt;">Inalfa Roof Systems Group BV</li>
2371. <li style="margin-top:12pt; margin-bottom:12pt;">Valmet Automotive</li>
2372. <li style="margin-top:12pt; margin-bottom:12pt;">Johnan America Inc.</li>
2373. </ul>
2374. <p align="justify"><strong>Recent Breakthroughs in the Global Automotive Sunroof Market:</strong></p>
2375. <ul type="disc">
2376. <li style="margin-top:12pt; margin-bottom:12pt;">In May 2023, Gabrial India entered a partnership with Inalfa Roof Systems to produce sunroofs for SUVs and sedans. The company intends to invest USD 20.72 million to establish a new facility in Chennai and Tamil Nadu. This facility, which is set to commence operations in the first quarter of 2024, will have the capacity to manufacture 200,000 sunroofs annually in its initial phase.</li>
2377. <li style="margin-top:12pt; margin-bottom:12pt;">In February 2023, Vayve Mobility, based in India, revealed plans to launch a solar-powered electric vehicle named Eva. It will feature 150-watt solar panels integrated into its sunroof, offering a daily range of 10 to 12 km or an annual range of 3,000 km.</li>
2378. </ul>
2379. <p><strong>Browse More Insights Towards Automotive:</strong></p>
2380. <ul type="disc">
2381. <li style="margin-bottom:12pt;"><strong>Electric Vehicle Solar Sunroof Market: </strong><strong>https://www.towardsautomotive.com/insights/electric-vehicle-solar-sunroof-market-sizing</strong></li>
2382. <li style="margin-bottom:12pt;"><strong>Medium Duty Truck Market: </strong><strong>https://www.towardsautomotive.com/insights/medium-duty-truck-market-sizing</strong></li>
2383. <li style="margin-bottom:12pt;"><strong>U.S. Electric Vehicle Market: </strong><strong>https://www.towardsautomotive.com/insights/us-electric-vehicle-market-sizing</strong></li>
2384. <li style="margin-bottom:12pt;"><strong>Electric Vehicle Taxi Market:</strong> <strong>https://www.towardsautomotive.com/insights/electric-vehicle-taxi-market-sizing</strong></li>
2385. <li style="margin-bottom:12pt;"><strong>E-SUVs Market: </strong><strong>https://www.towardsautomotive.com/insights/e-suvs-market-sizing</strong></li>
2386. <li style="margin-bottom:12pt;"><strong>Tanker Truck Market: </strong><strong>https://www.towardsautomotive.com/insights/tanker-truck-market-sizing</strong></li>
2387. <li style="margin-bottom:12pt;"><strong>India Electric Vehicle Adhesive Market: </strong><strong>https://www.towardsautomotive.com/insights/india-electric-vehicle-adhesive-market-sizing</strong></li>
2388. <li style="margin-bottom:12pt;"><strong>Micro Electric Vehicles Market: </strong><strong>https://www.towardsautomotive.com/insights/micro-electric-vehicle-market-sizing</strong></li>
2389. <li style="margin-bottom:12pt;"><strong>Asia Pacific Automotive Aluminum Die Casting Market: </strong><strong>https://www.towardsautomotive.com/insights/asia-pacific-automotive-parts-aluminum-die-casting-market-sizing</strong></li>
2390. <li style="margin-bottom:12pt;"><strong>Automotive Planetary Gear Systems Market: </strong><strong>https://www.towardsautomotive.com/insights/automotive-planetary-gear-market-sizing</strong></li>
2391. </ul>
2392. <p align="justify"><strong>Segments Covered in the Report</strong></p>
2393. <p align="justify"><strong>By Vehicle Class</strong></p>
2394. <ul type="disc">
2395. <li style="margin-top:12pt; margin-bottom:12pt;">Economics</li>
2396. <li style="margin-top:12pt; margin-bottom:12pt;">Medium Priced</li>
2397. <li style="margin-top:12pt; margin-bottom:12pt;">Luxury</li>
2398. </ul>
2399. <p align="justify"><strong>By Propulsion Type</strong></p>
2400. <ul type="disc">
2401. <li style="margin-top:12pt; margin-bottom:12pt;">ICE</li>
2402. <li style="margin-top:12pt; margin-bottom:12pt;">Electric</li>
2403. </ul>
2404. <p align="justify"><strong>By Material Type</strong></p>
2405. <ul type="disc">
2406. <li style="margin-top:12pt; margin-bottom:12pt;">Glass</li>
2407. <li style="margin-top:12pt; margin-bottom:12pt;">Fabric</li>
2408. </ul>
2409. <p align="justify"><strong>By Product Type</strong></p>
2410. <ul type="disc">
2411. <li style="margin-top:12pt; margin-bottom:12pt;">Panoramic Sunroofs</li>
2412. <li style="margin-top:12pt; margin-bottom:12pt;">In-Built Sunroof</li>
2413. <li style="margin-top:12pt; margin-bottom:12pt;">Others (Tilt &amp; Slide, Pop Up, and Top Mount)</li>
2414. </ul>
2415. <p align="justify"><strong>By Operation Type</strong></p>
2416. <ul type="disc">
2417. <li style="margin-top:12pt; margin-bottom:12pt;">Electric</li>
2418. <li style="margin-top:12pt; margin-bottom:12pt;">Manual</li>
2419. </ul>
2420. <p><strong>By Region</strong></p>
2421. <ul type="disc">
2422. <li style="margin-top:12pt; margin-bottom:12pt;">North America</li>
2423. <li style="margin-top:12pt; margin-bottom:12pt;">Latin America</li>
2424. <li style="margin-top:12pt; margin-bottom:12pt;">Europe</li>
2425. <li style="margin-top:12pt; margin-bottom:12pt;">Asia and Pacific</li>
2426. <li style="margin-top:12pt; margin-bottom:12pt;">MEA</li>
2427. </ul>
2428. <p><strong>For pricing details and customized market report options, click here: </strong><strong>https://www.towardsautomotive.com/price/1041</strong></p>
2429. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><strong>sales@towardsautomotive.com</strong><strong> </strong></p>
2430. <p>Subscribe to our Annual Membership and gain access to the latest insights and statistics in the automotive industry. Stay updated on automotive industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the competition with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of automotive<strong>: </strong><strong>Get a Subscription</strong><strong> </strong></p>
2431. <p><strong>About Us</strong></p>
2432. <p>Towards Automotive is a premier research firm specializing in the automotive industry. Our experienced team provides comprehensive reports on market trends, technology, and consumer behaviour. We offer tailored research services for global corporations and start-ups, helping them navigate the complex automotive landscape. With a focus on accuracy and integrity, we empower clients with data-driven insights to make informed decisions and stay competitive. Join us on this revolutionary journey as we work together as a strategic partner to reinvent your success in this ever-changing automotive world. </p>
2433. <p><strong>Our Trusted Data Partners</strong></p>
2434. <p><strong>Precedence Research</strong><strong> | </strong><strong>Statifacts</strong><strong> | </strong><strong>Towards Packaging</strong><strong> | </strong><strong>Towards Healthcare</strong><strong> | </strong><strong>Towards Food and Beverages</strong><strong> | </strong><strong>Towards Chemical and Materials</strong><strong> | </strong><strong>Towards Consumer Goods</strong><strong> | </strong><strong>Towards Dental</strong></p>
2435. <p><img alt="" src='https://ml.globenewswire.com/media/YTUyNThhYTAtMzdiZS00ZjE5LWFmZDEtMWI0NGQzOWI3MWYzLTEyMTM4NDktMjAyNS0wNC0yMS1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' />Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.</p>
2436. <p>The post <a rel="nofollow" href="https://dailyindianews.com/automotive-sunroof-market-size-to-apex-usd-16-41-bn-by-2034-says-industry-experts/2025/373764/">Automotive Sunroof Market Size to Apex USD 16.41 Bn by 2034, says Industry Experts</a> appeared first on <a rel="nofollow" href="https://dailyindianews.com">Daily India News</a>.</p>
2437. ]]></content:encoded>
2441. </item>
2442. </channel>
2443. </rss>
2444.  

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

1. Download the "valid RSS" banner.

2. Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)

3. Add this HTML to your page (change the image src attribute if necessary):

   <a href="http://www.feedvalidator.org/check.cgi?url=https%3A//dailyindianews.com/feed/"><img src="valid-rss-rogers.png" alt="[Valid RSS]" title="Validate my RSS feed" /></a>

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//dailyindianews.com/feed/

Home · About · News · Docs · Terms